Document:

EXHIBIT 10.5

	(1)		CRT
                                            PIONEER FUND LP

 

AND

 

	(2)		CENTRY
                                            PHARMA, INC.

 

 

 

____________________________________________

 

LICENCE AGREEMENT

 

____________________________________________

 

     

     

    

 

This Licence Agreement (the “Agreement”) is entered
into on 19 May 2021 (the “Effective Date”) by and between:

 

		(1)	CRT PIONEER FUND LP, a limited partnership established
in England and Wales under number LP 14391 with its registered office at [***] (“CPF”), acting by its general partner,
CRT Pioneer GP Limited, a company registered in England and Wales with registered number 07933818 whose registered office is at [***]
(the “General Partner”); and

 

		(2)	CENTRY PHARMA, INC., a corporation incorporated under the laws of Delaware with its registered
office at 1 bridge plaza, 2nd Floor, Fort Lee, New Jersey, 07024 (“Centry”),

 

Each of CPF (acting by the General
Partner) and Centry a “Party” and together the “Parties”.

 

WHEREAS

 

		(A)	CPF is a limited liability partnership formed pursuant to a limited partnership agreement between the
General Partner, the European Investment Fund, CRT (as defined below), BACIT Discovery Limited, and CRT Pioneer CIP LP. The General Partner
has the right to enter into legal agreements on behalf of CPF by which CPF is then bound.

 

		(B)	Centry is a corporation focused on the acquisition, development and commercialization of first and/or
best in class drug candidates for the treatment of serious conditions of unmet medical need or with limited treatment options.

 

		(C)	CPF is party to a licence and collaboration agreement whereby it obtained certain rights relating to Licensed
Compounds from ICR and CRT (as defined below) dated 12 August 2015 (the “Upstream Licence”) as amended from time to
time.

 

		(D)	CPF and Centry have agreed to enter into a licence on the following terms for the further development
and commercialisation of Licensed Compounds and Licensed Products in the Territory.

 

NOW IT IS HEREBY AGREED
as follows:

 

		1.	DEFINITIONS

 

In this Agreement,
except where the context requires otherwise, the following words and expressions shall have the following meanings:

 

		1.1.	“Affiliate” shall mean, with respect to any Person, any other Person which directly
or indirectly controls, is controlled by, or is under common control with, such Person. For the purposes of this definition, the term
 “control” shall mean, with respect to a Person, that such Person owns, or directly or indirectly controls, at least
fifty percent (50%) of the voting stock or other ownership interest of the other Person, or if it directly or indirectly possesses the power to direct or cause the direction of the management and policies of the other Person by any means whatsoever.

 

    - 2 - 

     

    

 

		1.2.	“Affordable” means in relation to a Licensed Product: (i) a determination by the UK
Pricing Authority that such Licensed Product should be used within the National Health Service (or any successor); and (ii) approval by
the UK Pricing Authority of the price proposed by Centry or its Sub-Licensee in relation to sales of that Licensed Product in the United
Kingdom (or one or more constituent countries thereof).

 

		1.3.	“Agreement” means this agreement and each of the Schedules as amended from time to
time in accordance with Clause 22.1.

 

		1.4.	“Applicable Law” or “Law” means all applicable laws, statutes, rules,
regulations and other pronouncements having the effect of law of any federal, national, multinational, state, provincial, county, city
or other political subdivision, agency or other body, domestic or foreign, including any applicable rules, regulations, guidelines, or
other requirements of the Competent Authorities that may be in effect from time to time.

 

		1.5.	“Arising Intellectual Property” means all Materials and Know How (other than that comprised
in Licensed Intellectual Property) conceived or generated after the Effective Date by or on behalf of Centry, or licensed to Centry, in
the course of exercising the licence rights granted under Clause 5.1, that is Controlled by Centry; and any intellectual property rights
which claim any such Materials and/or inventions described or comprised in such Know How, to the extent such Materials, Know How and intellectual
property rights relate to and are reasonably necessary for the research, development, manufacture, use or commercialization of Licensed
Products.

 

		1.6.	“Background Intellectual Property” means the Background Patents; the Background Know
How; and the Background Materials.

 

		1.7.	“Background Know How” means Know How (a) licensed to CPF pursuant to the Upstream Licence;
and/or (b) described in Schedule 8.

 

		1.8.	“Background Materials” means the Materials in existence at the Effective Date and which
are: (a) licensed to CPF pursuant to the Upstream Licence; and/or (b) described in Schedule 8.

 

		1.9.	“Background Patents” means the Patents set out in Schedule 9 and any Patents
claiming priority therefrom.

 

		1.10.	“Biomarker” means an endogenous characteristic that is objectively measured and evaluated
as an indicator or predictor of normal biological or pathogenic processes or pharmacological responses to a therapeutic intervention.

 

    - 3 - 

     

    

 

		1.11.	“Business Day” means a day other than a Saturday, Sunday or any public holiday in England
or New York City, New York.

 

		1.12.	“Commencement” means, in relation to a clinical trial, the date upon which administration
of a Licensed Product to the first human subject has occurred, whether such subject is a healthy volunteer or a patient.

 

		1.13.	“Commercially Reasonable Efforts” means with respect to Centry’s efforts, the
efforts and resources commonly used by a biotechnology company with similar resources available to the relevant project as Centry (or,
where applicable, its Sub-Licensee) for a product at a similar stage in its life cycle, with the objective of developing such product
in a diligent and timely manner, taking into consideration its safety, efficacy and the patent or other proprietary position.

 

		1.14.	“Competent Authority” means any local or national agency, court, authority, department,
inspectorate, minister, ministry official or public or statutory person (whether autonomous or not) of, or of any government of, any country
having jurisdiction over the Agreement or either of the Parties (such as the Financial Services Authority or any successor entity) or
over the development or marketing of medicinal products (such as the FDA or the European Medicines Agency).

 

		1.15.	“Compound Intellectual Property” means any Licensed Intellectual Property to the extent
that it is: (i) a Licensed Compound; or (ii) directly related to Licensed Compounds, including their use in the Field. For the avoidance
of doubt Compound Intellectual Property excludes Exclusive Biomarkers.

 

		1.16.	“Confidential Information” means any information, in tangible or non-tangible form
(including oral disclosure) including Know How, research and development plans, information relating to the customers, suppliers, business
partners, clients, finances, business plans and products (in each case actual or prospective) of a Party, the terms of this Agreement,
and any other technical or business information (whether or not marked as confidential), which is obtained by either Party from the other
(or its representatives) pursuant to this Agreement. Licensed Know How shall be deemed the Confidential Information of each Party.

 

		1.17.	“Control” means, as the context requires: (i) with respect to any item of Intellectual
Property or right under any Intellectual Property, the possession by a Party (whether by ownership or license, other than pursuant to
this Agreement) of the ability to grant access (by license or sublicense), without violating the terms of any agreement or other arrangement
with any Third Party existing at the time; or otherwise (ii) the possession (directly or indirectly) of fifty percent (50%) or more of
the voting stock or other equity interest of a subject entity with the power to vote, or the power in fact to control the management decisions
of such entity through the ownership of securities or by contract or otherwise and “Controlling” and “Controlled
by” shall be construed accordingly.

 

		1.18.	“CPF Indemnified Parties” means [***] and their respective officers, employees and
agents.

 

    - 4 - 

     

    

 

		1.19.	“CRT” means Cancer Research Technology Limited, a company registered in England and
Wales under number 1626049 with registered office at 2 Redman Place, London, E20 1JQ, England.

 

		1.20.	“CRUK” means Cancer Research UK, a company limited by guarantee (registered in England
and Wales under number 4325234) and a charity (registered in England under number 1089464 and registered in Scotland under number SC041666
and in the Isle of Man under number 1103) of 2 Redman Place, London, E20 1JQ, United Kingdom.

 

		1.21.	“Data Room” means the documents in the data room hosted by Firmex as at the Effective
Date.

 

		1.22.	“Development Plan” means a detailed plan which describes: (i) the Key Activities; (ii)
the relevant timescales within which it is intended that such Key Activities will be taken; and (iii) the estimated costs associated with
each Key Activity. The first Development Plan is provided in Schedule 4.

 

		1.23.	“EC” means the European Commission.

 

		1.24.	“Effective Date” means the date this Agreement is made as further set out above.

 

		1.25.	“Encumbered” in relation to any Intellectual Property means an option, restriction,
right of first refusal, third-party right or interest, assignment by way of security, other encumbrance or a security interest of any
kind or another type of preferential arrangement (including a title transfer or retention arrangement) having similar effect howsoever
arising over or in respect of the Intellectual Property.

 

		1.26.	“Exclusive Other Arising Intellectual Property” has the meaning given in Clause 18.3(c).

 

		1.27.	“Exclusive Biomarkers” means all Biomarkers which function as a diagnostic or efficacy
or prognostic marker exclusively for use in conjunction with a Licensed Product. For the sake of clarity, Exclusive Biomarkers excludes
any Biomarkers which function (to any reasonably measurable degree) as a diagnostic, efficacy or prognostic marker in relation to any
compound which is not a Licensed Compound, a class of compounds or more than one molecular target.

 

		1.28.	“Executive Officers” means the Chief Executive Officer of Centry, and a Director of
the General Partner or, in each case such other authorised officer of a Party as may be substituted from time to time upon the giving
of written notice to the other Party.

 

		1.29.	“Expert” means a suitably qualified independent expert appointed by agreement between
the Parties. However, in the event that the Parties are unable to reach agreement within fifteen (15) Business Days of either CPF on the
one hand and Centry on the other seeking in writing to the other to appoint such expert, each Party shall submit two (2) names to the
President for the time being of the Association of the British Pharmaceutical Industry (or any successor body thereto), who shall select
an individual from the names submitted.

 

    - 5 - 

     

    

 

		1.30.	“Extended Exclusivity Period” means the later of:

 

		(a)	any period during which one of the following subsists in respect of a Licensed Product in the relevant
country: Orphan Drug Designation, paediatric designation or other exclusivity (excluding a Patent) granted by a Competent Authority beyond
the expiry of the relevant Patent; or

 

		(b)	the expiry of [***] ([***]) [***] from the date of the First Commercial Sale of that Licensed Product
(or former Licensed Product) in the relevant country by Centry or a Sub-Licensee on an arm’s length terms.

 

		1.31.	“FDA” means the United States Food and Drug Administration or any successor to it.

 

		1.32.	“Field” means the treatment, prophylaxis, and/or diagnosis of diseases and conditions.

 

		1.33.	“Financing Commitment” has the meaning set out in Clause 17.2.

 

		1.34.	“Financing Condition Precedent” has the meaning set out in Clause 3.1.

 

		1.35.	“First Commercial Sale” means, with respect to a Licensed Product, the first transfer
or disposition for value of such Licensed Product to a Third Party, after all relevant Regulatory Authorisations for the transfer or disposition
of such Licensed Product have been obtained in respect of the relevant region or country.

 

		1.36.	“Force Majeure” means in relation to either Party any event or circumstance which is
beyond the reasonable control of that Party, which event or circumstance that Party could not reasonably be expected to have taken into
account at the Effective Date and which results in or causes the failure of that Party to perform any or all of its obligations under
this Agreement including act of God, lightning, fire, storm, flood, earthquake, strike, lockout or other industrial disturbance, war,
terrorist act, blockade, revolution, riot, insurrection, civil commotion, public demonstration, sabotage, act of vandalism, explosion,
provided that lack of funds shall not be interpreted as a cause beyond the reasonable control of that Party.

 

		1.37.	“Generic Competition” means with respect to a Licensed Product in any particular country
in the Territory, the existence on the market of any Generic Product in competition with such Licensed Product in such country where the
unit volume of Generic Products sold in such country by one (1) or more Third Parties in a Calendar Quarter is (a) at least [***] percent
([***]%) (“Level 1 Generic Competition”), or (b) at least [***] percent ([***]%) (“Level 2 Generic Competition”),
in each case of (a) or (b), of the unit volume of Licensed Products sold in such country to end users by Centry, its Affiliates and Sub-Licensees
(or its or their distributors). Unless otherwise agreed by the Parties, the unit volumes of each Generic Product sold during a Calendar
Quarter will be as reported by IQVIA or any successor to
IQVIA or any other independent sales auditing firm reasonably agreed upon by the Parties.

 

    - 6 - 

     

    

 

		1.38.	“Generic Product” means any pharmaceutical product that (a) is sold by a Third Party
other than pursuant to any rights granted by Centry; and (b) contains the same active pharmaceutical ingredient (or one which is substantially
the same, such as a hydrate or salt of the active pharmaceutical ingredient) as the Licensed Product; and (c) was granted pursuant to
an application for a marketing authorisation that relies on data held by a regulatory authority in relation to a Licensed Product.

 

		1.39.	“ICR” means the Institute of Cancer Research: Royal Cancer Hospital, a company limited
by guarantee (Company number 00534147) a college of the University of London and a charity exempt from registration with registered office
at 123 Old Brompton Road, London SW7 3RP, England.

 

		1.40.	“IND” means an investigational new drug application filed with the FDA, or the equivalent
application or filing filed with any equivalent Competent Authority outside the United States of America (including any supranational
agency such as the European Medicines Agency) necessary to commence human clinical trials in such jurisdiction.

 

		1.41.	“Indication” means a disease classification as defined within the ‘International
Statistical Classification of Diseases and Related Health Problems’ as published from time to time by the World Health Organization
(e.g. “[***]”, “[***]”, “[***]” and “[***]”).

 

		1.42.	“Intellectual Property” means Materials, Patents and Know How.

 

		1.43.	“JDC” means the joint development committee established by the Parties in accordance
with Clause 4.

 

		1.44.	“Key Activity” means any of the following in relation to a Licensed Product:

 

		(a)	significant research activity related to biological processes that a Licensed Product would or could affect,
including, but not limited to, animal studies;

 

		(b)	active preclinical work required for any contemplated clinical trial, including any toxicology or pharmacokinetic
work;

 

		(c)	active planning of a clinical trial (or in the event of issues arising
with a Competent Authority in relation to a clinical trial, active negotiation with such Competent Authority and/or replanning of the
clinical trial);

 

		(d)	actively seeking to obtain the necessary IND or other approvals to carry out a clinical trial;

 

		(e)	active enrolment of patients into, or participation of patients in, a clinical trial, where relevant in
accordance with the protocol in order to determine if the primary end point has been met;

 

    - 7 - 

     

    

 

		(f)	active monitoring, analysis or reporting on the data arising from a clinical trial where relevant in accordance
with the protocol in order to determine if the primary end point has been met;

 

		(g)	manufacture or formulation of a Licensed Product for use in a clinical trial, including active process
development work in support of planned manufacture; and

 

		(h)	preparation for and making submissions to regulatory agencies for an NDA or awaiting the outcome of such
submission.

 

		1.45.	“Know How” means technical and other information which is not in the public domain
including, ideas, concepts, inventions, discoveries, data, formulae, algorithms, specifications, clinical data, information relating to
Materials (including biological and chemical structures and functions as well as methods for synthesising chemical compounds), procedures
for experiments and tests, results of experimentation and testing, results of research and development including laboratory records and
data analyses. Information in a compilation or a compilation of information may be Know How notwithstanding that some or all of its individual
elements are in the public domain.

 

		1.46.	“Licensed Compound” means the compound known as CCT361814 which is further described
in the Development Plan together with any compound which is claimed, even if not specifically exemplified, in a Patent comprised in the
Licensed Patents (including the HSF1 compounds included in Schedule 3, Part 1 of the Upstream Licence).

 

		1.47.	“Licensed Intellectual Property” means Licensed Patents, Licensed Know How, and Licensed
Materials. For clarity, the Licensed Intellectual Property shall not include any Patents, Know How or Materials Controlled by any Affiliate
of CPF.

 

		1.48.	“Licensed Know How” means all of the Background Know How and any Know How that has
been assigned to or licensed to CPF pursuant to the Upstream Licence and / or any Third Party CRO Contract, that in each case relates
to and is reasonably necessary for the research, development, manufacture, use or commercialization of Licensed Products.

 

		1.49.	“Licensed Materials” means all Materials Controlled by CPF to which it has rights under
the Upstream Licence and / or Third Party CRO Contracts that, in each case, relate to Licensed Products including all drug substance precursors,
drug substance, drug product, formulations for all modes of delivery, relevant excipients, assays, reagents and other relevant tangible
materials.

 

		1.50.	“Licensed Patents” means any Background Patent together with any Patent Rights Controlled
by CPF during the Term that claim any of the Licensed Know How including: (a) an issued or granted patent, including any extension, supplemental
protection certificate, registration, confirmation, reissue, reexamination, extension or renewal thereof; (b) a pending patent application,
including any continuation, divisional, continuation-in-part, substitute or provisional application thereof; and (c) all counterparts
or foreign equivalents of any of the foregoing issued by or filed in any country or other jurisdiction, in each case that relate to and
are reasonably necessary for the research, development, manufacture, use or commercialization of the Licensed Products.

 

    - 8 - 

     

    

 

		1.51.	“Licensed Products” means any product: (i) which falls within the scope of one (1)
or more Valid Claims of any of the Licensed Patents in the relevant country or territory; and/or (ii) containing a Licensed Compound;
and/or (iii) which product was developed using or incorporating any part of the Licensed Intellectual Property, including in each case
any metabolites, prodrugs, salts, hydrates, solvates, esters, intermediates, polymorphs, isomers, analogues and derivatives of any Licensed
Compounds; and in each case including for the avoidance of doubt any product developed by Centry or any Sub-Licensee (or any Third Party
to which rights are granted directly or indirectly by Centry or any Sub-Licensee) that meet the requirements of one of the foregoing clauses
(i), (ii) or (iii).

 

		1.52.	“Major Markets” means the United Kingdom, the United States, France, Italy, Germany,
Spain and Japan and “Major Market” shall mean any one of them.

 

		1.53.	“Material” means any chemical or biological material including any: organic or inorganic
element or compound; nucleotide or nucleotide sequence including DNA and RNA sequences; gene; vector or construct including plasmids,
phages, bacterial vectors, bacteriophages and viruses; host organism including bacteria, fungi, algae, protozoa and hybridomas; eukaryotic
or prokaryotic cell line or expression system or any development strain or product of that cell line or expression system; protein including
any peptide or amino acid sequence, enzyme, antibody or protein conferring targeting properties and any fragment of a protein or a peptide
enzyme or antibody; drug or pro-drug; assay or reagent; any other genetic or biological material or micro-organism or any transgenic animal;
and any physical property rights relating to any of the foregoing.

 

		1.54.	“Milestone Event” has the meaning given in Clause 7.2.

 

		1.55.	“Milestone Payment” has the meaning given in Clause 7.2.

 

		1.56.	“NDA” means an application for approval to market a product commercially such as
                                                             the New Drug Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR.§ 314.3 et seq, or a
                                                             Biologics License Application filed pursuant to the requirements of the FDA, as more fully defined in 21 CFR § 601, or a
                                                             Marketing Authorisation application filed pursuant to the requirements of European Directive 2001/ 83/ EC, or any equivalent or
                                                             similar application filed with any other Competent Authority in
any country or region in the Territory, together, in each case, with all additions, deletions or supplements thereto.

 

    - 9 - 

     

    

 

		1.57.	“Net Sales” means the gross amount invoiced by Centry, its Affiliates or any Sub-Licensee
(such entities are each a “Selling Party”) to Third Parties for sale of Licensed Products in the Territory, less, to
the extent deducted from or on such invoice consistent with generally accepted accounting principles, consistently applied, the following
items:

 

		(a)	customary and reasonable trade, quantity, and cash discounts and wholesaler and pharmacy allowances including
initial stocking and distribution allowances; provided that, in the case of pharmacy incentive research programs, hospital performance
incentive research program chargebacks, disease management research programs, similar research programs or discounts and wholesaler allowances
on “bundles” of products, all discounts, wholesaler allowances and the like shall be allocated among products on the basis
on which such discounts, wholesaler allowances or the like were actually granted or, if such basis cannot be determined, in proportion
to the respective list prices of such products;

 

		(b)	customary and reasonable credits, rebates chargebacks, and administrative fees (including, but not limited
to, those to managed-care entities, pharmacy benefit managers, and government agencies and programs), patient rebates, and discounts,
and allowances or credits to customers on account of rejection or returns (including, but not limited to, wholesaler and retailer returns)
or affecting such product;

 

		(c)	freight, fees for services charges, postage and duties, shipping and insurance charges relating to such
product;

 

		(d)	sales taxes (such as value added tax or its equivalent) and excise taxes, other consumption taxes, customs
duties and compulsory payments to governmental authorities and any other governmental charges imposed upon the importation, use or sale
of such product to Third Parties (excluding any taxes paid on the income from such sales), to the extent the Selling Party is not otherwise
entitled to a credit or a refund for such taxes, duties or payments made;

 

		(e)	amounts accrued or provided for in respect of bad debts; and

 

		(f)	commissions allowed or paid to Third Party distributors, Third Party brokers, or Third Party agents other
than sales personnel, sales representatives, and sales agents employed by a Selling Party.

 

Each of the deductions
set out above shall be determined on an accrual basis in accordance with International Financial Reporting Standards (IFRS).

 

    - 10 - 

     

    

 

For the purposes of
determining Net Sales, Licensed Products shall be deemed to be sold when invoiced and a “sale” shall not include transfers,
uses or dispositions of sample product for promotional, preclinical or clinical trial, regulatory or governmental purposes in all cases
provided that a “for profit” price is not charged. For purposes of calculating Net Sales, sales between or among the Selling
Parties shall be excluded from the computation of Net Sales, but sales by a Selling Party to Third Parties shall be included in the computation
of Net Sales.

 

With respect to Licensed
Products that are sold as Combination Products (as defined below), then the Net Sales attributable to such Combination Product shall be
calculated by multiplying actual Net Sales of such Combination Product by the fraction A/(A+B) where: A is the weighted average sale price
in the applicable country of the Licensed Product contained in such Combination Product, and B is the weighted average sale price in such
country of the other therapeutically active ingredients or components contained in such Combination Product.

 

If “A” or
 “B” cannot be determined by reference to non-Combination Product sales as described above, then Net Sales will be calculated
as above, but the weighted average sale price in the above equation shall be determined by mutual agreement reached in good faith by the
Parties prior to the end of the accounting period in question based on an equitable method of determining the same that takes into account,
in the applicable country, variation in dosage units and the relative fair market value of each therapeutically active ingredient in the
Combination Product.

 

As used in this definition
of Net Sales, “Combination Product” means a product that contains a Licensed Compound and one or more additional active ingredients
or components (whether co-formulated or co-packaged) that are not a Licensed Compound. Pharmaceutical dosage form vehicles, adjuvants
and excipients shall be deemed not to be “active ingredients.”

 

With respect to any
dispute between the Parties with respect to the determination of Net Sales of Combination Products, such dispute may be referred by either
Party to the Expert for determination in accordance with Clause 31.

 

		1.58.	"Non-Compound Intellectual Property" means any Licensed Intellectual Property other than
Compound Intellectual Property.

 

		1.59.	“Oncology Indication” means an Indication in the range [***] (e.g. “C50 Malignant
neoplasm of Breast”, “C92 Myeloid leukaemia”).

 

		1.60.	“Other Arising Intellectual Property” means all Arising Intellectual Property that
is not Owned Arising Intellectual Property.

 

		1.61.	“Orphan Drug Designation” means designation as an orphan drug or equivalent under relevant
national or other applicable regulations and/or legislation in any part of the world, including under the US Orphan Drug Act of 1983 or
Orphan Drug Regulation 141/2000 in the European Union.

 

    - 11 - 

     

    

 

		1.62.	“Owned Arising Intellectual Property” means all Arising Intellectual Property that
(a) is owned by Centry; and (b) relates directly to the Licensed Compound.

 

		1.63.	“Patent Costs” means any external out of pocket costs and expenses incurred in filing,
prosecuting, maintaining, defending and enforcing the Licensed Patents, including official filing, prosecution, maintenance and renewal
fees, patent attorney, translation, legal and other professional fees and expenses and costs and expenses associated with any opposition
or interference action.

 

		1.64.	“Patents” means any patent applications, patents, author certificates, inventor certificates,
utility models, and all foreign counterparts of them and includes all divisionals, renewals, continuations, continuations-in-part, extensions,
reissues, substitutions, confirmations, registrations, revalidations and additions of or to them, as well as any Supplementary Protection
Certificate, or any like form of protection.

 

		1.65.	“Person” shall mean an individual, corporation, partnership, limited liability company,
trust, business trust, association, joint stock company, joint venture, pool, syndicate, sole proprietorship, unincorporated organization,
governmental authority or any other form of entity not specifically listed herein.

 

		1.66.	“Phase I Trial” means a clinical trial in which a Licensed Product is administered
to human subjects at multiple dose levels with the primary purpose of determining safety, metabolism, and pharmacokinetic and pharmacodynamic
properties of the Licensed Product, and consistent with 21 CFR § 312.21(a) and any microdosing clinical trial conducted pursuant
to the FDA’s 2006 Guidance on Exploratory Investigational New Drugs or any equivalent arrangements.

 

		1.67.	“Phase Ib Trial Expansion Cohort Dose” means the dose of Licensed Product selected
for the administration to an expansion cohort of patients following the completion the ascending dosing levels of subjects in a Phase
1 Trial.

 

		1.68.	“Phase II Trial” means a clinical trial in which a Licensed Product is administered
to human subjects which provides for the initial trial of the Licensed Product on a limited number of patients for the purpose of determining
dose and evaluating safety and preliminary efficacy in the proposed therapeutic indication and consistent with 21 C.F.R. § 312.21
(b) or its equivalents in other jurisdictions.

 

		1.69.	“Phase III Trial” means a clinical trial in
                                                                                             which a Licensed Product is administered to human subjects that is prospectively designed to establish the therapeutic benefit of
                                                                                             the Licensed Product in a larger patient sample and to further demonstrate the Licensed Product’s safety in patients with the
                                                                                             target disease in a particular indication in a manner sufficient to obtain regulatory approval to market such Licensed Product and
                                                                                             consistent with 21 C.F.R. § 312.21 (c) or its equivalents in other jurisdictions.

 

 

    - 12 - 

     

    

 

		1.70.	“Price Approval” means, in those countries in the Territory where a Competent Authority
may approve or determine pricing and/or pricing reimbursement for pharmaceutical products, such approval or determination.

 

		1.71.	“Progress Report” means a reasonably detailed written report produced by Centry in
respect of: (i) the progress of development of Licensed Products against the current Development Plan and actual costs incurred in comparison
to the estimated costs set out in the Development Plan; (ii) the progress of any applications for Regulatory Authorisation and (where
relevant) Price Approvals; and (iii) the progress of and plans for marketing and sale of Licensed Products.

 

		1.72.	“Quarter” means any of the three-monthly periods commencing on the first day of any
of the months of January, April, July, and October in any Year and “Quarterly” or “Calendar Quarter”
has a corresponding meaning.

 

		1.73.	“Regulatory Authorisations” means all authorisations, approvals, clearances, and licences
of a Competent Authority (including an NDA) that may be required in any country of the Territory prior to commercial sale of the relevant
Licensed Product in the Field, including any necessary variations thereto, but excluding any Price Approvals.

 

		1.74.	“Signature Fee” means the non-refundable sum of three million five hundred thousand
dollars (USD $3,500,000).

 

		1.75.	“Sub-Licensee” means a person to whom a sub-licence is granted in accordance with Clause
5.5 in respect of the whole or any part of the rights granted under this Agreement.

 

		1.76.	“Sub-Licence Provisions” means those provisions to be included in a sub-licence pursuant
to Clause 5.5 and as set out in Schedule 5.

 

		1.77.	“Supplementary Protection Certificate” means a right based on a patent pursuant to
which the holder of the right is entitled to exclude third parties from using, making, having made, selling or otherwise disposing or
offering to dispose of, importing or keeping the product to which the right relates, such as supplementary protection certificates in
Europe, and any similar right anywhere in the world.

 

		1.78.	“Target Patent Country” means any one of the countries listed in Schedule 6.

 

		1.79.	“Technology Transfer” means the transfer by or on behalf of CPF to Centry of an electronic
copy of the Data Room.

 

		1.80.	“Term” means the term of this Agreement determined in accordance with Clause 17.1.

 

    - 13 - 

     

    

 

		1.81.	“Territory” means worldwide.

 

		1.82.	“Third Party” means a person other than a Party, or a Sub-Licensee.

 

		1.83.	“Third Party CRO Contract” means a contract, other than the Upstream Licence, between
CPF and a Third Party Service Provider which was entered into for the purpose of the research and/or development of Licensed Compounds.

 

		1.84.	“Third Party Service Provider” means a Third Party who provides research, development
and/or manufacturing services to Centry in connection with Licensed Products, including contract research organisations, universities
and hospitals. However, a Tobacco Party may not act as a Third Party Service Provider.

 

		1.85.	“Tobacco Party” means: (i) any person who develops, sells or manufactures tobacco products;
and/ or (ii) any person which makes the majority of its profits from the importation, marketing, sale or disposal of tobacco products.
Furthermore, Tobacco Party shall include any person that is Controlled by or under common Control with any of the persons referred to
in (i) and/or (ii).

 

		1.86.	“UK Pricing Authority” means any supra-national, national or regional government department,
authority, agency or entity (including a non-departmental public body or similar entity) with responsibility for evaluating the cost effectiveness
of medicinal products in the United Kingdom (or one or more constituent countries thereof) or otherwise determining whether the NHS (or
constituent parts thereof) should purchase medicinal products.

 

		1.87.	“Valid Claim” means either:

 

		(a)	a claim of an issued and unexpired Licensed Patent (which include any Patent term extension or Supplementary
Protection Certificate) in the relevant country in the Territory which covers the Licensed Product and that: (i) has not been revoked
or held unenforceable or invalid by a decision of a court or other governmental agency of competent jurisdiction, unappealable or unappealed
within the time allowed for appeal; or (ii) has not been abandoned, disclaimed, or admitted to be invalid or unenforceable through reissue
or disclaimer or otherwise; or

 

		(b)	a claim of a pending patent application, which claim has been filed in good faith, and such application
has been pending for less than [***] ([***]) years, and has not been abandoned or finally disallowed without the possibility of appeal
or re-filing of the application.

 

		1.88.	“Year” means a calendar year.

 

    - 14 - 

     

    

 

		2.	INTERPRETATION

 

		2.1.	In this Agreement:

 

		(a)	unless the context requires otherwise, all references to a particular Clause, paragraph or Schedule shall
be references to that clause, paragraph or schedule, in or to this Agreement;

 

		(b)	the table of contents and headings are inserted for convenience only and shall be ignored in construing
this Agreement;

 

		(c)	unless the contrary intention appears, words importing the masculine gender shall include the feminine
and vice versa and words in the singular include the plural and vice versa;

 

		(d)	unless the contrary intention appears, words denoting persons shall include any individual, partnership,
company, corporation, joint venture, trust association, organisation or other entity, in each case whether or not having separate legal
personality; and

 

		(e)	references to the words “include” or “including” shall be construed without limitation
to the generality of the preceding words.

 

		3.	CONDITION PRECEDENT

 

		3.1.	This Agreement shall only be effective once Centry has:

 

		(a)	secured a minimum of [***] dollars (USD $[***]) in financing in a designated escrow account to be used
to establish Centry’s operations and otherwise to support Centry’s performance of its obligations pursuant to the Development
Plan and this Agreement (for avoidance of doubt, such funds are anticipated to be released in full to Centry from escrow upon or shortly
after the Effective Date); and

 

		(b)	provided evidence of obtaining such financing to CPF’s reasonable satisfaction;

 

(a) and (b) together
the “Financing Condition Precedent”.

 

		4.	JOINT DEVELOPMENT COMMITTEE

 

		4.1.	Within thirty (30) days after the Effective Date, the Parties
shall establish a joint development committee (“JDC”). The JDC shall have responsibility for:

 

		(a)	overseeing the Research Programme (as defined in Clause 8.1);

 

		(b)	overseeing the filing and maintenance of the Licensed Patents;

 

		(c)	advise and assist in the resolution of any scientific or technical difficulties that arise as the result
of the Research Programme;

 

    - 15 - 

     

    

 

		(d)	oversee the support to be provided by ICR to effect the transfer of the rights contemplated under this
Agreement to Centry;

 

		(e)	overseeing pre-clinical development of Licensed Products prior to the Commencement of the first Phase
I Trial; and

 

		(f)	overseeing the conduct of the Phase I Trial(s) by Centry.

 

		4.2.	Membership

 

		(a)	The JDC shall be comprised of [***] ([***]) representatives in total (each a “JDC Member”),
each having relevant expertise. The number of JDC Members shall be [***] ([***]) from Centry, [***] ([***]) from CPF and [***] ([***])
from ICR. The total number of JDC Members may be changed by unanimous vote of the JDC from time to time as appropriate.

 

		(b)	The initial JDC Members for Centry shall be: [***]; for CPF: [***]; and for ICR: [***].

 

		(c)	Each Party may replace its respective JDC Members with new persons (with appropriate expertise to replace
the outgoing members) at any time, with prior written notice to the other Parties. From time to time, the JDC may establish subcommittees
to oversee particular projects or activities, and such subcommittees will be constituted as the JDC determines.

 

		4.3.	Meetings

 

The JDC shall meet
approximately every six (6) weeks until the first patient has been dosed in a Phase I Trial and thereafter two (2) times annually, or
more or less often as agreed by the Parties. JDC meetings shall be held by telephone conference or where appropriate, in person or by
video. The members of the JDC also may convene or be polled or consulted from time to time by means of telecommunications, video conferences,
electronic mail or correspondence, as deemed necessary or appropriate. Unless otherwise agreed, the location of face-to-face meetings
of the JDC shall alternate between the offices of Centry and CPF or such other place as the Parties may agree. The chair of the JDC meetings
shall be a Centry JDC Member. The Parties shall determine the form of the meeting.

 

		4.4.	Decision Making

 

Decisions of the JDC
shall be made by consensus, with each JDC Member acting in good faith. In the event that the JDC Members are unable to reach such a consensus
[***]shall have the final decision-making authority except (a) where such dispute relates to [***] shall have final decision making authority;
and (b) where such dispute relates to [***] shall have the final decision-making authority until such time as [***] and
thereafter [***]shall have the final decision-making authority. In no case shall either Party be permitted to exercise its final decision
making authority with a result that conflicts with the terms of this Agreement.

 

    - 16 - 

     

    

 

		4.5.	No Further Obligation

 

The JDC shall not
take any decision that obliges ICR to undertake any work outside of the Research Programme.

 

		4.6.	Minutes

 

Minutes of the JDC
meetings shall be taken, and shall, at a minimum, record all decisions made. The minutes of each meeting of the JDC shall be prepared
by Centry. Drafts of the minutes shall be delivered to a designated Centry, CPF and ICR JDC Member for approval within seven (7) days
after the respective meeting. A copy of the final minutes of each meeting as approved shall be sent to each JDC Member within seven (7)
days of receiving the draft minutes.

 

		4.7.	Expenses

 

Centry, CPF, and ICR
shall each bear all expenses of its own JDC Members related to such members’ participation on the JDC and attendance at JDC meetings.

 

		4.8.	Disbanding of JDC

 

The JDC shall be disbanded
upon the later of: (i) completion of the first Phase I Trial; or (ii) the termination of all activities under the Research Programme.

 

		5.	LICENCE

 

		5.1.	Subject to the provisions of this Agreement, the terms of the Upstream Licence and Centry’s satisfaction
of the Financing Condition Precedent, CPF agrees to grant and hereby grants to Centry a licence under the Licensed Intellectual Property
to research, develop, use, keep, make, have made, import, sell and otherwise dispose of Licensed Products in the Field in the Territory
for the Term. Such licence shall be exclusive to the extent that CPF is able to grant such an exclusive licence (pursuant to the terms
of the Upstream Licence or otherwise). For the avoidance of doubt CPF is able to grant an exclusive licence with respect to the Background
Patents. To the extent that CPF is not able to grant an exclusive licence the licence shall be non-exclusive.

 

		5.2.	No licence to use any Intellectual Property is granted to Centry, or any Sub-Licensee, or is implied except
as expressly granted in this Agreement.

 

    - 17 - 

     

    

 

		5.3.	CPF hereby reserves and excepts from the licence under Clause 5.1 a [***] for ICR and CRUK, including
any scientists funded and employed by ICR or CRUK, to:

 

		(a)	[***].

 

		(b)	[***];

 

		(c)	[***]; and

 

		(d)	[***].

 

		(e)	[***].

 

		5.4.	Centry shall have no right to grant sub-licences (except to Third Party Service Providers on the basis
set out in Clause 5.5(f)) prior to the earlier of (i) a Licensed Product satisfying the second Milestone Event (Declaration of the recommended
Phase II Trial or Phase Ib Trial Expansion Cohort Dose) and the receipt by CPF of cleared funds of the associated Milestone Payment; and
(ii) [***] ([***]) [***]after the Effective Date.

 

		5.5.	Subject to Clause 5.4, Centry shall be entitled to grant sub-licences in respect of the rights granted
under this Agreement, provided that with respect to any sub-licence granted to an entity:

 

		(a)	at least [***] ([***]) days prior to grant it informs CPF in writing of the terms of such sub-licence,
including the identity of the proposed Sub-Licensee;

 

		(b)	within [***] ([***]) Business Days of the grant of any sub-licence, Centry shall provide CPF with a true
copy of such sub-licence at Centry’s expense and Centry acknowledges that CPF shall be entitled to share a copy of such sub-licence
with CRT and ICR in accordance with the terms of the Upstream Licence;

 

		(c)	Centry shall ensure that there are included in the terms of any sub-licence substantially equivalent obligations
on the part of the Sub-Licensee to those applying to Centry pursuant to this Agreement. In particular, Centry shall ensure that any sub-licence
has provisions which secure CPF’s, ICR’s, and CRT’s rights pursuant to Clause 16 (Confidentiality), 11.9 (Patent Enforcement),
13.1 (Indemnity), 18.1 (Effects of Termination). Centry shall additionally ensure that there are included in the terms of any sub-license
substantially equivalent obligations and undertakings to those set out in the sub-license provisions as set forth in Schedule 5
and shall use Commercially Reasonable Efforts to ensure that all Sub-Licensees comply with the same;

 

    - 18 - 

     

    

 

		(d)	any sub-licence granted by Centry shall be expressed to terminate automatically on the termination of
this Agreement for any reason. Notwithstanding the foregoing, in connection with such termination, provided (a) such Sub-Licensee is not
in material breach of the terms of the applicable sub-licence with Centry and fails to cure such material breach within the applicable
cure period thereunder, and (b) the termination of this Agreement was not caused by breach of the obligations under such applicable sub-licence,
CPF shall upon the reasonable request of the relevant Sub-Licensee grant to the affected Sub-Licensee a sub-licence on materially the
same terms to that contained in the terminated sub-licence, except that the affected Sub-Licensee shall only be required to pay CPF the
amounts that Centry would have been required to pay CPF hereunder on account of or in connection with such Sub-Licensee’s activities under
such direct sub-licence with CPF, and provided that this shall not result in CPF taking on any more onerous obligations or assuming any
liability other than it is under pursuant to this Agreement;

 

 

 

		(e)	no sub-licence shall be granted to a Tobacco Party; and

 

		(f)	the sub-licence shall be entered into on an arms-length basis.

 

		5.6.	The obligations in Clause 5.5(a) to (e) shall not apply in relation to contracts Centry enters into with
Third Party Service Providers, provided that: (a) such contracts relate to the provision of research, development and/or manufacturing
services to Centry in connection with Licensed Products; and (b) no rights are granted to the Third Party to: (i) research, develop or
manufacture its own Licensed Products; or (ii) sell Licensed Products.

 

		5.7.	The grant of a sub-licence pursuant to Clause 5.4 shall be without prejudice to Centry’s obligations
under this Agreement.

 

		5.8.	The right to grant sub-sub-licenses
                                            shall be permitted only on terms materially equivalent to Clause 5.4 (including for the avoidance
                                            of doubt inclusion in each sub-sub-license of an indemnity from the Sub-Licensee in favour
                                            of CPF Indemnified Parties) and Centry shall procure that a copy of each sub-sub-license
                                            is supplied to CPF within [***] ([***]) days of its execution. Any act or omission of any
                                            Sub-Licensee which, if it were the act or omission of Centry would be a breach of any of
                                            the provisions of this Agreement, will be deemed to be a breach of this Agreement by Centry
                                            who will be liable to CPF (as the case may be) accordingly. Centry shall be responsible for
                                            the performance or non-performance of its Sub-Licensees hereunder. In the event of a material
                                            breach by a Sub-Licensee under a sub-licence agreement with Centry that results in a material
                                            breach by Centry under this Agreement, then without prejudice to CPF’s rights under
                                            this Agreement with respect to such breach, Centry shall either terminate such sub-licence
                                            agreement or otherwise cure such material breach, in each case, at Centry’s discretion.

 

		5.9.	Upon Centry’s reasonable request CPF will transfer to Centry ownership of the Materials listed in
Part A of Schedule 8 and, subject to the agreement of a suitable assignment agreement, assign the related third-party contracts listed
in Part B of Schedule 8 subject to such third-parties granting the necessary consent to do so. Such Materials are provided to Centry as-is
and without warranty, including any implied warranties of merchantability or fitness for a particular purpose.

 

    - 19 - 

     

    

 

		6.	PERFORMANCE

 

		6.1.	Centry shall use Commercially Reasonable Efforts to:

 

		(a)	carry out the Development Plan, as amended from time to time, at its own cost and expense;

 

		(b)	pursue Regulatory Authorisation and (where applicable) Price Approvals in each of the Major Markets for
those Licensed Products in clinical development;

 

		(c)	develop
                                            and commercialise in each of the Major Markets at least one Licensed Product;

 

		(d)	ensure that (i) each Licensed Product receiving a Regulatory Authorisation that allows such Licensed Product
to be sold in the United Kingdom is made available for purchase throughout the United Kingdom within [***] ([***]) months of such Regulatory
Authorisation, and (ii) any Licensed Product that has received a United Kingdom-specific Regulatory Authorisation in respect of an Oncology
Indication is made available following First Commercial Sale throughout the United Kingdom at an Affordable price; and

 

		(e)	develop [***] ([***]) Licensed Product in at least [***] ([***]) Oncology Indication.

 

		6.2.	Centry shall:

 

		(a)	provide CPF with a Progress Report at least once every [***]months ([***]) months;

 

		(b)	promptly respond to any reasonable queries that CPF may have following receipt of a Progress Report and/or
updated Development Plan;

 

		(c)	at CPF’s request, meet, once per Year, with CRT and/or ICR in attendance alongside CPF (either in
person or by teleconference if a face-to-face meeting is not practical) to discuss the content of a particular Progress Report and/or
updated Development Plan;

 

	 	(d)	 consider in good faith any comments provided by CPF at any time concerning a Progress Report or the Development Plan;

 

	 	(e)	 at CPF’s request, identify and provide an explanation for any significant differences between the Development Plan and those activities
actually undertaken; and

 

		(f)	update the Development Plan and provide a copy of the same to CPF at least once every [***] ([***]) months.

 

    - 20 - 

     

    

 

		6.3.	Notwithstanding Clause 6.1(e) if Centry:

 

		(a)	reasonably
                                            believes that pursuing an Oncology Indication is likely to result in a product which would
                                            offer no substantial benefit to the patient population over existing drugs, or drugs in development,
                                            for the Oncology Indications for which the Licensed Product would be most suitable, or

 

		(b)	wishes
                                            to develop and commercialise (or grant rights to a Third Party to develop or commercialise)
                                            a Licensed Product in an Indication other than an Oncology Indication (an “Other
                                            Indication”) (i.e concurrently or in addition to development and commercialisation
                                            of a Licensed Product in an Oncology Indication),

 

then in either the
case of (a) or (b), Centry shall provide written notice to CPF (an “Other Indication Notice”). Where an Other Indication
Notice is provided in connection with the foregoing (a), Centry shall also set out its reasons, with supporting evidence, for such belief.
Subject to providing an Other Indication Notice to CPF, Centry shall not need to obtain the consent of CPF (or CRT or ICR) to pursue
(or to grant rights to any Sub-Licensee to pursue) the research, development or commercialization of a Licensed Product in an Other Indication
concurrently with the research, development or commercialization of Licensed Products in an Oncology Indication, provided that Centry
complies with its obligations under this Agreement, including pursuant to Clauses 6.1 and 6.2, in an Oncology Indication. For clarity,
where an Other Indication Notice is delivered by Centry pursuant to subclause (a) of this Clause 6.3, in
connection with a decision by Centry or a Sub-Licensee to cease or scale back development and commercialization in an Oncology Indication,
then Clause 6.1 and Schedule 5, Paragraph 2 (a) – (e) shall apply to such Other Indication in lieu of an Oncology Indication mutatis
mutandis, and shall determine the scope of Centry’s and/or such Sub-Licensee’s obligations, as applicable, with respect
to the development and commercialisation of Licensed Products in an Other Indication following such Other Indication Notice.

 

		6.4.	If at any time during the course of the development or commercialisation of a Licensed Product, Centry
fails to meet one or more of its obligations under Clauses 6.1 or 6.2 in relation to such Licensed Product for a period of six (6) months
or more, save where due to the acts or omissions of CPF, then CPF shall have the right to give written notice to Centry requesting detailed
written justification for such failure and Centry shall provide such detailed written justification to CPF within thirty (30) days of
the date of CPF’s request. Where remedy is possible Centry shall use its Commercially Reasonable Efforts to take substantive steps
to remedy such failure within sixty (60) days of the date of CPF’s request. If Centry fails to provide such justification to CPF
within thirty (30) days of the date of CPF’s request and/or use its Commercially Reasonable Efforts to take substantive steps to
remedy such failure within [***] ([***]) days of the date of CPF’s request, then, on notice by CPF to Centry (to be given in CPF’s
sole discretion), this Agreement will terminate in respect of the relevant Licensed Product. Any dispute between the Parties as to whether
a diligence failure has arisen or whether Centry has used its Commercially Reasonable Efforts to take substantive steps to remedy a diligence
failure shall be resolved by the Expert.

 

    - 21 - 

     

    

 

 

	7.	CONSIDERATION

 

	7.1.	Centry shall pay the Signature Fee within [***] ([***]) [***] of the Effective Date.

 

	7.2.	Milestone Payments. Upon the first occurrence of each of the events set out in Schedule 1
(each a “Milestone Event”) (or where such payment arises as the result of a “Missed Event” pursuant to
Clause 7.3) Centry shall pay to CPF the relevant payment set out in Schedule 1 (each a “Milestone Payment”).
Milestone Payments shall become due when the associated Milestone Event is reached by the first Licensed Product. (for the avoidance of
doubt no Milestone Payments would be payable in relation to further Licensed Products).

 

	7.3.	Milestone Payment Adjustments. The following adjustments shall apply to Milestone Payments pursuant
to Clause 7.2:

 

		(a)	Missed Event. Should any of the Milestone Events (A) to (E) occur at a time where a prior Milestone
Event has not yet occurred all prior Milestone Events will be deemed to have occurred and the related Milestone Payments will become payable.
By way of example, should the Milestone Event (B) (Declaration of the recommended Phase II Trial or Phase Ib Trial expansion cohort dose)
occur prior to Milestone Event (A) (Dosing of the third patient in the first Phase I Trial for a Licensed Product) the Milestone Payment
due upon occurrence of Milestone Event (A) of $[***] shall be due in addition to the Milestone Payment due upon occurrence of Milestone
Event (B) of $[***].

 

		(b)	Phase I or II Trial. In the event that a Phase I Trial or Phase II Trial is not initially designated
as a registration study but such Phase I Trial or Phase II Trial is later designated as such or serves as a basis for an NDA or equivalent
submission in any Major Market then to the extent not already settled Milestone Event (D) (Dosing of the first patient in the first Phase
II Trial or Phase III Trial designated as a Registration Study for a Licensed Product) shall be deemed to have occurred on the date that
such study was first designated as such.

 

		(c)	Marketing Approval Milestones. Milestone Events (F) to (N) are each a “Marketing Approval
Milestone” and together the “Marketing Approval Milestones”. Should Centry apply for and receive a tumour
or indication agnostic approval (a “Pan Approval”) from either the FDA and or the EC then such approval will trigger
the next two Marketing Approval Milestones (inclusive of the Marketing Approval Milestone that would have been reached if the approval
was not a Pan Approval) in the relevant Territory. By way of example, if the first marketing approval in the USA is for a specific indication
and the second marketing approval is a Pan Approval then the Milestone Payment of $[***] shall be due upon the occurrence of Milestone
Event (F) and upon Pan Approval the Milestone Payment of $[***] due upon the occurrence of Milestone Event (G) and the Milestone Payment
of $[***] due upon the occurrence of Milestone Event (H) shall both be due.

 

    - 22 -

     

    

 

		(d)	AS Milestones. If, within [***] of the date of grant of a Pan Approval in the USA or the EU, fewer
than [***] Marketing Approval Milestones have been paid for such territory then:

 

		(i)	A number of subsequent Marketing Approval Milestones that occur on the third, and fourth indications in
such territory (in the case of the USA, Milestone Events H, and I, and in the case of the EU, Milestone Events, L, and M) will be redesignated
as additional sales milestones (“AS Milestones”).

 

		(ii)	The number of Marketing Approval Milestones redesignated pursuant to Clause 7.3(d)(i) as AS Milestones
shall equal [***] ([***]) minus the number of Marketing Approval Milestones already paid. By way of example, should a Pan Approval be
granted in the USA and [***] years following the date of such Pan Approval only Milestone Events F and G have been paid [***] ([***])
Marketing Approval Milestones shall be redesignated as AS Milestones.

 

		(iii)	[***] percent ([***]%) of the aggregate value of the AS Milestones shall be payable on the achievement
of Milestone Event (P) and [***] percent ([***]%) of the aggregate value of the AS Milestones shall be payable on the achievement of Milestone
Event (Q). Should Milestone Event (P) or Milestone Event (Q) already have occurred, then the associated percentage of the aggregate value
of the AS Milestones shall become immediately due and payable on the third anniversary of the date of the Pan Approval.

 

	7.4.	Sales Milestone Payments. Upon the first occurrence of each of the events set out in Schedule 2
(each a “Sales Milestone Event”) Centry shall pay to CPF the relevant payment set out in Schedule 2 (a “Sales
Milestone Payment”). Sales Milestone Payments are each only payable on one occasion and are based on Net Sales of all Licensed
Products.

 

	7.5.	Royalties. Centry shall pay to CPF the royalties on Net Sales as set out in Schedule 3 on a Licensed
Product by Licensed Product, and country by country basis until the later of:

 

		(a)	the date when the Licensed Product is no longer within the scope of a Valid Claim of a Licensed Patent
in the country of sale or manufacture; or

 

		(b)	the expiry of any Extended Exclusivity Period in the relevant country,

 

By way of example,
should Net Sales equal $[***] in a Calendar Year, the royalties would be calculated as follows:

 

[***]% x $[***] =
$[***]

 

[***]%
x $[***] = $[***]

 

[***]%
x $[***] = $[***]

 

Total
= $[***]

 

    - 23 -

     

    

 

	7.6.	Generic Reduction. If a Generic Product for a Licensed Product is being sold in such country, the
royalties payable by Centry in respect of that country and that Licensed Product shall, subject to Clause 7.8, be reduced by (i) [***]
percent ([***]%) from the first full Calendar Quarter after the date on which Level 1 Generic Competition first exists in such country,
and (ii) [***] percent ([***]%) from the first full Calendar Quarter after the date on which Level 2 Generic Competition first exists
in such country, but only for so long as the applicable (Level 1 or Level 2) Generic Product is being sold in such country.

 

	7.7.	If Centry reasonably determines, upon the written advice of intellectual property counsel of at least
15 years’ experience in pharmaceutical patents, that a license to patent rights from a Third Party covering the composition of matter
or method of use of a Licensed Compound is necessary for Centry to develop, manufacture and/or commercialize such Licensed Compound, Centry
may, subject to Clause 7.8, obtain such a Third Party license and deduct from any royalties due hereunder an amount equal to [***] percent
([***]%) of any royalties paid by Centry to such Third Party.

 

	7.8.	Notwithstanding the provisions of Clauses 7.6 and 7.7 in no event may the royalties payable to CPF be
reduced to less than [***] percent ([***]%), provided always that Centry may carry forward and offset against future royalty payments,
any amounts not able to be deducted or offset as a result of the application of this Clause 7.8.

 

	7.9.	Within [***] ([***]) days after the end of each Quarter during the Term of the Agreement following the
First Commercial Sale of a Licensed Product, Centry shall furnish to CPF a quarterly written report showing in reasonably specific detail:

 

		(a)	The calculation of Net Sales during such Quarter;

 

		(b)	the calculation of royalties, if any, that have accrued based upon such Net Sales,

 

		(c)	the withholding taxes, if any, required by law to be deducted with respect to such sales; and

 

		(d)	the exchange rates, if any, used in determining the amount of United States dollars.

 

	8.	RESEARCH SUPPORT

 

	8.1.	Centry shall support a programme of research work to be carried out principally at the ICR (the “Research
Programme”). Centry shall negotiate the specifics of such Research Programme, with a target budget of US$[***] in good
faith with the ICR within a reasonable period following the Effective Date. The Parties shared intention is that the Research Programme
will be focused on the mechanism of action of CCT361814 and the identification of patient selection biomarkers. Execution of the Research
Programme will be overseen by the JDC.

 

    - 24 -

     

    

 

	9.	PAYMENT

 

	9.1.	All payments due to CPF under this Agreement shall be made in United States Dollars (USD) in cleared funds
to the following bank account or such other account as CPF may notify Centry from time to time:

 

Account name: [***]

 

Account number: [***]

 

Sort code: [***]

 

IBAN: [***]

 

	9.2.	Where Licensed Products are sold in a currency other than United States Dollars (USD) the rate of exchange
to be used for converting such other currency into United States Dollars (USD) shall be the relevant average of the exchange rate (local
currency per USD$1) published in the Wall Street Journal, under the heading “Currency Trading”, on the first Business Day
on which the royalty is received in cleared funds by Centry.

 

	9.3.	All costs of transmission and currency conversion shall be borne by Centry.

 

	9.4.	Taxes:

 

		(a)	All payments under this Agreement are exclusive of Taxes howsoever arising. The Parties shall issue invoices
for all goods and services supplied under this Agreement consistent with indirect Tax requirements.

 

		(b)	All payments hereunder will be made net of any applicable withholding or similar Taxes and the payor
                                                                                                         may withhold any such withholding or similar Taxes from payments made hereunder. The payor will provide the payee with official
                                                                                                         receipts issued by the appropriate taxing authority or other evidence as is reasonably requested by the payee to establish that such
                                                                                                         Taxes have been paid. If, after any payment has been made, it is determined by the appropriate taxing authorities that additional
                                                                                                         withholding Taxes are due with respect to such payment, the payee will directly pay such amounts or reimburse the payor for any
                                                                                                         payment that the payor makes. For purposes of this Agreement, “Taxes” shall mean and include without limitation
                                                                                                         (i) taxes on gross or net income, profits and gains; and (ii) all other taxes, levies, charges and withholdings of any nature,
                                                                                                         including any excise, property, value added, sales, use, consumption,
occupation, transfer, franchise and payroll taxes and all customs, duties and other governmental impositions whatsoever which such party
may be or become bound to pay to any governmental entity, together with all penalties, charges and interest relating to the foregoing.
The Parties shall cooperate in accordance with applicable laws to minimize Taxes in connection with this Agreement. Each Party agrees
to provide reasonable assistance to the other Party with respect to any claim of refund or exemption from Taxes under any relevant agreement
or treaty which is in effect to ensure that any amounts required to be withheld pursuant to this Clause 9.4(b) are reduced in amount to
the fullest extent permitted by applicable laws. Any and all expenses incurred by a Party in providing such assistance shall be fully
reimbursed by the other Party.

 

    - 25 -

     

    

 

		(c)	Notwithstanding the foregoing, if Centry redomiciles, or if its assignee pursuant to Clause 20 is domiciled
at the time of such assignment, or subsequently redomiciles to a jurisdiction outside the United States (other than the United Kingdom)
and, if as a result of such action, Centry (or its assignee pursuant to Clause 20) is required by applicable law to withhold Taxes in
respect of any amount payable under this Agreement, and such withholding Taxes exceed the amount of withholding Taxes that would have
been applicable if such action had not occurred, then any such amount payable shall be increased to take into account such increased withholding
Taxes as may be necessary so that, after making all required withholdings CPF (or its assignee pursuant to Clause 20) receives an amount
equal to the sum it would have received had no such increased withholding been made; provided, however, Centry will have no obligation
to pay any additional amount under Clause 9.4(b) or this Clause 9.4(c) to the extent that such increased withholding Tax would not have
been imposed but for (A) the assignment by CPF pursuant to Clause 20 of its rights under this Agreement, the assignment or transfer of
any interest in CPF by its direct and indirect owners, or any redomiciliation of CPF (including CPF’s direct and indirect owners),
or (B) the failure by CPF (including its direct and indirect owners) to comply with the requirements of Clause 9.4(d).

 

		(d)	Each Party shall provide a properly completed and duly executed IRS Form W-9 to the other Party in accordance
with Clause 9.4(c). Each Party, including but not limited to the direct or indirect owners of CPF, and any other direct or indirect recipient
of payments under this Agreement shall provide to the other Party, within [***] ([***]) [***] following the Effective Date and at such
other time or times as reasonably requested by such other Party or as required by applicable laws, such properly completed and duly executed
documentation (for example, IRS Forms W-8 or W-9) as will permit payments made under this Agreement to be made without, or at a reduced
rate of, withholding for Taxes.

 

	9.5.	Within [***] ([***]) days after the end of each Quarter, Centry shall send to CPF a written statement
detailing in respect of that Quarter (including a nil report if appropriate):

 

    - 26 -

     

    

 

		(a)	any Milestone Event achieved by it or any Sub-Licensee and any Milestone Payment which became due to CPF;

 

		(b)	the quantity of Licensed Product sold or otherwise disposed of by Centry or any Sub-Licensees in the Territory;

 

		(c)	the Net Sales in respect of each such type of Licensed Product in each country of the Territory;

 

		(d)	the aggregate Net Sales in respect of that Quarter for Licensed Product;

 

		(e)	the type and value of deductions made in the calculation of Net Sales by type of Licensed Product and
country;

 

		(f)	subject to Clause 9.2, any currency conversions, showing the rates used;

 

		(g)	any further information necessary for the calculation of Net Sales of Licensed Products and/or the royalties
due to CPF; and

 

		(h)	the amount of the royalties due to CPF in respect of that Quarter.

 

	9.6.	Where CPF does not receive payment of any sums properly due and payable to it under this Agreement within
the relevant period, interest shall accrue on such sum at the rate equivalent to an annual rate of [***] percent ([***]%) over the then
current base rate of the Bank of England, calculated on a daily basis, without prejudice to the payee’s right to receive payment
within the relevant period.

 

	9.7.	Centry shall notify CPF in writing within [***] ([***]) days of the occurrence of any Milestone Event.

 

	10.	ACCOUNTS

 

	10.1.	Centry shall:

 

		(a)	keep and notwithstanding the expiry or termination of this Agreement, maintain and shall use its Commercially
Reasonable Efforts to procure that each Sub-Licensee keeps and maintains, for at least [***] ([***]) [***], true and accurate accounts
and records (including any underlying documents supporting such accounts and records) in sufficient detail to enable the amount of all
sums payable under this Agreement to be determined; and

 

		(b)	during the Term and thereafter until the period of [***] ([***]) [***] relevant to the accounts and records
has expired, no more frequently than once a [***], at the reasonable request of CPF and at the expense of CPF
from time to time, permit or procure permission for a qualified accountant nominated by CPF, and reasonably acceptable to Centry, to inspect
and audit those accounts and records and, to the extent that they relate to the calculation of those sums, to take copies of them.

 

    - 27 -

     

    

 

	10.2.	If, following any inspection pursuant to Clause 10.1(b), and in the absence of manifest error, CPF’s
nominated accountant certifies that the payments in respect of any Quarter or Year fall short of the sums which were properly payable
in respect of that Quarter or Year under this Agreement, CPF shall send a copy of the certificate to Centry and Centry shall, within seven
(7) days of the date of receipt of the certificate, pay the shortfall to CPF, and if the shortfall exceeds [***] per cent ([***]%) of
the sum properly payable, Centry shall also reimburse to CPF its costs and expenses in making the inspection (for the avoidance of doubt
including any fees charged by the nominated accountant).

 

	10.3.	CPF shall cause its accounting firm to retain all financial information subject to review under this Clause
10 in strict confidence; provided, however, that Centry shall have the right to require that such accounting firm, prior to conducting
such audit, enter into an appropriate non-disclosure agreement with Centry regarding such financial information. The accounting firm shall
disclose to CPF only whether the reports are correct or not and the amount of any discrepancy. No other information shall be shared. CPF
shall treat all such financial information as Centry’s Confidential Information.

 

	10.4.	If, within seven (7) days of the date of receipt by Centry of any certificate produced pursuant to Clause
10.2, Centry notifies CPF in writing that it disputes the certificate, the dispute shall be referred for resolution by the Expert in accordance
with Clause 31.

 

	11.	INTELLECTUAL PROPERTY MANAGEMENT

 

	11.1.	All Patent Costs incurred after the Effective Date shall be met solely by Centry.

 

	11.2.	The ownership of the Licensed Intellectual Property shall, at all times, remain vested solely in CRT,
ICR and/or CPF as applicable.

 

	11.3.	Subject to Clauses 11.4, 11.5, 11.6 and 11.7 Centry shall be responsible for filing, prosecuting, and
maintaining the Licensed Patents in CRT, ICR or CPF’s sole name and will use its Commercially Reasonable Efforts to maximise the
duration and scope of the Licensed Patents in the Target Patent Countries.

 

	11.4.	Notwithstanding anything to the contrary in this Agreement, until Centry has satisfied the Financing Commitment
CPF shall have the final decision making authority relating to the filing strategy for the Licensed Patents, as further set out in Clause
4.4.

 

    - 28 -

     

    

 

	11.5.	Centry shall discuss the filing strategy for the Licensed Patents with CPF and shall take into consideration
all comments received from CPF in respect of such strategy. If Centry elects not to file a Patent application, in any Target Patent Country,
Centry shall promptly notify CPF of such decision and CPF shall have the right (but not the obligation) to file such an application and
may transfer this right to CRT in its sole discretion. If CPF elects to exercise such right by notice in writing to Centry, CPF shall
thereafter be solely responsible for the expense of filing, prosecuting and maintaining the corresponding Patent, which shall be excluded
from the definition of Licensed Patents and the license granted under Clause 5.

 

	11.6.	Centry shall keep CPF reasonably informed in writing as to the prosecution and/or maintenance status of
the Licensed Patents and shall promptly provide CPF with a copy of all submissions made to or responses received from the relevant Patent
offices and all correspondence to and responses received from the relevant Patent agent in relation to the Licensed Patents in each applicable
country of the Territory. Centry shall use Commercially Reasonable Efforts to notify CPF at least [***] ([***]) [***] prior to any restriction
of scope of any of the Licensed Patents.

 

	11.7.	If Centry elects not to prosecute and/or maintain any part of the Licensed Patents in any Target Patent
Country, Centry shall notify CPF in writing at least [***] ([***]) [***] prior to the expiration of any applicable time bars. During the
aforementioned [***] ([***]) [***] notice period, Centry shall continue to prosecute and maintain the Licensed Patents in question. On
the expiry of such notice period:

 

		(a)	the licence granted pursuant to Clause 5.1 shall terminate in respect of the Licensed Patents identified
in such notice;

 

		(b)	Centry shall, at CPF’s request, promptly transfer to CPF any and all documents and information in
Centry’s control relating to such Licensed Patents; and

 

		(c)	CPF shall be free to prosecute or abandon such Licensed Patents at its sole discretion and to grant rights
thereunder to any person without further reference to Centry.

 

	11.8.	Each Party will promptly notify the other Parties in writing as soon as it becomes aware of any infringement
or suspected infringement by a Third Party of any of the Licensed Patents or any unauthorised use of the Licensed Know How or the Licensed
Materials.

 

	11.9.	Provided Centry has a licence under this Agreement in relation to the relevant Licensed Patent and country
(and where local law permits), within such country Centry may:

 

		(a)	at its own cost and subject to Clause 11.10, bring proceedings in its own name or, if required by law,
jointly with CPF, for infringement of the Licensed Patents in the Field; and

 

		(b)	in any such proceedings settle any claim for infringement of the Licensed Patents in the Field, provided
it obtains the prior written consent of CPF, where any such settlement would result in a restriction to the scope of such Licensed Patent.

 

    - 29 -

     

    

 

	11.10.	Any damages, profits, and awards of whatever nature recovered by Centry for such infringement shall be
treated as Net Sales subject to a deduction for Centry’s external legal expenses insofar as these are not recovered from a Third
Party provided always, where damages are also awarded to CPF to the extent that this would otherwise result in a double receipt by CPF
of royalties Centry shall be entitled to deduct any such duplicated payment from any royalties payable to CPF. In any such proceedings,
CPF shall, at Centry’s cost, promptly provide Centry with all documents and assistance as Centry may reasonably require. Centry
shall promptly provide CPF with notice of such proceedings and keep CPF regularly informed of progress and promptly provide CPF with such
information as CPF may require including copies of all documents filed at court in the proceedings. If CPF are joined to proceedings pursuant
to this Clause 11.10 or otherwise, Centry shall indemnify and hold harmless the CPF Indemnified Parties and the inventors named in any
Licensed Patents (the “CPF Indemnitees”) from and against any and all claims, demands, losses, causes of action, damages and
expenses (including without limitation, legal fees) arising from or in connection with such proceedings. If Centry does not exercise its
right to bring proceedings pursuant to Clause 11.9 within [***] ([***]) [***] of written request to bring proceedings from CPF, then CPF
shall be entitled, but not obliged to bring such proceedings at its own cost. If necessary, including to recover damages, subject to Centry’s
consent (such consent not to be unreasonably withheld or delayed it being agreed that the lack of indemnity protection for Centry would
be reasonable grounds to refuse consent) CPF may require Centry to join in such proceedings. In any such proceedings the Parties not bringing
the proceedings (“Inactive Parties”) shall promptly provide the Party bringing proceedings (“Active Party”)
with all documents and assistance as the Active Party may reasonably require and the Active Party shall promptly provide the Inactive
Parties with notice of such proceedings.

 

	11.11.	The Parties shall, at the request of any of them and at the expense of the requesting Party but for no
further consideration, enter into such confirmatory Patent licences relating to the Licensed Patents, substantially in the form set out
in Schedule 7, as may be necessary or desirable in accordance with the relevant law and practice in each country in the Territory
for registration at the relevant patent offices so that this Agreement need not be registered or recorded unless the Parties are required
to do so by law. If there are any inconsistencies between the terms of any such confirmatory Patent licence and the provisions of this
Agreement, this Agreement shall prevail.

 

	11.12.	With respect to each Licensed Product, Centry shall, at the time of receipt of the relevant Regulatory
Authorisation, or such other time as appropriate, apply for a Supplementary Protection Certificate, Patent term extension and/or any other
exclusivity in respect of such Licensed Product. At Centry’s reasonable request and sole cost, CPF will provide reasonable assistance
to Centry in connection with any such applications.

 

    - 30 -

     

    

 

	12.	WARRANTY

 

	12.1.	Each Party acknowledges that, in entering into this Agreement, it does not do so in reliance on any warranty
or other provision except as expressly provided in this Agreement, and all conditions, warranties, terms and undertakings implied by statute,
common law or otherwise are excluded from this Agreement to the fullest extent permissible by law.

 

	12.2.	Each Party warrants to the other Party that it has the power and authority and the legal right to enter
into this Agreement to which it is a Party and to perform its obligations hereunder and has taken all necessary action on its part required
to authorise the execution and delivery of this Agreement to which it is a Party. This Agreement has been duly executed and delivered
on behalf of such Party and in the case of CPF execution on its behalf by the General Partner constitutes a legal, valid and binding execution
and is enforceable against it in accordance with its terms.

 

	12.3.	CPF warrants that: (i) the Data Room includes a complete list or description of all information in CPF’s
possession that CPF believes to be material to the manufacture, use, or composition of CCT361814 and (ii) the Upstream Agreement: (a)
has not been amended as of the Effective Date other than as disclosed in the Data Room, (b) is in full force and effect, (c) has not been
materially breached by CPF or, to CPF’s knowledge, by any other party thereto and (d) no party thereto has waived any of its materials
rights thereunder.

 

	12.4.	CPF covenants that (i) CPF shall not, without the prior written consent of Centry, waive its rights under
or agree to any amendment of the Upstream Agreement if such waiver or amendment would prejudice or impair any rights granted to Centry
hereunder, including the scope of any rights granted herein to the Licensed Intellectual Property and (ii) if any party to the Upstream
Agreement provides notice to any other party of a breach of the Upstream Agreement, that CPF will provide written notice thereof to Centry
within ten (10) Business Days and shall provide Centry, on an ongoing basis, with such additional information in connection therewith
as Centry may reasonably request.

 

	12.5.	Except as expressly set forth herein, CPF does not give any warranty, representation or undertaking in
relation to the Licensed Intellectual Property, including any warranty, representation or undertaking:

 

		(a)	as to the efficacy, usefulness, completeness or accuracy of the Licensed Intellectual Property; or

 

		(b)	that any of the Licensed Patents is or will be valid or that any of the applications within the Licensed
Patents will proceed to grant; or

 

		(c)	that the use of any Licensed Intellectual Property, including without limitation any invention claimed
in a Licensed Patent, or the exercise of any rights granted under this Agreement will not infringe the intellectual property or other
rights of any other person.

 

    - 31 -

     

    

 

	13.	INDEMNITY

 

	13.1.	Centry shall indemnify, defend and hold harmless CPF Indemnified Parties from and against any and all
Third Party claims, demands, losses, damages, costs and expenses (including, without limitation, legal fees) (together “Losses”)
to which any CPF Indemnified Party may become subject as a result of any claim, demand, action, suit, investigation, or other proceeding
by any Third Party (each a “Third Party Claim”) arising from or in connection with (a) the exercise by Centry or a
Sub-Licensee of the rights granted in Clause 5.1 or the actions of Centry, or a Sub-Licensee in relation to a Licensed Product; (b) the
negligence or wilful misconduct of Centry or any of its Affiliates, licensees or subcontractors, (c) the performance by or on behalf of
Centry or any of its Affiliates, or Third Party Service Providers of Centry’s obligations under this Agreement, or (d) the breach
by Centry of any warranty, representation, covenant, or agreement made by Centry under this Agreement; except, in each case, to the extent
such losses result from any act or omission of any CPF Indemnitee for which CPF is obligated to indemnify under Section 13.2.

 

	13.2.	CPF shall indemnify, defend and hold harmless Centry, and its Affiliates, its Sub-Licensees and its and
their respective directors, officers, employees, and agents (each, a “Centry Indemnified Party”) from and against any
and all Losses to which any Centry Indemnified Party may become subject as a result of any Third Party Claim to the extent such Losses
arise from or in connection with (a) the negligence or wilful misconduct of CPF or any of its Affiliates, licensees or subcontractors,
(b) the performance by or on behalf of CPF or any of its Affiliates, or Third Party Service Providers of CPF’s obligations under
this Agreement, or (c) the breach by CPF of any warranty, representation, covenant, or agreement made by CPF under this Agreement; except,
in each case, to the extent such losses result from any act or omission of any Centry Indemnified Party for which Centry is obligated
to indemnify under Section 13.1.

 

	13.3.	Promptly after receipt by CPF of any claim or alleged claim or notice of the commencement of any action,
administrative or legal proceeding, or investigation to which the indemnity provided for in this Clause 13 may apply, CPF shall give written
notice to Centry of such fact and Centry shall have the option to assume the defence thereof by election in writing within [***] ([***])
[***] of receipt of CPF’s notice. If Centry fails to make such election, a CPF Indemnified Party may assume such defence and Centry
will be liable for the legal and other expenses consequently incurred in connection with such defence.

 

	13.4.	The Parties will co-operate in good faith in the conduct of any defence, will provide such reasonable
assistance as may be required to enable any claim to be defended properly and the Party with conduct of the action shall promptly
provide to the other Party copies of all correspondence and documents and notice in writing of the substance of all oral communications
relating to such action.

 

    - 32 -

     

    

 

	13.5.	Prior to commencing any proceedings under this Clause 13, upon the request of CPF, Centry shall (or shall
procure that its Sub-Licensee shall) enter into a separate agreement with CPF (or at CPF’s request, with any other CPF Indemnified
Parties) pursuant to which Centry (or the Sub-Licensee if applicable) shall indemnify the CPF Indemnitees in respect of any and all potential
Third Party claims, demands, losses, damages, costs and expenses (including, without limitation, legal fees) which might arise directly
or indirectly as a consequence of such proceedings being concluded successfully or unsuccessfully (including without limitation any anti-trust
proceedings commenced by a Third Party (for example, alleging that the price of any Licensed Product has been kept artificially high through
the maintenance of Patents which are invalid and/or unenforceable for any reason)).

 

	13.6.	Should Centry assume conduct of the defence:

 

		(a)	Any CPF Indemnified Party may retain separate legal advisers, at its sole cost and expense;

 

		(b)	Centry will not, except with the written consent of such CPF Indemnified Party, such consent not to be
unreasonably withheld, delayed or conditioned, consent to the entry of any judgment or enter into any settlement provided always, that
if the CPF Indemnified Parties shall not consent to such entry of judgment or settlement, and such judgment or settlement does not involve
an admission of liability on the part of any CPF Indemnified Party then the amount which the CPF Indemnified Parties shall be entitled
to recover from Centry pursuant to this Clause 13 shall be limited to the amount that they would have received if the action would otherwise
have been settled; and

 

	13.7.	No CPF Indemnified Party shall admit liability in respect of, or compromise or settle any such action
without the prior written consent of Centry, such consent not to be unreasonably withheld, conditioned or delayed.

 

	14.	INSURANCE

 

	14.1.	Centry shall put in place and maintain, during the Term and for at least [***] ([***]) [***] following
the Term, comprehensive product liability insurance and general commercial liability insurance through a reputable insurance company.
Such insurance shall be at Centry’s own cost and expense.

 

	14.2.	At CPF’s request, Centry shall provide CPF with a certificate evidencing the coverage required pursuant
to Clause 14.1 and the noting of CPF’s interest in such insurance.

 

    - 33 -

     

    

 

	15.	LIMITATION OF LIABILITY

 

	15.1.	Subject to Clause 15.3 neither Party, nor its Affiliates, nor any of their respective directors, officers,
employees, or agents shall have any liability of any type (including contractual or tortious liability) arising out of or in connection
with this Agreement in respect of:

 

		(a)	any consequential or indirect loss; and/or

 

		(b)	any loss of goodwill, opportunity, profit or contract, in either case even if advised in advance of the
possibility of such losses.

 

	15.2.	Subject to Clause 15.3 CPF’s liability to Centry including for its breach of this Agreement, CPF’s
negligence, or arising in any other way out of or in connection with this Agreement shall not exceed [***] USD ($[***]) in aggregate.

 

	15.3.	Nothing in this Agreement shall limit or exclude either Party’s liability (or that of their respective
Affiliates or sub-licensees) for:

 

		(a)	Death or personal injury caused by its negligence;

 

		(b)	fraud or fraudulent misrepresentation; or

 

		(c)	any other liability which cannot be limited or excluded under Applicable Law.

 

	16.	CONFIDENTIALITY

 

	16.1.	Each Party (the “Receiving Party”) undertakes with each other Party (the “Disclosing
Party”) that it shall keep, and it shall procure that its respective directors, partners, officers, employees and agents (collectively,
 “Representatives”) shall keep, secret and confidential all Confidential Information of the Disclosing Party and shall
not publish or disclose the same or any part of the same to any person whatsoever for [***] ([***]) [***] from the date of receipt other
than:

 

		(a)	in the case of Centry to: (i) Sub-Licensees and Third Party Service Providers, subject to compliance with
Clauses 5.3, 5.5 and 20 respectively; (ii) investors in Centry pursuant to its obligations under applicable laws and regulations (in particular
but without limitation those of the Financial Conduct Authority); (iii) Competent Authorities in the Territory as necessary in communications
relating to the Licensed Products; (iv) potential Sub-Licensees and potential Third Party Service Providers; and (v) ICR, provided that
any such persons have agreed to be bound by a legal obligation of confidentiality no less restrictive than that set forth in this Clause
16;

 

		(b)	in the case of CPF (a) to ICR, CRUK and CRT, (b) to CPF’s potential or actual investment bankers,
acquirers, lenders, investors or collaborators, and (c) legal advisors of any of the foregoing in (a) and (b), provided that any such
persons have agreed to be bound by a legal obligation of confidentiality similar to those set forth in this Clause 13.

 

		(c)	in the case of each Party, to its Representatives directly or indirectly concerned in the exercise of
the rights granted under this Agreement.

 

    - 34 -

     

    

 

	16.2.	Each Party shall ensure that each of its Representatives to whom any Confidential Information is disclosed
shall previously have been informed of the confidential nature of the Confidential Information and shall have agreed to be bound by a
legal obligation of confidentiality no less restrictive than that set forth in this Clause 16.

 

	16.3.	The provisions of Clauses 16.1 and 16.2 shall not apply to Confidential Information which:

 

		(a)	the Receiving Party can demonstrate by reference to written records to have been in its possession (other
than under an obligation of confidence to the Disclosing Party or to a Third Party) at the date of receipt;

 

		(b)	the Receiving Party can demonstrate by reference to written records that it received from a Third Party
without obligation of confidence to the Disclosing Party after receipt from the Disclosing Party;

 

		(c)	enters the public domain otherwise than through a breach of any obligation of confidentiality owed to
the Disclosing Party; or

 

		(d)	the Receiving Party can prove it has independently developed without direct or indirect access to any
of the Disclosing Party’s Confidential Information.

 

	16.4.	The Receiving Party may disclose Confidential Information to the extent that such disclosure is:

 

		(a)	necessarily required of the Receiving Party by order of a Competent Authority or otherwise by applicable
law; provided, that the Receiving Party shall, to the extent practicable in the time available and where legally permissible, first have
given notice to the Disclosing Party and shall provide such assistance to the Disclosing Party as it may reasonably require in order for
it to make an application to quash any such order or obtain a protective order requiring that the Confidential Information the subject
of such order be held in confidence by such Competent Authority or, if disclosed, be used only for the purpose for which the order was
issued; and provided further that if such order is not quashed or a protective order is not obtained, the Confidential Information disclosed
in response to such order shall be limited to that information that is legally required to be disclosed in response to such order;

 

		(b)	made by the Receiving Party to a patent authority as may be necessary or useful for the purposes of obtaining
or enforcing a Licensed Patent (consistent with the terms and conditions of Clauses 11.3 and 11.9), provided, however, that reasonable
measures shall be taken to assure confidential treatment
of such information, to the extent such protection is available; or

 

		(c)	required with regard to the disclosure requirements of a national securities exchange or other stock market
or of a related regulatory body on which the Receiving Party’s securities are or are proposed to be traded, provided it has used
reasonable endeavours in the time available to provide notice to the Disclosing Party of the terms of any such disclosure beforehand.

 

    - 35 -

     

    

 

	16.5.	The Receiving Party agrees that the disclosure of the Disclosing Party’s Confidential Information
without the express written consent of the Disclosing Party may cause irreparable harm to the Disclosing Party, and that any breach or
threatened breach of this Agreement by the Receiving Party may entitle the Disclosing Party to injunctive relief, in addition to any other
legal remedies available to it, in any court of competent jurisdiction.

 

	16.6.	The provisions of this Clause 16 shall remain in force for a period of [***] ([***]) [***] from the expiry
or termination of this Agreement.

 

	17.	TERM AND TERMINATION

 

	17.1.	This Agreement will become effective on the Effective Date. Subject to the provisions of this Clause 17.1
it will remain effective in each country of the Territory until the expiry of the obligation upon Centry to pay royalties in relation
to that country pursuant to this Agreement.

 

	17.2.	CPF shall have the right to terminate this Agreement on [***] ([***]) [***] written notice in the event
that Centry has not, demonstrated to CPF’s reasonable satisfaction within eighteen months of the Effective Date:

 

		(a)	Received, in addition to the amount referred to in Clause 3,
a minimum amount of [***] dollars (USD $[***]) in financing to be used to fund Centry’s operations and otherwise to support Centry’s
performance of its obligations pursuant to this Agreement; provided that, if Centry has secured a minimum of [***] dollars (US$[***])
but such amounts are to be received in tranches (or are otherwise subject to conditions or the passage of time prior to receipt), then
Centry shall summarise the amounts, tranching and conditions related thereto in writing and provide the same to CPF (the “Written
Notice”) and thereafter CPF shall in its absolute discretion decide whether to waive its rights under this Clause 17.2 within
fifteen (15) Business Days of receipt of the Written Notice; and

 

		(b)	provide evidence of obtaining such financing to CPF’s
reasonable satisfaction;

 

(a) and (b) together
the “Financing Commitment”.

 

    - 36 -

     

    

 

	17.3.	Without prejudice to any other rights of the Parties, this Agreement
may be terminated by notice in writing:

 

		(a)	by either Party if the other Party is in material breach of any of its obligations under this Agreement
and in the case of a remediable breach fails to remedy the breach within ninety (90) Business Days of written notice containing full particulars
of the breach and requiring it to be remedied;

 

		(b)	by either Party if a voluntary arrangement is proposed or approved or an administration order is made,
or a receiver or administrative receiver is appointed of any of the other Party’s assets or undertakings or a winding-up resolution
or petition is passed (otherwise than for the purpose of solvent reconstruction or amalgamation, in particular with respect to any reorganisation
of the structure of the relevant Party) or if any circumstances arise which entitle a court or a creditor to appoint a receiver, administrative
receiver or administrator or make a winding-up order or similar or equivalent action is taken against or by the relevant Party by reason
of its insolvency or in consequence of debt;

 

		(c)	by CPF if Centry (or any Affiliate or Sub-Licensee) challenges or seeks to challenge the validity of any
of the Licensed Patents (either by making, causing to be made, or assisting with respect to a filing in any patent office or court), and
Centry shall forthwith in writing notify CPF of any decision to challenge the Licensed Patents which it makes or of which it becomes aware;

 

		(d)	by CPF in the event of a change of Control of Centry where the new Controlling party is a Tobacco Party;

 

		(e)	in accordance with Clause 19.2 or

 

		(f)	in accordance with Clause 6.4.

 

	18.	EFFECTS OF TERMINATION

 

	18.1.	Upon the termination of this Agreement for any reason:

 

		(a)	payment of royalties and all other sums due to CPF shall become payable to CPF immediately upon notice
of termination of this Agreement;

 

		(b)	Centry shall, within fourteen (14) days of notice of termination of this Agreement provide CPF with a
final written statement detailing, in respect of the time elapsed since the last report under Clause 9.5, the matters set out in Clause
9.5;

 

    - 37 -

     

    

 

		(c)	Centry shall consent to the revocation of any confirmatory patent licence relating to the Licensed Patents
granted pursuant to Clause 11.11 and the cancellation of the registration of any such licence in any register;

 

		(d)	Centry shall promptly transfer to CPF (or any person nominated by CPF) any and all documents and information
in Centry’s Control relating to the Licensed Patents and CPF shall assume responsibility for the prosecution and maintenance of
the same;

 

		(e)	the licences granted to Centry pursuant to Clause 5 shall terminate forthwith and Centry shall (and unless
a licence is granted directly to the Sub-Licensee shall procure that its Sub-Licensees shall) immediately cease to exploit the Licensed
Intellectual Property in any way, either directly or indirectly;

 

		(f)	Centry shall, at the request and option of CPF, return or destroy the Licensed Know How and the Licensed
Materials in its possession or control; and

 

		(g)	in the event that Centry has signed a sub-licence, such sub-licence shall terminate and (in accordance
with Clause 5.5(d)) CPF shall immediately grant to the affected Sub-Licensee a sub-licence on materially the same terms as those set-
out in this Agreement and in particular this shall not result in CPF taking on any more onerous obligations than it is under pursuant
to this Agreement.

 

	18.2.	Upon termination of this Agreement pursuant to Clause 17.2:

 

		(a)	Centry shall at its cost and at CPF’s request, transfer to CPF (or its nominee) as soon as practicable
any Regulatory Authorisations, Price Approvals and other permits and applications relating to Licensed Products; and cancel, and consent
to the cancellation by CPF, of the registration of this Licence Agreement with any national Patent registry or other relevant Competent
Authority; and

 

		(b)	should CPF grant a licence to a Third Party to the Licensed Intellectual Property and/or the Arising Intellectual
Property to further develop Licensed Compounds (a “Re-Partnering Licence”) CPF shall pay to Centry [***]% of any milestone
payments received under such Re-Partnering Licence, capped at [***]% of the costs invested by Centry in the course of its obligations
pursuant to the Development Plan, for the avoidance of doubt such costs excluding any fees or payments made by Centry to CPF pursuant
to this Agreement.

 

    - 38 -

     

    

 

	18.3.	Except where this Agreement is subject to termination by Centry pursuant to Clause 17.3(a), in the event
that CPF desires to proceed with the development and/or exploitation of any Licensed Products:

 

		(a)	Centry shall, at CPF’s cost, within [***] ([***]) days of the date of termination of this Agreement
disclose to CPF (or its nominee) all Arising Intellectual Property, and transfer any documents and information within Centry’s control
relating to the filing and prosecution of any Patents comprised in Arising Intellectual Property;

 

		(b)	Centry shall assign to CPF all Owned Arising Intellectual Property;

 

		(c)	Centry hereby grants to CPF as the case may be a royalty-free and fully paid-up (subject to Clause 18.3(e)),
perpetual, irrevocable, sub-licensable, worldwide licence under the Other Arising Intellectual Property to research, develop, make, have
made, market, use and sell Licensed Products. Such licence shall be exclusive in respect of any Other Arising Intellectual Property that
relates solely to Licensed Products (“Exclusive Other Arising Intellectual Property”) and otherwise non-exclusive;

 

		(d)	CPF shall be solely responsible for the prosecution and maintenance of all Patents comprised within Exclusive
Other Arising Intellectual Property (at CPF’s sole expense);

 

		(e)	Centry shall inform CPF of any amounts that are or shall be payable by CPF to any Third Party relating
to the Other Arising Intellectual Property within [***] ([***]) days of the date of termination. CPF may refuse to take a license of any
such Other Arising Intellectual Property that would create a payment obligation upon CPF in which case the relevant intellectual property
rights shall be excluded from the definition of Arising Intellectual Property. If CPF does not refuse to take such a license, CPF shall
be solely responsible for any amounts that have been disclosed to it and that are payable to any Third Party from which Centry licensed
any intellectual property that is within the Other Arising Intellectual Property to the extent such amounts are payable in connection
with CPF’s receipt or exercise of such license from Centry; and

 

		(f)	Centry shall, at CPF’s request and cost, transfer to CPF (or its nominee) as soon as practicable
any Regulatory Authorisations, Price Approvals and other permits and applications relating to Licensed Products; and cancel, and consent
to the cancellation by CPF, of the registration of this Licence Agreement with any national Patent registry or other relevant Competent
Authority.

 

	18.4.	In the event that CPF does not take up the licence set out in Clause 18.2, the right to take such licence
shall pass to CRT or ICR mutatis mutandis.

 

	18.5.	Clauses 1, 2, 5.3, 10, 11.10, 13, 14, 15, 16, 18, and 21-30 inclusive as well as any other clauses which
by their nature should survive, shall survive termination of this Agreement and shall be binding on the respective successors, assigns
and associated companies of each Party.

 

    - 39 -

     

    

 

	19.	FORCE MAJEURE

 

	19.1.	If a Party is unable to carry out any of its obligations under this Agreement due to Force Majeure (the
 “Non-Performing Party”) this Agreement shall remain in effect but the Non-Performing Party’s relevant obligations
under this agreement and the relevant obligations of the other Parties (the “Innocent Parties”) under this Agreement
shall be suspended for the duration of the circumstance of Force Majeure provided that:

 

		(a)	the suspension of performance is of no greater scope than is required by the Force Majeure;

 

		(b)	the Non-Performing Party gives the Innocent Parties prompt notice describing the circumstance of Force
Majeure, including the nature of the occurrence and its expected duration, and continues to furnish regular reports during the period
of Force Majeure;

 

		(c)	the Non-Performing Party uses all reasonable efforts to remedy its inability to perform and to mitigate
the effects of the circumstance of Force Majeure; and

 

		(d)	as soon as practicable after the event which constitutes Force Majeure the Parties shall discuss how best
to continue their operations as far as possible in accordance with this Agreement.

 

	19.2.	If the Force Majeure continues for [***] ([***]) [***] or more, the Innocent Party may give twenty (20)
Business Days written notice to terminate this Agreement to the Non-Performing Party and termination shall occur if the Force Majeure
is continuing at the end of that twenty (20) Business Day notice period.

 

	20.	ASSIGNMENT AND SUB-CONTRACTING

 

	20.1.	This Agreement shall be binding upon and inure to the benefit of the Parties, their successors, and their
assigns. This Agreement shall only be assignable:

 

		(a)	By either Party with the written consent of the other Party;

 

		(b)	by a Party without the consent of the other Party, to any successor to all or substantially all the assets
of its business to which this Agreement relates; or

 

		(c)	pursuant to Clause 20.2.

 

	20.2.	CPF shall have the right to assign the right to receive income pursuant to this Agreement.

 

	20.3.	Centry may not sub-contract its obligations under this Agreement to any person other than a Third Party
Service Provider. Centry shall ensure that an appropriate written agreement is put in place with each Third Party Service Provider. Upon
request Centry shall provide CPF with a summary of all arrangements currently in place or being negotiated with Third Party Service Providers.

 

    - 40 -

     

    

 

	21.	NOTICES

 

	21.1.	All notices shall be in writing and sent by hand, email, or recorded delivery and shall be deemed to be
properly served (i) if sent by hand, when delivered at the relevant address; (ii) if sent by recorded delivery, three (3) Business Days
after posting; (iii) if sent by email, when transmitted, provided a confirmatory copy is sent by post within twenty four (24) hours of
transmission, and shall be sent to the following addresses or email address as may be amended by the relevant Party in writing:

 

CPF:

 

CRT Pioneer Fund

C/O Sixth Element
Capital

4 Claridge Court

		[***]	

Email: [***]

For the attention
of: [***]

 

Centry:

 

Centry Pharma, Inc.

1 Bridge Plaza

2nd Floor

Fort Lee

New Jersey

07024

 

	22.	VARIATION

 

	22.1.	No variation, modification, amendment, extension or release from any provision of this Agreement shall
be effective unless it is in writing, signed by each of the Parties.

 

	23.	ENTIRE AGREEMENT

 

	23.1.	This Agreement, together with the mutual confidentiality agreement between CPF, Centry, and Sixth Element
Capital LLP dated 21 September 2020, constitutes the entire agreement between the Parties and any Affiliate and supersedes and extinguishes
all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, relating
to its subject matter. Each Party acknowledges that in entering into this Agreement it does not rely on any statement, representation,
assurance or warranty (whether made innocently or negligently) that is not set out in this Agreement. Each Party agrees that it shall
have no claim for innocent or negligent misrepresentation
or negligent misstatement based on any statement in this Agreement.

 

    - 41 -

     

    

 

 

		24.	FURTHER ASSURANCE

 

		24.1.	Each Party shall do all such other acts and things, and execute and provide all such documents at the
other Party’s request and cost as may be necessary or desirable to give effect to the purposes of this Agreement.

 

		25.	NO PARTNERSHIP

 

		25.1.	Nothing in this Agreement shall constitute, create, or be deemed to constitute a joint venture, agency,
partnership or other co-operative venture between the Parties. Neither of the Parties shall have any authority to bind the other Party
in any way except as provided in this Agreement.

 

		26.	COSTS

 

		26.1.	Each Party shall bear its own legal costs, legal fees and other expenses incurred in the negotiation,
preparation, execution and implementation of this Agreement and the documentation referred to herein.

 

		27.	WAIVER

 

		27.1.	No relaxation, forbearance, waiver or indulgence by either Party in enforcing any of the terms or conditions
of this Agreement or the granting of time by either Party to the other shall prejudice, affect or restrict the rights and powers of such
Party, unless contained in a writing signed by the Party charged with such waiver. The waiver of any breach of any term or any condition
of this Agreement shall not be construed as a waiver of any subsequent breach of a term or condition of the same or of a different nature.

 

		28.	SEVERABILITY

 

		28.1.	If the whole or any part of this Agreement is or becomes or is declared illegal, invalid or unenforceable
in any jurisdiction for any reason (including by reason of the provisions of any legislation and/or by reason of any court or Competent
Authority):

 

		(a)	in the case of the illegality, invalidity or unenforceability of the whole of this Agreement it shall
terminate only in relation to the jurisdiction in question; or

 

		(b)	in the case of the illegality, invalidity or unenforceability of a part of this Agreement that part shall
be severed from this Agreement in the jurisdiction in question and that illegality, invalidity or unenforceability shall not in any way
whatsoever prejudice or affect the remaining parts of this Agreement which
shall continue in full force and effect and in no circumstances shall sums paid by Centry to CRT under this Agreement be repayable.

 

    - 42 - 

     

    

 

		28.2.	If in the reasonable opinion of a Party any severance under this Clause 28 materially affects the commercial
basis of this Agreement, the Parties shall negotiate in good faith to modify the Agreement to preserve, to the extent possible, their
original intent.

 

		29.	EXECUTION

 

		29.1.	This Agreement may be executed in any one or more number of counterpart agreements each of which, when
executed, shall be deemed to form part of and together constitute this Agreement.

 

		30.	ANNOUNCEMENTS, PUBLICATIONS, AND USE OF NAMES

 

		30.1.	Save as provided in Clause 30.2 neither Party shall make, or procure or permit the making of, any press
release or other public announcement (including on any website or in any company publication) in relation to this Agreement without first
obtaining the written approval of the other Party to any such release or announcement, which shall not unreasonably be withheld, conditioned
or delayed.

 

		30.2.	The Parties will agree upon a press release to announce the execution of this Agreement. Any Party may
make an announcement with respect to this Agreement or any ancillary matter if required by law or the regulations of any stock exchange
to which it is subject, without the other Party’s consent provided it has used reasonable endeavours in the time available to consult
with the other Party on the terms of any such announcement beforehand.

 

		30.3.	Centry shall: (a) ensure that the ICR’s researchers shall be named as authors on the first publication
of any Licensed Intellectual Property in accordance with customary standards of scientific attribution; and (b) acknowledge ICR’s
involvement in the research and development of any Licensed Product (which, in the case of a Sub-Licensee is the subject of such sub-licence)
in any academic publication, other trade publication or press release relating to that Licensed Product provided always that Centry shall
have no liability to CPF if, subject to Centry having taken the steps set out in the remainder of this Clause 30.3, the Sub-Licensee does
not agree to the provisions of this Clause 30.3 or subsequently breaches these provisions. In the event of a breach by a Sub-Licensee
of the provisions of this Clause 30.3, and on receipt of written notice from CPF notifying Centry of such breach (which may be delivered
by email), Centry hereby undertakes to notify the Sub-Licensee of such breach and to request future adherence to the terms of this Clause
30.3. No Party shall use the name or marks of any other (including CRUK), other than as provided in Clause 30.1 and 30.2 without the prior
written consent of that Party which shall be at that Party’s sole discretion.

 

    - 43 - 

     

    

 

		30.4.	CPF and Centry acknowledge the importance of publications to the academic standing of ICR. The Parties
agree that prior to the grant of a sub-licence by Centry any publication or presentation of a Licensed Product or the results of any clinical
trial shall appropriately cite the contributions of the Parties and CRUK to research. Subsequent to the grant of a sub-licence by Centry
any publication or presentation at an academic conference or in an academic journal in respect of the development of a Licensed Product
or the results of any clinical trial, and any marketing materials (including flyers) produced by Centry referring to Licensed Product
development shall appropriately cite the contributions of the Parties, and all other relevant parties, (including ICR, CRUK and the researchers
undertaking the research, using customary standards of scientific attribution. In particular, no publication at an academic conference
or in an academic journal shall be made identifying the chemical structure of a Licensed Compound which does not include ICR authors without
the prior written consent of ICR. Each Party shall provide the others with any publication or presentation for an academic conference
or in an academic journal at least [***] ([***]) [***] prior to submission for presentation or publication so that Confidential Information
of the other Parties can be deleted and Patent protection sought, if desired and applicable. If any Party notifies the other Parties within
such period that it desires to file a Patent application on any inventions, then submission of such publication or presentation shall
be delayed for an additional period of:

 

		(a)	[***] ([***]) [***] to the extent that the publication or presentation
contains information which describes compound structures comprised within Licensed Intellectual Property; or

 

		(b)	[***] ([***]) [***] where the publication or presentation contains information which relates to the Licensed
Intellectual Property exclusively licensed to Centry, other than compound structures;

 

		(c)	[***] ([***]) [***] where the publication or presentation contains
information which relates to Non-Compound Intellectual Property; and

 

		(d)	no delay in the event that the publication or presentation only
contains chemical structures and other materials and data which are already in the public domain,

 

			while such Patent application is prepared and filed. If no comments are provided during the
                                                                              applicable review period, the Parties will be free to make such presentation or publication without further obligation to the other
                                                                              Party. Following approval of any publication or presentation, the publishing Party shall be free to publish the content of the
                                                                              publication or presentation in any other format (including on its website) without referring such (subsequent) publication or
                                                                              presentation to the other Parties.

 

    - 44 - 

     

    

 

		31.	DISPUTE RESOLUTION AND GOVERNING LAW

 

		31.1.	In the event that a determination of the Expert is sought under this Agreement:

 

		(a)	the opinion of that Expert (who shall act as an expert and not as an arbitrator) shall be final and binding
on the Parties;

 

		(b)	each Party shall make written submissions to the Expert and to the other Parties within ten (10) Business
Days of the Expert’s appointment;

 

		(c)	each Party shall have ten (10) Business Days to respond to the other Parties’ submissions;

 

		(d)	the Parties shall request that the Expert deliver his opinion within a further twenty (20) Business Days;
and

 

		(e)	the costs associated with the appointment of the Expert shall be borne in such proportions as the Expert
may determine to be fair and reasonable in all the circumstances or, if no such determination is made by the Expert, by the Parties (or
where the dispute involves only two Parties, by those two Parties) in equal proportions.

 

		31.2.	It shall be a condition precedent to the commencement of any action in court or other tribunal (save an
action for an interim injunction) in respect of any dispute relating to this Agreement that the Parties have sought to resolve the dispute
by a Party notifying the other Parties in writing for resolution to the Executive Officers who shall meet (whether in person or via teleconference)
within twenty-one (21) days of such notice to seek resolution in good faith. If the Executive Officers are unable to resolve the dispute
at such meeting, any Party may pursue any remedy available to such Party at law or in equity, subject to the terms and conditions of this
Agreement.

 

		31.3.	This Agreement shall be governed by and construed in accordance with the laws of England and Wales and
the Parties agree, subject to Clauses 31.1 and 31.2, to submit to the exclusive jurisdiction of the English courts in respect of any dispute
arising out of or in connection with this Agreement (except in respect of disputes under Clause 16 where jurisdiction is non-exclusive).

 

		32.	RIGHTS OF THIRD PARTIES 

 

		32.1.	Save that CPF’s officers, employees, and agents may enforce Clauses 13.1 and 15.1 no term of this
Agreement is enforceable under the Contracts (Rights of Third Parties) Act 1999 by a person who is not a party to this Agreement. Notwithstanding
this Clause 32.1, the Parties shall be entitled to amend, suspend, cancel or terminate this Agreement or any part of it in accordance
with Clause 22 without the consent of any Third Party.

 

{Signatures Follow}

 

    - 45 - 

     

    

 

	 	The Parties hereby execute this Agreement by their duly authorised representatives:

 

	 	For CRT PIONEER FUND LP acting by CRT Pioneer GP Limited its general partner:

 

	 	Signature:	 	 
	 	 	 	 
	 	Name:	 	 
	 	 	 	 
	 	Title:	 	 

 

	 	For CENTRY PHARMA, INC:

 

	 	Signature:	 	 
	 	 	 	 
	 	Name:	 	 
	 	 	 	 
	 	Title:	 	 

 

    - 46 - 

     

    

 

SCHEDULE 1 – DEVELOPMENTAL MILESTONES

 

	Milestone	Event	Payment
	(A)	Dosing of the third patient in the first Phase I Trial for a Licensed Product	$[***]
	(B)	Declaration of the recommended Phase II Trial or Phase Ib Trial expansion cohort dose	$[***]
	(C)	Dosing of the first patient in the first Phase II Trial for a Licensed Product	$[***]
	(D)	Dosing of the first patient in the first Phase II Trial or Phase III Trial designated as a Registration Study for a Licensed Product	$[***]
	(E)	Acceptance of the first NDA or equivalent submission for a Licensed Product in any Major Market.	$[***]
	(F)	Grant of FDA marketing authorisation of a Licensed Product in a first indication	$[***]
	(G)	Grant of FDA marketing authorisation of a Licensed Product in a second indication	$[***]
	(H)	Grant of FDA marketing authorisation of a Licensed Product in a third indication	$[***]

 

    - 47 - 

     

    

 

	(I)	Grant of FDA marketing approval of a Licensed Product in a fourth indication	$[***]
	(J)	Grant of a marketing authorisation of a Licensed Product in a first indication in either the EU or UK	$[***]
	(K)	Grant of a EU marketing authorisation of a Licensed Product in a second indication in either the EU or UK	$[***]
	(L)	Grant of a EU marketing authorisation of a Licensed Product in a third indication in either the EU or UK	$[***]
	(M)	Grant of a EU marketing authorisation of a Licensed Product in a fourth indication in either the EU or UK	$[***]
	(N)	First marketing approval of a Licensed Product in Japan	$[***]

 

    - 48 - 

     

    

 

SCHEDULE 2 – SALES BASED MILESTONES

 

	Milestone	Event	Payment
	(O)	First Year in which annual Net Sales (of all Licensed Products sold) exceed $[***]	$[***]
	(P)	First Year in which annual Net Sales (of all Licensed Products sold) exceed $[***]	$[***]
	(Q)	First Year in which annual Net Sales (of all Licensed Products sold) exceed $[***]	$[***]
	(R)	First Year in which annual Net Sales (of all Licensed Products sold) exceed $[***]	$[***]

 

 

    - 49 - 

     

    

 

SCHEDULE 3 – ROYALTIES

 

	Portion of Net Sales in a Calendar Year	Royalty Percentage on such portion
	Less than $[***] million	[***]%
	$[***] million – $[***] million	[***]%
	$[***] million – $[***] million	[***]%
	Greater than $[***] million	10%

 

    - 50 - 

     

    

 

SCHEDULE 4 - DEVELOPMENT PLAN

 

[***]

 

    - 51 - 

     

    

 

SCHEDULE 5 – SUB-LICENCES

 

		1.	The Sub-Licensee may only use the rights granted to it to develop treatments for Indications other than
an Oncology Indication, where the Sub-Licensee reasonably believes that pursuing an Oncology Indication is likely to result in a product
which would offer no substantial benefit to the patient population over existing drugs, or drugs in development, for the Oncology Indications
that the Licensed Product would be most suitable for. In such circumstances the Sub-Licensee shall provide written notice to the Licensee
setting out its reasons, with supporting evidence, for such belief (“Other Indication Notice”) and shall not commence
using the rights so granted for an Indication other than an Oncology Indication until it has explored with the Licensee, CRT and ICR options
for continuing to develop the rights granted to it for an Oncology Indication.

 

2.           
The Sub-Licensee will use Commercially Reasonable Efforts to:

 

		a.	Nominate a Pre-Clinical Candidate (if not already nominated);

 

		b.	develop at least one Licensed Product suitable for use in human clinical trials;

 

		c.	pursue Regulatory Authorisation and (where applicable) Price Approvals in each of the Major Markets for
those Licensed Products in clinical development;

 

		d.	make each Licensed Product available for purchase throughout the United Kingdom within [***] ([***]) [***]
of such Licensed Product receiving a European wide Regulatory Authorisation for launch;

 

e.    without
prejudice to the generality of the foregoing, develop and commercialise in each of the Major Markets at least one Licensed Product. In
the event that a Licensed Product is launched or ready to be launched in the United Kingdom which has received a Regulatory Authorisation
in respect of an Oncology Indication, the Sub-Licensee will ensure that such Licensed Product is made available throughout the United
Kingdom at an Affordable price;

 

		f.	provide Licensee with a Progress Report at least once every [***] ([***]) [***];

 

		g.	promptly respond to any reasonable queries that Licensee may have following receipt of a Progress Report;

 

		h.	at Licensee’s request, meet, [***], with Licensee (either in person or by teleconference if a face-to-face
meeting is not practical) to discuss the content of a particular Progress Report; and

 

		i.	provide Licensee with a development plan and update the development plan and provide a copy of the same
to Licensee at least once every [***] ([***]) [***].

 

    - 52 - 

     

    

 

		3.	Any damages, profits, and awards of whatever nature recovered by the Sub-Licensee for any infringement
of the rights sublicensed to it shall be treated as Net Sales subject to a deduction for the Sub-Licensee’s external legal expenses
insofar as these are not recovered from a Third Party. In any such proceedings, Licensee shall, at the Sub-Licensee’s cost, promptly
provide the Sub-Licensee with all documents and assistance as the Sub-Licensee may reasonably require. The Sub-Licensee shall promptly
provide Licensee with notice of such proceedings and keep Licensee regularly informed of progress and promptly provide Licensee with such
information as Licensee may require including copies of all documents filed at court in the proceedings. If Licensee is joined to proceedings
pursuant to this Clause or otherwise, the Sub-Licensee shall indemnify and hold harmless Licensee and the inventors named in any Licensed
Patents (the “Indemnities”) from and against any and all claims, demands, losses, causes of action, damages and expenses (including
without limitation, legal fees) arising from or in connection with such proceedings. If the Sub-Licensee does not exercise its right to
bring proceedings within thirty (30) days of written request to bring proceedings from Licensee, then Licensee or its nominee shall be
entitled, but not obliged to bring such proceedings at its own cost. If necessary, (including to recover damages), the Sub-Licensee shall
join in such proceedings. Save as provided above, whichever Party brings the proceedings shall be entitled to all monies recovered where
in such proceedings. In any such proceedings the Party not bringing the proceedings (“Inactive Party”) shall promptly provide
the Party bringing proceedings (“Active Party”) with all documents and assistance as the Active Party may reasonably require
and the Active Party shall promptly provide the Inactive Party with notice of such proceedings.

 

		4.	The Sub-Licensee shall indemnify, defend and hold harmless CRT/ICR Indemnified Parties from and against
any and all Third Party claims, demands, losses, damages, costs and expenses (including, without limitation, legal fees) arising from
or in connection with the exercise by the Sub-Licensee or its permitted sublicensee of the rights granted to it or the actions of the
Sub-Licensee, or its permitted sublicensee in relation to a Licensed Product.

 

    - 53 - 

     

    

 

		5.	Prior to commencing any proceedings pursuant to Clause 11.8, the Licensee shall (or shall procure that
its Sub-Licensee shall) enter into a separate agreement with CRT and ICR pursuant to which the Licensee (or the Sub-Licensee if applicable)
shall indemnify the CRT/ICR Indemnitees in respect of any and all potential Third Party claims, demands, losses, damages, costs and expenses
(including, without limitation, legal fees) which might arise directly or indirectly as a consequence of such proceedings being concluded
successfully or unsuccessfully (including without limitation any anti-trust proceedings commenced by a Third Party (for example, alleging
that the price of any Licensed Product has been kept artificially high through the maintenance of Patents which are invalid and/or unenforceable
for any reason)).

 

		6.	Promptly after receipt by Licensee of any claim or alleged claim or notice of the commencement of any
action, administrative or legal proceeding, or investigation to which the indemnity provided for in paragraph 4 may apply, Licensee shall
give written notice to the Sub-Licensee of such fact and the Sub-Licensee shall have the option to assume the defence thereof by election
in writing within thirty (30) days of receipt of Licensee’s notice. If the Sub-Licensee fails to make such election, the Indemnified
Party may assume such defence and the Sub-Licensee will be liable for the legal and other expenses consequently incurred in connection
with such defence. The Parties will co-operate in good faith in the conduct of any defence, will provide such reasonable assistance as
may be required to enable any claim to be defended properly and the Party with conduct of the action shall promptly provide to the other
Party copies of all correspondence and documents and notice in writing of the substance of all oral communications relating to such action.

 

		7.	Should the Licensee assume conduct of the defence:

 

		·	the Indemnified Party may retain separate legal
advisers, at its sole cost and expense save that if the Sub-Licensee denies the applicability of the indemnity or reserves its position
in relation to the same, the indemnity [in this Clause] shall extend to the Indemnified Party’s costs and expenses;

 

		·	the Sub-Licensee will not, except with the written
consent of the Indemnified Party, such consent not to be unreasonably withheld, delayed or conditioned, consent to the entry of any judgment
or enter into any settlement provided always, that if the Indemnified Party shall not consent to such entry of judgment or settlement,
and such judgment or settlement does not involve an admission of liability on the part of Indemnified
Party then the amount which the Indemnified Party shall be entitled to recover from the Licensee pursuant to this paragraph shall be limited
to the amount that they would have received if the action would otherwise have been settled; and

 

		·	Licensee shall not admit liability in respect
of, or compromise or settle any such action without the prior written consent of the Sub-Licensee, such consent not to be unreasonably
withheld, conditioned or delayed. 

 

		8.	Reasonably prior to Commencement of any human being dosed with the Licensed Product, the Sub-Licensee
shall put in place and thereafter maintain, at its own cost, comprehensive product liability insurance and general commercial liability
insurance through a reputable insurance company. At Licensee’s request, the Sub-Licensee shall provide Licensee with a certificate
evidencing the coverage required hereby, and the amount thereof and the noting of Licensee’s interest. Such insurance shall be maintained
for not less than [***] ([***]) [***] following the expiration or termination of this sublicence for any reason.

 

    - 54 - 

     

    

 

SCHEDULE 6 – TARGET PATENT COUNTRIES

 

[***]

 

    - 55 - 

     

    

 

SCHEDULE 7 – CONFIRMATORY PATENT
LICENCE

 

THIS AGREEMENT is made the ___________day of______________________202[●]

 

		1)	CRT PIONEER FUND LP (the “CPF”),
a limited liability partnership established in England and Wales under number LP 14391 with registered office at 4 Claridge Court, Lower
Kings Road, Berkhamsted, Hertfordshire, HP4 2AF, acting by its general partner, CRT Pioneer GP Limited, a company registered in England
and Wales with registered number 07933818 whose registered office is at 4 Claridge Court, Lower Kings Road, Berkhamsted, Hertfordshire,
HP4 2AF (the “General Partner”); and

 

		2)	CENTRY PHARMA, INC [a company registered in/incorporated in/ established under the laws of [●●●]
under number [●●●] with registered office/principal place of business at [●●●] (“CENTRY”).

 

RECITALS:

 

By an agreement (the “Main
Agreement”) dated __________________ and made between CPF and Centry, CPF agreed for the consideration therein contained,
among other things, to grant to Centry a license under [Country/region Patent No.__________ ] (the
 “Patent”) of which this Agreement is a confirmatory license.

 

OPERATIVE PROVISIONS:

 

		1.	In pursuance of the Main Agreement and for the consideration referred to in the Main Agreement CPF hereby grants to Centry the [exclusive]
license from the ________ day of_____________ 20___ to research, develop, use, keep, make, have made, import, sell and otherwise dispose
of Licensed Products (as defined in the Main Agreement) in the Field (as defined in the Main Agreement) in the Territory (as defined in
the Main Agreement) for the life of the Patent and subject to the provisions of the Main Agreement.

 

		2.	Subject to the provisions of the Main Agreement this Agreement shall terminate without notice in the event of the termination for
any reason of the Main Agreement.

 

    - 56 - 

     

    

 

IN WITNESS of which this Agreement has been executed
as a deed and delivered the day and year first above written.

 

	EXECUTED as a deed 	)	Name (PRINT):	 
	 	 	 	 
	For and on behalf of	)	Title (PRINT):	 
	 	 	 	 
	CRT PIONEER FUND
  LP	)	Signature:	 

 

		)	Date:	 

 

	 	)	Name (PRINT) 	 
	 	 	 	 
	 	)	Title (PRINT)	 
	 	 	 	 
	 	)	Signature:	 
	 	 	 	 
	 	)	Date:	 

 

acting by a Director and its Secretary / two Directors

 

	EXECUTED as a deed	)	Name (PRINT):	 
	 	 	 	 
	For and on behalf of	)	Title (PRINT):	 
	 	 	 	 
	CENTRY PHARMA, INC	)	Signature:	 

 

		)	Date:	 

 

	 	)	Name (PRINT):	 
	 	 	 	 
	 	)	Title (PRINT):	 
	 	 	 	 
	 	)	Signature:	 
	 	 	 	 
	 	)	Date:	 

 

acting by a Director and its Secretary / two Directors

 

    - 57 - 

     

    

 

SCHEDULE 8 – BACKGROUND KNOW-HOW
AND MATERIALS

 

Part A

 

Drug Substance

 

[***]

 

Drug Product

 

 

[***]

 

Part B

 

The Know How and Materials assigned or licensed to CPF pursuant to
the following Agreements:

 

		-	Master Services Agreement between CPF and [***] dated [***]

		-	Amended and Restated [***]and CPF dated [***]

		-	Agreement with [***] dated [***]

		-	Agreement with [***], [***], [***]

		-	Agreement with [***]

 

    - 58 - 

     

    

 

SCHEDULE 9 – BACKGROUND PATENTS

 

[***]

 

    - 59 -Exhibit 10.6 

 

CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED
FROM THE EXHIBIT BECAUSE IT BOTH (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. SUCH EXCLUDED INFORMATION
HAS BEEN MARKED WITH “[***].”

 

 

 

 

LICENCE AGREEMENT

 

between

 

THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH

 

and

 

NUVECTIS PHARMA, INC.

 

University of Edinburgh

Legal Services

Old College

South Bridge

Edinburgh, EH8 9YL

Ref: [***]

 

     

     

    

 

Table of Contents

 

	1.	DEFINITIONS	6
	1.1	Interpretation	28
	2.	GRANT OF RIGHTS	28
	2.1	Licences	29
	2.2	Scope of licences	29
	2.3	Formal licences	29
	2.4	Sub-licensing	30
	2.5	Special case of sub-licensing.  	31
	2.6	Humanitarian use	31
	2.7	Reservation of rights	31
	2.8	Provision of Licensed Know-How, Licensed Compound Know-How, Licensed Compounds and Licensed Materials	32
	2.9	Academic Research Licence to Nuvectis Results and Nuvectis IP	32
	3.	PAYMENTS	32
	3.1	Signature Fee	32
	3.2	Annual Fee	32
	3.3	Milestone Payments.	32
	3.4	Royalties on Net Sales of Licensed Products.  	33
	3.6	Sub-Licensee Revenues.	33
	3.7	Minimum Annual Royalty	34
	3.8	Non-monetary consideration	34
	3.9	Combination products.	34
	3.10	Royalty stacking.	35
	3.11	Generic Reduction	36
	3.12	Absolute floor to reductions	36
	3.13	Historical Patent Costs	36
	4	PAYMENT TERMS AND AUDIT RIGHTS	35
	4.1	Payment frequency.	36
	4.2	Payment mechanism.	36
	4.3	Exchange controls.	36
	4.4	Royalty statements.	37
	4.5	Records.	37
	5	DILIGENCE, COMMERCIALISATION AND ADDITIONAL OBLIGATIONS	39
	5.1	Development and Commercialisation.	39
	5.2	Specific diligence conditions.	40

 

    2 

     

    

 

	5.3	Development Plan.	40
	5.4	Progress Report.	40
	5.5	Remedial action.	40
	5.6	Referral to Expert.	40
	5.7	Applicable Laws.	41
	5.8	Marketing Authorisation.	41
	5.9	Insurance.	41
	5.10	Additional Obligations.	42
	5.11	EAMS and PIP.	42
	6.	INTELLECTUAL PROPERTY	43
	6.1	Filing, Prosecution and Maintenance of Licensed Patents and Additional Licensed Patents	43
	6.2	Step-In.  	44
	6.3	Infringement by Third Parties.	44
	6.4	Challenge to the Licensed Technology.	45
	6.5	Response to infringement of or challenge to Licensed Patents and/or Additional Licensed Patents.	45
	6.6	Infringement of third party rights.	45
	6.7	Collaboration Option IP.	46
	6.8	Non delegation.	46
	6.9	Restriction on enforcement.	46
	6.10	Ownership of Licensed Patents and Additional Licensed Patents	46
	6.11	Ownership of Collaboration IP	46
	6.12	Nuvectis Improvements and Nuvectis Improvement IP	46
	6.13	Disclosures	48
	7.	JOINT ADVISORY COMMITTEE .	46
	7.1	Composition.	46
	7.2	Replacements	47
	7.3	Purpose.	47
	7.4	Decisions	47
	7.5	Frequency	49
	7.6	Quorum	50
	7.7	Location	50
	7.8	Minutes	50
	7.9	Expenses	50
	7.10 	JAC Manager	50
	8 	CONFIDENTIAL INFORMATION AND PUBLICATION	48
	8.1 	Confidentiality obligations.	48
	8.2 	Additional confidentiality obligations.	49

 

    3 

     

    

 

	8.3 	Exceptions to confidentiality obligations.	49
	8.4	Required disclosure.	49
	8.5	Permitted disclosure. 	50
	8.6	Additional University permitted disclosure.	50
	8.8	Confidentiality of this Agreement.	50
	8.9	Permitted Reporting.	50
	8.10	Publication.	51
	9	WARRANTIES	51
	9.1	Mutual warranties.	51
	9.2	University warranty. 	52
	9.3	Acknowledgements. 	52
	9.4	No other warranties	52
	10	INDEMNITY AND LIMITATION OF LIABILITY	53
	10.1	Indemnity.	53
	10.2	Limitation of liability.  	53
	10.3	Exceptions to limitation of liability.	54
	10.4	University liability cap.	54
	11	TERM AND TERMINATION	54
	11.1	Commencement and expiry.	54
	11.2	Termination for breach.	54
	11.3	Termination by the University.  	54
	11.4	Termination by Nuvectis.	55
	12	CONSEQUENCES OF TERMINATION	55
	12.1	Termination without prejudice to accrued rights.	55
	12.2	Surviving provisions.  	55
	12.3	Return of Confidential Information.	55
	12.4	Termination of licences. 	56
	12.5	Transfer of Licensed Products, Additional Licensed Products, Nuvectis IP and Nuvectis
    Results.	56
	12.6	Third Party Rights.	58
	12.7	Sub-licensees.	58
	12.8	Certain Provisions. 	58
	12.9	Payments.	58
	13	GENERAL	58
	13.1	Entire agreement. 	58
	13.2	Announcements and use of names. 	58
	13.3	Force majeure. 	59
	13.4	Amendment.  	59

 

    4 

     

    

 

	13.5	Assignment.	59
	13.6	Third party rights..	59
	13.7	Waiver.	59
	13.8	Relationship of the Parties.  	59
	13.9	Notices.	60
	13.10	Law and jurisdiction.	60
	13.11	Further action.  	60
	13.12	Escalation	63

 

	SCHEDULE 1 LICENSED PATENTS	61
	SCHEDULE 2 LICENSED COMPOUND KNOW-HOW	62
	SCHEDULE 3 LICENSED KNOW-HOW	63
	SCHEDULE 4 PART A: LICENSED MATERIALS and PART B: LICENSED COMPOUNDS 	69
	SCHEDULE 5 COLLABORATION IP	70
	SCHEDULE 6 DEVELOPMENT PLAN	71
	SCHEDULE 7 MILESTONE PAYMENTS	85
	SCHEDULE 8 DEVELOPMENT MILESTONES	88
	SCHEDULE 9 THIRD PARTY RIGHTS AND OBLIGATIONS	89
	SCHEDULE 10 EXPERT DETERMINATION PROCEDURE	93
	SCHEDULE 11 UNIVERSITY BANK DETAILS	73
	SCHEDULE 12 CONFIRMATORY FORMAL LICENCES	74

 

    5 

     

    

 

THIS AGREEMENT
is made on __________________________________

 

BETWEEN

 

		(1)	THE
                                            UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, a charitable body registered in Scotland
                                            under registration number SC005336, incorporated under the Universities (Scotland) Acts and
                                            having its main administrative offices at Old College, South Bridge Edinburgh, EH8 9YL (the
                                            “University”); and

 

		(2)	NUVECTIS
                                            PHARMA INC, a corporation with a principal place of business at 1 Bridge Plaza N., Suite
                                            275, Fort Lee, NJ, 07024 (“Nuvectis”).

 

INTRODUCTION

 

		(A)	Nuvectis
                                            wishes to acquire a licence under the Licensed Technology for the development and commercialisation
                                            of Licensed Products and/or Additional Licensed Products.

 

		(B)	Nuvectis
                                            and University have entered or will enter into the Development Collaboration Agreement on
                                            or around the Effective Date pursuant to which Nuvectis shall engage and fund University
                                            to perform certain research activities related to SRC Inhibitors.

 

		(C)	University
                                            is willing to grant, and Nuvectis is willing to take, a licence under the Licensed Technology
                                            on the terms of this Agreement.

 

The
Parties agree as follows:

 

		1.	DEFINITIONS

 

In
this Agreement, the following words shall have the following meanings:

 

	Acquisition
    Event	means (A) the
    acquisition by any person or entity who or which, together with all associates of such person or entity, shall become the beneficial
    owner of fifty percent (50%) or more of Nuvectis’s common stock then outstanding, through an unsolicited tender offer or exchange
    offer or other acquisition of such number of shares by such person, or (B) a change in the majority of the board of directors, whether
    by resignation or removal, which change occurs as a result of the acquisition of a Controlling interest in the outstanding voting
    stock of Nuvectis by any person or entity; (C) a merger, consolidation, or reorganisation between Nuvectis and another entity with
    Nuvectis being either the surviving entity or the acquired entity, or the transfer of assets into Nuvectis for fifty percent (50%)
    or more of Nuvectis’s equity securities or securities exercisable or convertible into Nuvectis’s equity securities by
    any person or entity; (D) any sale, lease, assignment, transfer or other conveyance of all or substantially all of Nuvectis’s
    assets to any person or entity in one or a series of related transactions;

 

    6 

     

    

 

	Additional
    Licensed Patents	means
    any Patents (excluding Licensed Patents and Improvement Compound Patents) filed on or after
    the Effective Date and claiming (i) any substantial and material confidential information within the Licensed Know-How and/or Collaboration
    Non-Compound IP; and/or (ii) compounds, the discovery of which by Nuvectis required the substantial and material use of  confidential
    information within the Licensed Know-How and/or Collaboration Non-Compound IP; and (iii) any Patents claiming priority from the Patents
    described in clauses (i) and/or (ii). Additional Licensed Patents owned  solely by the University pursuant to the Development
    Collaboration Agreement in respect of Collaboration IP developed solely by the University or jointly with Nuvectis are licensed under
    this Agreement as part of the Collaboration IP and shall be detailed in Schedule 5, as updated from time to time, under the heading
    Additional Licensed Patents; provided that the failure to add any specific Additional Licensed Patent to such schedule shall not
    cause such Additional Licensed Patent not to constitute an Additional Licensed Patent and provided further that if University owns
    or Controls any rights to any Additional Licensed Patents that are not licensed to Nuvectis hereunder, such Patents shall not constitute
    Additional Licensed Patents for the purposes of this Agreement; 
	Additional
    Licensed Product(s)	means
    any product, other than the Licensed Products, the use, manufacture, sale, offer for sale or import of which, but for the licenses
    granted herein, infringe any Valid Claim of any Additional Licensed Patents; 
	Affiliate	means
    with respect to a Party, any entity or person that Controls, is Controlled by, or is under common Control with that Party;
	Agreement	means
    this agreement including its Schedules;
	Annual
    Fee	means
    (i) [***], and (ii) [***];
	Biomarker	means an
    endogenous characteristic that is objectively measured and evaluated as an indicator or predictor of normal biological or pathogenic
    processes or pharmacological responses to a therapeutic intervention;

 

    7 

     

    

 

	BLA	means
    a Biologic Licence Application as defined by the US Food and Drug Administration or any equivalent marketing approval for a biological
    product in any other territory;
	Business
    Day	means
    a day other than a day which is a Saturday, Sunday or public holiday in Scotland;
	Collaboration
Compound IP 
	means any
    Collaboration IP to the extent that it is directly related to the Licensed Compounds (including but not limited to data generated
    on the Licensed Compounds and their use in the Field). For the avoidance of doubt, Collaboration Compound IP [***];
	 	 
	Collaboration
Non-Compound IP 
	means any Collaboration
    IP which is relevant to the discovery, development or commercialization of Licensed Products but which is not directly related to
    the Licensed Compounds or other chemical compounds generated under the DCA (including but not limited to generic target Know-How,
    biomarkers, research tools, assays);

     

	Collaboration
    Option IP

     
	means any Collaboration
    IP other than Collaboration Compound IP and/or Collaboration Non-Compound IP;

     

	[***]	[***];

     

	Confidential
    Information 	of a Party
    (the “Disclosing Party”) means all information of a confidential or proprietary nature which is obtained directly
    or indirectly from the Disclosing Party or any of its Affiliates by the other Party (the “Receiving Party”) or
    any of its Affiliates at any time before, on, or after the Effective Date, without regard to the form or manner in which such information
    is disclosed or obtained (including information disclosed orally, in writing or by observation), and includes the terms of this Agreement
    which shall be the Confidential Information of both Parties;

 

    8 

     

    

 

	Collaboration
    IP	means
    the University’s rights in all Results and Intellectual Property Rights in the Results which are Controlled by the University
    and arising under or in performance of the Development Collaboration Agreement. Collaboration IP shall be set out in Schedule 5 as
    updated from time to time. Collaboration IP comprises the Collaboration Compound IP, Collaboration Non-Compound IP and Collaboration
    Option IP. The JAC shall determine the division of the Collaboration IP into the aforesaid three categories of IP and update Schedule
    5 accordingly; provided that the failure to add any specific Collaboration IP to such schedule shall not cause such Collaboration
    IP not to constitute part of the Collaboration IP;
	Combination
    Product	means
    a pharmaceutical product containing  Licensed Product in combination with one or more other active pharmaceutical ingredient
    other than the Licensed Compound, including any co formulation, co-packaged product, bundled product, or other type of combination
    product;
	Control
    (as used in the definition of “Affiliates”)	means, for
    purposes of the definition of Affiliates, in relation to any entity:

     

    (a) having,
    directly or indirectly, the power to direct, or cause the direction of, the management and policies of that entity, whether through
    the ownership of voting securities in that or any other entity, by contract or otherwise; or

     

    (b) holding,
    directly or indirectly, such securities (or other rights) as confer on the holder thereof the right to exercise more than fifty percent
    of all votes exercisable in general meeting of the members of such entity; or

     

    and in this
    definition the term “entity” shall include, without limitation, any corporation or partnership wherever established.
    An entity which Controls another entity (“Subsidiary”), shall be deemed to also Control any further entities Controlled
    by such Subsidiary;

     

	Control	means
    in relation to any Intellectual Property Rights and/or the Licensed Materials, the legal authority or right of the relevant Party,
    whether by ownership or by license, to grant the right to use such Intellectual Property Rights and/or the Licensed Materials or
    a license under such Intellectual Property Rights and/or the Licensed Materials to another person in accordance with this Agreement,
    without violating any applicable laws, breaching the terms of any agreement with a third party, or misappropriating the proprietary
    or trade secret information or other Know-How of a third party and Controlled shall be construed accordingly;
	Data
    Room	means
    the data room converted into a file and sent to Nuvectis on [***];
	Development
    Collaboration 

Agreement or DCA  	means the
    Development Collaboration Agreement executed on or around the date of this Agreement between the University and Nuvectis; 

 

    9 

     

    

 

	Developing
    Country	means
    any of those countries whose gross national income per capita falls within the “low income” or “lower-middle income”
    analytical income categories as published by the World Bank from time to time (or, in the event that the World Bank ceases to produce
    an index of countries based on such categories, the nearest possible equivalent index produced by the World Bank or another body
    of comparable international standing) but excluding China, India and Russia;
	Development
    Milestones

     
	means
    the Development Milestones set out in Schedule 8; 
	Development
    Milestone Date

     
	means
    the Development Milestone Date set out in Schedule 8;   
	Development
    Plan	means
    a detailed plan which describes: (i) the Key Activities; (ii) the relevant timescales within which such Key Activities will be taken;
    and (iii) the estimated costs associated with each Key Activity. Such plan will reflect best industry practice and describe the development
    of Licensed Products across a range of Oncology Indications taking into consideration any safety/efficacy constraints. The Development
    Plan at the Effective Date is annexed at Schedule 6 and shall be updated by Nuvectis in accordance with Clause 5.3;                     
	Demonstrating
    POC	means
    for the purposes of Milestone No 1 in the Milestones:  demonstrating [***].  If
    Milestone No 1 is achieved during the term of the DCA, Nuvectis and the University will formally record it at the JAC meetings scheduled
    pursuant to Clause 7;
	Diligent
    and Reasonable Endeavours	means
    the efforts and resources commonly used by a drug development company of similar size and resources to Nuvectis and/or its Affiliates
    for a product at a similar stage in its life cycle, with the objective of developing such product in a diligent and timely manner,
    taking into consideration its safety, efficacy and the Patent or other proprietary position and all other relevant commercial factors
    when using sound and reasonable scientific, medical and business practice and judgement in order to develop the Licensed Products
    and/or Additional Licensed Products as applicable; 
	Disclosing
    Party	means as
    is defined in Confidential Information; 

 

    10 

     

    

 

	Dose Escalation
    Clinical Trial 

    

    

    

    EAMS (or Early Access to Medicines Schemes)
	means a study
    in which the primary aim is to estimate the maximum tolerated dose of a Licensed Product whether or not as part of a Phase I Clinical
    Trial, in patients and/or healthy volunteers;

     

    means schemes
    (whether statutory or not) offered by any Regulatory Authority directed towards making available, on an expedited basis, medicines
    that have potential benefit to patients with no treatment options, or that offer a major therapeutic advantage over existing treatments
    such as the UK’s Medicines and Healthcare Products Regulatory Agency’s (MHRA’s) “Promising Innovative Medicines”
    (or PIM) designations, or any successor or similar scheme;

     

	[***]	means
    the SRC inhibitor [***] as described in the patents claiming
    priority to patent [***]and listed in Schedule 1;
	Edinburgh
    Innovations	means
    Edinburgh Innovations Limited (company number SC148048), the innovation management service for the University;    
	Effective
    Date	means
    the date as written above;
	Executive
    Officers 	means
    the Chief Executive Officer of Nuvectis and the Chief Executive Officer of Edinburgh Innovations or such other authorised officer
    of a Party as may be substituted from time to time by the Parties’ mutual agreement;
	Expansion
    Clinical Trial	means
    a human clinical trial in which the primary aim is to identify a recommended Phase II Clinical Trial dose (RP2D) by further exploration
    of the dose and dosing schedule as identified in the Dose Escalation Trial; and obtain preliminary evidence of efficacy;  
	Expert	means
    the independent expert who shall be appointed and act in accordance with the provisions of Schedule 10;  
	Expert
    Appointment Body 	means
    the President of the Licensing Executives  Society of Britain and Ireland; 
	Extended Exclusivity
    Period

     
	means with
    respect to a Licensed Product and/or any Additional Licensed Product in a country in the Territory, the period of time during which
    Nuvectis and/or any of its Affiliates and/or Sub-Licensees has been granted the exclusive legal right (excluding a Patent) by a Regulatory
    Authority in such country to sell the Licensed Product and/or any Additional Licensed Product, including through clinical trial data
    exclusivity, Orphan Drug Designation or paediatric designation, or other regulatory data exclusivity;

 

    11 

     

    

 

	FDA	means
    the United States Food and Drug Administration or any successor to it;
	Field	means
    the diagnosis, prophylaxis, treatment or management of any disease or disorder;
	Financing
    Event 	means
    in connection with the development of the Licensed Technology: the paying over of money to Nuvectis by an investor or investors (which
    may include existing shareholders and directors) in consideration of the allotment and issue of shares and/or securities in the equity
    share capital of Nuvectis to such party or its nominee whether in one transaction or a series of related transactions and/or the
    grant of any rights to subscribe for or convert into shares or securities forming part of the equity share capital of Nuvectis; and/or
    any Acquisition Event and includes for the avoidance of doubt any initial public offering occurring before, on or after the Effective
    Date, regardless of the time of filing;
	First
    Commercial Sale 	means, with
    respect to any Licensed Product and/or Additional Licensed Product, the first lawful sale, transfer or disposition for value of such
    Licensed Product and/or Additional Licensed Product in the Territory by Nuvectis, any Affiliate of Nuvectis, or Sub-Licensee, the
    Marketing Authorisation Application of which has received acceptance by a Regulatory Authority;

     

	Force
    Majeure Event 	means any event
    which arises from or is attributable to acts, events, omissions or accidents beyond the reasonable control of Nuvectis, including
    without limitation earthquakes, governmental regulation, fire, flood, labor difficulties, interruption of supply of key raw materials,
    civil disorder, and acts of God, which events render Nuvectis’s performance of the obligations in this Agreement impracticable
    or impossible, except that:

     

    (a) lack of
    funds; and

     

    (b) default
    or misconduct by any third party employed or engaged as an agent or contractor by Nuvectis;

     

    shall not constitute
    a Force Majeure Event unless caused by events or circumstances which are themselves Force Majeure Events;

 

    12 

     

    

 

	Generic
    Competition	means
    with respect to Licensed Product in any particular country in the Territory, the existence on the market of any Generic Product in
    competition with such Licensed Product in such country where the unit volume of Generic Products sold in such country by one (1)
    or more Third Parties (excluding any Sub-Licencee) in a Quarter is (a) at least [***] percent ([***]%)
    (“Level 1 Generic Competition”), or (b) at least [***] percent ([***]%)
    (“Level 2 Generic Competition”), in each case of (a) or (b), of [***].  Unless otherwise agreed by
    the Parties, the unit volume of each Generic Product sold during a Quarter will be as reported by IQVIA or any successor to IQVIA
    or any other independent sales auditing firm reasonably agreed upon by the Parties;
	Generic
    Product	means
    any pharmaceutical product (other than Licensed Product and/or Additional Licensed Product and/or Combination Product) that (a) is
    sold by a Third Party (excluding any Sub-Licencee) other than pursuant to any rights granted by Nuvectis (or any Nuvectis Affiliate
    and/or any Sub-Licencee); and (b) contains  Licensed Compound in comparable quality and quantity; and (c) was granted pursuant
    to an application for Marketing Authorisation that relies on data held by a Regulatory Authority in relation to a Licensed Product;
	Good
    Clinical Practice	as
    defined in clause 2 of Article 1 of EU Directive 2001/20/EC;
	Good
    Industry Practice	means
    the exercise of that degree of skill, care, prudence, efficiency, foresight and timeliness as would be expected from a leading company
    within the pharmaceutical sector, including Good Clinical Practice, Good Laboratory Practice, Good Manufacturing Practice and Good
    Pharmacovigilance Practice;
	Good
    Laboratory Practice	as
    defined in Directives 2004/9/EC and 2004/10/EC;
	Good
    Manufacturing Practice	means the
    principles and guidelines of good manufacturing practice in respect of medicinal products for human use and investigational medicinal
    products for human use laid down in Commission Directive 2003/94/EC of 8 October 2003;

 

    13 

     

    

 

	Good
    Pharmacovigilance Practice	means
    the guideline on good pharmacovigilance practice published by the European Medicines Agency under Regulation (EU) 1235/2010, as amended
    by Regulation (EU) 1027/2012, and Directive 2010/84/EU, as amended by Directive 2012/26/EU, and the principles laid down in Commission
    Implementing Regulation (EU) 520/2012;
	[***]	means
    as is defined in Clause 12.5(a);
	Improvement(s)	means
    any analogue, modification, prodrug, salt, polymorph, metabolite, isomer or synthetic intermediate of a Licensed Compound (i) discovered
    solely by Nuvectis, its Affiliates or Sub-Licensees during the Term; or (ii) that was discovered solely by the University or jointly
    by Nuvectis and the University pursuant to the Development Collaboration Agreement.  Improvements licensed under this Agreement
    as part of the Collaboration IP shall be detailed in Schedule 5 as updated from time to time under the heading Improvement Compound
    Know-How and/or Improvement Compound Patent as the case may be;
	Improvement Compound IP	means Improvement Compound
    Know-How and Improvement Compound Patent;
	Improvement Compound Know-How	means
    Know-How that pertains to:

     

    (i)
    the composition of matter of an Improvement, and/or

     

    (ii)
    the manufacturing process, formulations or methods of delivery of an Improvement, and/or

     

    (iii)
    method(s) of using an Improvement;

     

	Improvement Compound Patent	means any and all Patent(s)
    claiming Improvement Compound Know-How; 
	IND 

    

    

    

    IND Acceptance	means
    an investigational new drug application filed with the FDA, or the equivalent application or filing filed with any equivalent Regulatory
    Authority outside the US (including any supranational agency such as the European Medicines Agency) necessary to commence human clinical
    trials in such jurisdiction;

     

    means
    the earlier of (a) receipt by Nuvectis, its Affiliate or a Sublicensee of written confirmation from a Regulatory Authority that human
    clinical studies may proceed under such IND, and (b) expiration of the applicable waiting period after which human clinical studies
    may proceed under such IND;

 

    14 

     

    

 

	Indication	means a disease
    classification as defined within the ‘International Statistical Classification of Diseases and Related Health Problems’
    as published from time to time by the World Health Organization (e.g. “C50 Malignant neoplasm of Breast”, “C92
    Myeloid leukaemia”, “B20 Human immunodeficiency virus [HIV] disease resulting in infectious and parasitic diseases”
    and “M34 Systemic sclerosis”);
	Insolvency
    Event	means, in relation
    to Nuvectis, any of the following events:

     

    (a) a meeting
    of creditors of Nuvectis being held or an arrangement or composition with or for the benefit of its creditors (including a voluntary
    arrangement as defined in the Insolvency Act 1986) being proposed by or in relation to Nuvectis;

     

    (b) a chargeholder,
    receiver, administrative receiver or other similar person taking possession of or being appointed over or any distress, execution
    or other process being levied or enforced (and not being discharged within seven days) on the whole or a material part of the assets
    of Nuvectis;

     

    (c) Nuvectis
    ceasing to carry on business, suspending, or threating to suspend, payment of its debts or is unable to pay its debts as they fall
    due or admits inability to pay its debts or is deemed to be unable to pay its debts within the meaning of section 123 Insolvency
    Act 1986;

     

    (d) Nuvectis
    or its directors or the holder of a qualifying floating charge or any of its creditors, appointing or making an application to the
    court for the appointment of, an administrator;

     

    (e) a petition
    being advertised or a resolution being passed or an order being made for the administration or the winding-up, bankruptcy or dissolution
    of Nuvectis; or

     

    (f) the happening
    in relation to Nuvectis of an event analogous to any of the above in any jurisdiction in which it is incorporated or resident or
    in which it carries on business or has assets;

 

    15 

     

    

 

	Intellectual
    Property Rights 	means Patents,
    Know-How, rights to inventions, supplementary protection certificates, copyright and related rights, trade marks and service marks,
    trade names and domain names, rights in get-up, goodwill and the right to sue for passing off and unfair competition, rights in designs,
    rights in computer software, database rights, rights to preserve the confidentiality of information (including rights in Know-How
    and trade secrets) and any other intellectual property rights, including all applications for (and rights to apply for and be granted)
    renewals or extensions of, and rights to claim priority from, such rights and all similar or equivalent rights or forms of protection
    which subsist or will subsist, now or in the future, in any part of the world;

     

	JAC

     
	means the joint
    advisory committee formed pursuant to the provisions of Clause 7;

     

	JAC Manager
    

     
	means as
    is defined in Clause 7.10;
	Key
    Activities	means any of
    the following in relation to a Licensed Product and/or Additional Licensed product:

                                                                                                 

    

    i.       significant
    research activity related to biological processes that a Licensed Product and/or Additional Licensed Product would or could affect,
    including, but not limited to, animal studies;

    ii.      active
    preclinical work required for any contemplated clinical trial, including any toxicology or pharmacokinetic work;

    iii.     active
    planning of a clinical trial (or in the event of issues arising with a Regulatory Authority in relation to a clinical trial, active
    negotiation with such Regulatory Authority and/or replanning of the clinical trial);

    iv.     actively
    seeking to obtain the necessary IND or other approvals to carry out a clinical trial;

    v.      active
    enrolment of patients into, or participation of patients in, a clinical trial, where relevant in accordance with the protocol in
    order to determine if the primary end point has been met;

    vi.     active
    monitoring, analysis or reporting on the data arising from a clinical trial where relevant in accordance with the protocol in order
    to determine if the primary end point has been met;

    vii.    manufacture
    or formulation of a Licensed Product and/or Additional Licensed Product for use in a clinical trial, including active process development
    work in support of planned manufacture; and

    viii.   preparation
    for and making submissions to regulatory agencies for an NDA or awaiting the outcome of such submission;

 

    16 

     

    

 

	Know-How	means
    technical and/or other information (whether patentable or not) (including information relating to inventions, discoveries, concepts,
    methodologies, models, algorithms, formulae, research, development and testing procedures, the results of experiments, tests and
    trials, manufacturing processes, techniques and specifications, quality control data, analyses, laboratory records, reports and submissions)
    which are proprietary and confidential and documented. Notwithstanding the foregoing, a proprietary and confidential compilation
    of information may be Know-How notwithstanding that some or all of its individual elements are in the public domain;
	Licensed Compounds	means (a) [***],
    and (b) any other compounds (including any deuterate, hydrate, solvate, salt, ester, racemate, polymorph, isomer) claimed in the
    Licensed Patents, including in each case any Improvement(s).  The Licensed Compounds in existence at the Effective Date
    are described in Schedule 4 Part B (including but not limited to [***]).
    Schedule 4 Part B will be updated from time to time by the JAC to identify any additional Licensed Compounds to be added to Schedule
    4 Part B after the Effective Date; provided that the failure to add any specific Licensed Compound to such schedule shall not cause
    such Licensed Compound not to constitute a Licensed Compound;
	Licensed Compound IP	means the Licensed Patents
    and the Licensed Compound Know-How; for the avoidance of doubt, excluding any such Patents and Know-How as solely relates to [***];
	Licensed Compound Know-How	means the Know-How owned or
    Controlled by the University which is directly related to Licensed Compounds, as set out in Schedule 2;
	Licensed Know-How	means Know-How owned or Controlled
    by the University that relates to the Licensed Product and is reasonably necessary or useful for the research, development, manufacture,
    use, or commercialization of the Licensed Product, other than the Licensed Compound Know-How, as detailed in Schedule 3; 
	Licensed
    Materials	means
    all tangible materials owned or Controlled by the University and relating to the Licensed Product as detailed in Schedule 4 Part
    A;

 

    17 

     

    

 

	Licensed
    Patents	means:

     

    (a)       the
    Patents set out in Schedule 1 and any Patents claiming priority therefrom, whether or not in existence at the Effective Date;

     

    (b)       all
    Improvement Compound Patents;

     

    (c)       any Patents filed on or after the Effective Date and claiming any Licensed Compound Know-How and/or Collaboration Compound IP;

     

    (d)       any Patents claiming priority from the Patents described in (a), (b) or (c);

     

	Licensed
    Product(s)	means
    any product and/or pharmaceutical composition(s) containing any Licensed Compound(s) either alone, or in combination with other agents,
    in each case in any form, presentation, formulation, delivery method or dosage form, including any deuterate, hydrate, solvate, analogue,
    modification, salt, ester, prodrug, racemate, polymorph, metabolite, isomer, derivative  or synthetic intermediate of any
    Licensed Compounds; 
	Licensed Technology
	means
    together the Licensed Compound IP, Licensed Know-How, the Licensed Compounds, Licensed Materials and the Collaboration IP; 
	Marketing
    Authorisation	means
    authorisation to place a medicinal or healthcare product on the market in the European Union or any part of it whether centrally
    or nationally authorised, or any equivalent authorisation granted by any Regulatory Authority in any country or region outside the
    European Union;
	Marketing
    Authorisation Application or MAA	means
    any application for a Marketing Authorisation;
	Major
    Markets	means [***];
	Milestones	means
    the Milestones detailed in Schedule 7;
	Milestone
    Event	means
    the Milestone Event detailed in Schedule 7;  
	Milestone
    Payment	means
    the Milestone Payment detailed in Schedule 7; 
	Minimum
    Annual Royalty 	means from
    the date of the First Commercial Sale of a Licensed Product and/or Additional Licensed Product for the Royalty Term: [***]($[***])
    in the Year of the First Commercial Sale, [***] ($[***]) in the second Year after the First Commercial Sale, and [***] ($[***]) per
    Year from the third Year onwards. The Minimum Annual Royalty will be credited against the earned royalty due and owing under this
    Agreement to the University for the Year in which the Minimum Annual Royalty payment was incurred;

 

    18 

     

    

 

	NDA	means
    a new drug application (as that term is used in Title 21 of the United States Code of Federal Regulations) filed with the FDA seeking
    regulatory approval to market and sell any Licensed Products and/or Additional Licensed Products in USA for a particular Indication,
    or a Marketing Authorisation Application filed pursuant to the requirements of European Directive 2001/ 83/ EC, or any equivalent
    or similar application filed with any other Regulatory Authority in any country or region in the Territory;
	Net
    Sales 	[***];

 

    19 

     

    

 

	Nuvectis Improvements
    and Nuvectis Improvement IP

     
	means
    as is defined in Clause 6.12 and for the avoidance of doubt, includes any Improvement Compound IP and/or Additional Licensed Patents
    respectively owned solely by Nuvectis, its Affiliates and/or Sub-Licensees;
	Nuvectis
    IP	means
    all Intellectual Property Rights generated at any time by or on behalf of Nuvectis and/or its Affiliates and/or any Sub-Licensee
    in connection with the exercise of the licences granted under this Agreement and/or under the DCA, including any Intellectual Property
    Rights comprised in or relating to any of the Nuvectis Results and includes Nuvectis Improvements and Nuvectis Improvement IP; 
	Nuvectis Results

     

     

     

     

     

     

    Oncology Indication
	means all technical
    data, Know-How, computer software, notes, chemical compounds, biological material, models, prototypes, specimens, drawings, reports
    and information, including all Product Safety Information and any further information generated under this Agreement, all documents
    concerning regulatory submissions and Marketing Authorisations, generated at any time by or on behalf of Nuvectis, its Affiliates
    and/or any Sub-Licensee in connection with the development, use, manufacture, supply or marketing of the Licensed Products and/or
    Additional Licensed Products;

     

    means the Indications
    defined under “Neoplasms” in the ‘International Statistical Classification of Diseases and Related Health Problems’
    as published by the World Health Organization as of the Effective Date;

     

	Orphan
    Drug Designation 	means
    designation as an orphan drug or equivalent under relevant national or other applicable regulations and/or legislation in any part
    of the world, including under the US Orphan Drug Act of 1983 or Orphan Drug Regulation 141/2000 in the European Union;

 

    20 

     

    

 

	Other
    Product 	means any product
    which incorporates a therapeutically effective active ingredient which is not part of the Licensed Technology and/or Nuvectis Improvements;

     

	Parties	means
    the University and Nuvectis and “Party” shall mean either of them;
	Patents	means:

     

    (a) any patent
    and patent applications;

     

    (b) any divisionals,
    continuations, continuations-in-part, extensions, counterparts or reissues (including foreign-filed counterparts or reissues), substitutions,
    confirmations, registrations, revalidations and additions of or to them; and

     

    (c) any patents,
    Supplementary Protection Certificates and similar rights that derive priority from or claim common priority with any of the foregoing;

     

	Patent
    Costs	means
    any costs and expenses incurred in filing, prosecuting, maintaining, defending and enforcing the Licensed Patents (and/or Additional
    Licensed Patents), including official filing, prosecution, maintenance and renewal fees, patent attorney, translation, legal and
    other professional fees and expenses and costs and expenses associated with any opposition or interference action;
	Pharmacovigilance	means the science
    and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem
    or any updated definition published by the World Health Organisation from time to time:

     

    (a) made before
    or after any Marketing Authorisation is granted in any country or region;

     

    (b) mandatory
    or voluntary;

     

    (c) spontaneous
    or periodic;

     

    (d) part of
    a Marketing Authorisation dossier or not;

     

	Phase
    I Clinical Trial	means a
    human clinical trial (in any country) that would satisfy the requirements of U.S. 21 CFR 312.21(a) or its non-U.S. equivalent the
    results of which could be used for a preliminary determination of safety in healthy individuals or patients in relation to a Licensed
    Product and/or Additional Licensed Product; 

 

    21 

     

    

 

	Phase
    II Clinical Trial	means
    a human clinical trial (in any country) that would satisfy the requirements of U.S. 21 CFR 312.21(b) or its non-U.S. equivalent the
    results of which could be used to establish the safety and efficacy of a Licensed Product and/or Additional Licensed Product in the
    target population and the results of which would contribute to the data package for a Phase III Clinical Trial. Phase II Clinical
    Trial shall include such human clinical study following completion of a dose-finding Phase I Clinical Trial or Phase I Clinical Trial
    portion of a “Phase Ib/IIa Clinical Trial”, which is usually exploratory and intended to obtain further information on
    safety and tolerability, pharmacokinetic or pharmacodynamic effects, dose-response, dose optimisation or (initial) efficacy of a
    product. If a study that is initiated as a Phase I Trial is expanded and the portion performed following such expansion meets the
    definition of a Phase II Trial then, from the date of expansion, that study shall be a Phase II Trial;
	Phase
    III Clinical Trial	means
    a human clinical trial (in any country) that would satisfy the requirements of U.S. 21 CFR 312.21(c) or its non-U.S. equivalent the
    results of which could be used to gather additional information about safety and effectiveness of a Licensed Product and/or Additional
    Licensed Product in a particular Indication in a manner sufficient to evaluate their overall benefit-risk relationship and file a
    BLA or NDA to obtain regulatory approval to market and sell that Licensed Product and/or Additional Licensed Product in any part
    of the Territory for the Indication being investigated by the study. Phase III Trial shall include such human clinical study following
    completion of the Phase II Trial portion of a “Phase IIb/IIIa” study. If a study that is initiated as a Phase II Trial
    is expanded and the portion performed following such expansion meets the definition of a Phase III Trial then, from the date of expansion,
    that study shall be a Phase III Trial;
	PIP	means an
    initial paediatric study plan (PSP) as described in § 505(B)(e) of the Federal Food, Drug, and Cosmetic Act as amended by the
    Food and Drug Administration Safety and Innovation Act or a paediatric investigation plan as described in Regulation (EC) 1901/2006
    Medicinal Products for Paediatric Use or any similar scheme anywhere in the Territory intended to improve access to medicines for
    children;

 

    22 

     

    

 

	Pivotal
    Clinical Trial	means
    a pivotal human clinical trial of a Licensed Product and/or Additional Licensed Product (whether or not denominated a “Phase
    3 Clinical Trial” under applicable regulations) with a defined dose or a set of defined doses of such Licensed Product and/or
    Additional Licensed Product designed to ascertain efficacy and safety of such Licensed Product and/or Additional Licensed Product
    for the purpose of enabling, without the performance of additional human clinical trials, the preparation and submission of an NDA
    or an MAA;
	POC	means
    proof of concept;
	Product
    Safety Information	means all filings,
    submissions, studies and reports concerning safety of the Licensed Products and/or Additional Licensed Products or Pharmacovigilance
    with or to any Regulatory Authority or a body designated or recognised by any Regulatory Authority for these purposes (including
    actual and suspected adverse event or adverse experience or drug reaction reports, product safety reports, risk management plans,
    Marketing Authorisation Applications and Marketing Authorisations) irrespective of whether:

     

    (a) made before
    or after any Marketing Authorisation is granted in any country or region in the Territory;

     

    (b) mandatory
    or voluntary;

     

    (c) spontaneous
    or periodic; or

     

    (d) part of
    a Marketing Authorisation dossier or not;

     

	Progress
    Report	means a
    detailed written report produced by Nuvectis in respect of: (i) the progress of development of Licensed Products against the Development
    Plan; (ii) activities undertaken within the preceding six (6) month period and technical developments including any negative findings
    or unexpected hurdles, progress against the Milestones and Development Milestones; (iii) the progress of any applications for Regulatory
    Approval and (where relevant) price approvals; (iv) the progress of and plans for the commercial exploitation of the Licensed Technology
    and marketing and sale of Licensed Products in the Major Markets for the subsequent twenty-four (24) months;

 

    23 

     

    

 

	Quarter
    or Quarterly	means
    the period beginning on the Effective Date and ending on the last day of the calendar quarter in which the Effective Date falls,
    and thereafter each successive period of three (3) consecutive calendar months ending on March 31, June 30, September 30 or December
    31;
	Receiving
    Party	means
    as is defined in Confidential Information;
	Regulatory
    Approval	means
    all regulatory approvals, clearances, licenses, registrations or authorizations (including all Marketing Authorisations) of a Regulatory
    Authority (including an NDA) necessary in any country in the Territory for the manufacturing, use, storage, import, transport, marketing,
    distribution and sale of Licensed Products and/or Additional Licensed Products, and in the European Economic Area and the United
    Kingdom, where necessary, payor approval of price and/or reimbursement for any Licensed Products and/or Additional Licensed Products
    in a regulatory jurisdiction;
	Regulatory
    Authority	means
    the FDA in the U.S, European Medicines Agency in the European Economic Area, Medicines and Healthcare products Regulatory Agency
    in the United Kingdom, and any supranational, federal, state or local regulatory agency, department, bureau or other governmental
    entity or any other regulatory authority(ies) in any country or region in the Territory that holds responsibility for granting Marketing
    Authorisation for a medicinal product in such country(ies), in each case together with any successor(s) thereto;
	Representatives	means trustees,
    council members, directors, officers, employees, students, contractors, or agents;

     

	Results
	means inventions,
    information, data, techniques, results, discoveries, software, materials, Know-How, developments or discoveries, whether or not patentable
    (regardless of the form or medium in which they are disclosed or stored);

 

    24 

     

    

 

	Royalty
    Term

     
	means, with
    respect to each Licensed Product and/or Additional Licensed Product in a country in the Territory, unless terminated in accordance
    with the provisions of Clause 11, the period beginning on the date of the First Commercial Sale of such Licensed Product and/or Additional
    Licensed Product in such country, and ending on the later to occur of: (a) the date when the Licensed Product and/or Additional Licensed
    Product is no longer within the scope of a Valid Claim of a Licensed Patent and/or Improvement Compound Patent and/or Additional
    Licensed Patents in the country of sale; or (b) the [***]
    anniversary of the date of the First Commercial Sale of that Licensed Product and/or Additional Licensed Product in the relevant
    country; or (c) the expiry of any Extended Exclusivity Period in the relevant country;

     

	SRC

     
	means the non-receptor
    tyrosine kinase SRC and any of its family members (YES, FGR, FYN, LCK, HCK, BLK, LYN and FRK);

     

	SRC
    Inhibitor 	means a compound
    that is an inhibitor of the SRC family kinases;

     

	Sub-Licensee
    	means any third
    party which is granted or receives a sub-licence of any of the rights licensed to Nuvectis under this Agreement;

     

	Sub-Licensee
    Revenue

     
	means any monetary
    and/or non-monetary consideration (including shares, options and others securities) received from time to time by Nuvectis in respect
    of any sub-licence granted by or through Nuvectis and/or its Affiliates under this Agreement and/or in consideration of the grant
    of the right to acquire such a sub-licence, including option fees, licence issue fees or other up-front payments, annual licence
    fees, milestones, or other lump sum payments which are directly attributable to the grant of the rights in question, but excluding
    (i) royalties (but without limiting Nuvectis’s obligation to pay royalties on Net Sales as provided herein) and (ii) research
    and development, to the extent not in excess of the cost to perform such activities and where the consideration is non-monetary (other
    than stock or shares), the open market value of such non-monetary consideration or if the open market value is not ascertainable,
    the value shall be assessed at the date the non-monetary consideration is received by Nuvectis or in the absence of agreement by
    the Parties, the value shall be determined by the Expert excluding in all cases above any income which forms part of the Net Sales
    and where shares, options, or other securities are obtained, then any payment of dividends or other income from such shares, options
    or other securities, and the purchase price paid for such securities;

     

	Supplementary
    Protection Certificate

     
	means a right
    based on a Patent pursuant to which the holder of the right is entitled to exclude third parties from using, making, having made,
    selling or otherwise disposing or offering to dispose of, importing or keeping the product to which the right relates, such as supplementary
    protection certificates in Europe, and any similar right anywhere in the world;

     

	Target Patent
    Country
	means Major
    Markets, Europe, China and Canada;

 

    25 

     

    

 

	Term	means
    as is defined in Clause 11.1;
	 

    Territory
	 

    means worldwide;

	 

    Third Party
	 

    means any person
    or entity other than the Parties and their respective Affiliates;

	 

    Third Party
    Service Providers
	 

    means a sub-contractor
    appointed by Nuvectis, any of its Affiliates and/or any of their Sub-Licensees for the provision of research, development and/or
    manufacturing services to Nuvectis, any of its Affiliates or any of their Sub-Licensee in connection with Licensed Products and/or
    Additional Licensed Products;

	 	 
	University
    Group 	means the University
    and any University Successor and each entity (howsoever constituted) controlled directly or indirectly by the University or a University
    Successor from time to time and any entity controlled directly or indirectly by the University or any University Successor to which
    all or a material part of the holding of the University Group in spin-out companies or the University Group's unlisted investment
    portfolio is transferred (individually a "University Group Member");

     

	University
    Successor 	means any entity
    (howsoever constituted) to which all or part of the University’s activities or statutory functions have been transferred or
    devolved or succeeding in whole or in part to the interest of the University;

 

	Valid
    Claim	means a claim
    of:

     

    (a) an issued
    and in force Patent which has not (i) expired; nor (ii) been permanently revoked, or found unenforceable or invalid by a court or
    other governmental agency of competent jurisdiction in a final and non-appealable judgment; nor (iii) been revoked, or found unenforceable
    or invalid by a court or other governmental agency of competent jurisdiction in an appealable judgement from which an appeal has
    not been taken in the time allowed; or

     

    (b) a pending
    Patent application which claim has not been (i) withdrawn, abandoned or finally disallowed without the possibility of appeal or refiling
    of the claim, or (ii) pending for more than [***] following
    the earliest filing date for which such application claims priority (unless and until such claim is granted) or is the result of
    amending another claim pending for more than [***] (either
    in the same application or in another application in the same jurisdiction);

 

    26 

     

    

 

	Wellcome
    Trust	means
    the Wellcome Trust a charity registered in England and Wales (registration number 210183); and
	Year	means
    each period beginning on January 1 and ending on December 31; provided that the first Year of the Term extends from the Effective
    Date to December 31 of the then-current Year, and the last Year extends from January 1 of such Year until the effective date of the
    termination or expiration of this Agreement.

		1.2	Interpretation

 

In
this Agreement:

 

		1.2.1	Clause
                                            and schedule headings shall not affect the interpretation of this Agreement;

 

		1.2.2	reference
                                            to the singular includes the plural and vice versa;

 

		1.2.3	reference
                                            to “writing” and “written” includes electronic mail;

 

		1.2.4	reference
                                            to “this Agreement” includes this Agreement as amended or supplemented from time
                                            to time;

 

		1.2.5	the
                                            words “include”, “including” and “in particular” are
                                            to be construed as being by way of illustration or emphasis only and are not to be construed
                                            so as to limit the generality of any words preceding them;

 

		1.2.6	a
                                            reference to a statute or statutory provision is a reference to it as amended, extended or
                                            re-enacted from time to time;

 

		1.2.7	a
                                            reference to a statute or statutory provision shall include any subordinate legislation made
                                            from time to time under that statute or statutory provision; and

 

		1.2.8	a
                                            reference to “and/or” shall be construed to mean if more than one option is applicable,
                                            both options (e.g. Licensed Products and Additional Licensed Products are being sold), but
                                            if there is only one option applicable, one option (e.g. only Licensed Products are being
                                            sold);

 

		1.2.9	a
                                            person includes a natural person, corporate or unincorporated body (whether or not having
                                            separate legal personality) and that person’s legal and personal representatives, successors
                                            and permitted assigns.

 

		2.	GRANT
                                            OF RIGHTS

 

		2.1	Licences.
                                            University hereby grants to Nuvectis, subject to the provisions of this Agreement,

 

		2.1.1	an
                                            exclusive licence, with the right to sublicense (in accordance with Clause 2.4 and 2.5),
                                            under Licensed Compound IP in the Field and in the Territory for the Term to develop, manufacture,
                                            have manufactured, use, have used, market, sell, have sold, offer to sell, have offered for
                                            sale, supply, dispose of and import, have imported, export, have exported and otherwise exploit
                                            Licensed Products, including the right to apply for Marketing Authorisations or carry out
                                            clinical trials for the purpose of obtaining a Marketing Authorisation;

 

    27 

     

    

 

 

		2.1.2	a non-exclusive licence, with the right
                                            to sublicense (in accordance with Clause 2.4 and 2.5) under Licensed Know-How, Licensed Materials
                                            and Collaboration Non-Compound IP in the Field and in the Territory for the Term to develop,
                                            manufacture, have manufactured, use, have used, market, sell, have sold, offer to sell, have
                                            offered for sale, supply, dispose of and import, have imported, export, have exported and
                                            otherwise exploit Licensed Products and/or Additional Licensed Products, including the right
                                            to apply for Marketing Authorisations or carry out clinical trials for the purpose of obtaining
                                            a Marketing Authorisation; and

 

		2.1.3	an exclusive licence, with the right
                                            to sublicense (in accordance with Clause 2.4 and 2.5) under any of the Collaboration Compound
                                            IP in the Field and in the Territory for the Term to develop, manufacture, have manufactured,
                                            use, have used, market, sell, have sold, offer to sell, have offered for sale, supply, dispose
                                            of and import, have imported, export, have exported and otherwise exploit Licensed Products,
                                            including the right to apply for Marketing Authorisations or carry out clinical trials for
                                            the purpose of obtaining a Marketing Authorisation.

 

		2.2	Scope of Licence. No right or
                                            licence is granted under this Clause to any Affiliate of Nuvectis except that Nuvectis is
                                            permitted to grant a sub-licence to any of its Affiliates in accordance with Clause 2.5.
                                            Except for the rights and licences expressly granted in this Agreement, University reserves
                                            all of its rights. Without limiting the foregoing, except as expressly set forth in this
                                            Agreement, under no circumstances will either Party and/or any of its Affiliates, as a result
                                            of this Agreement, obtain any ownership interest, license or other right (whether by implication,
                                            estoppel or otherwise) in or to any Intellectual Property Rights of the other Party and/or
                                            any of its Affiliates. Nuvectis will not use or practice any Licensed Technology outside
                                            the scope of or otherwise not in compliance with the rights and licenses granted to Nuvectis
                                            under this Agreement (and will procure same in respect of its Affiliates and/or Sub-Licensees).

 

		2.3	Formal licences. Each Party
                                            shall execute such confirmatory formal licences (the form of which is set out in Schedule
                                            12) as requested by the other Party which are necessary or appropriate for registration of
                                            the rights granted under this Agreement with patent offices and other relevant authorities.
                                            In the event of any conflict in meaning between any such licence and the provisions of this
                                            Agreement, the provisions of this Agreement shall prevail. Prior to the execution of any
                                            such formal licences, the Parties shall so far as possible have the same rights and obligations
                                            towards each other as if such licences had been granted.

 

		2.4	Sub-licensing. Nuvectis may
                                            grant sub-licences (through multiple tiers) of its rights under this Agreement, provided
                                            that:

 

		(1)	the granting of any sub-licences shall
                                            not relieve Nuvectis of any obligations or duties imposed on it under this Agreement;

 

		(2)	it shall not grant or allow the grant
                                            of any sub-licences to (i) a tobacco company (being any entity identified as such in the
                                            Cancer Research UK Code of Practice on Tobacco Industry Funding to Universities); or (ii) a party which is actively and/or currently
engaged in the manufacture, production or sale of weapons or ammunition;

 

    28 

     

    

 

		(3)	subject to the provisions of Clause 2.5,
                                            such sub-licence shall be on arm’s length commercial terms reflecting the market value
                                            of the rights granted;

 

		(4)	[***];

 

		(5)	[***];

 

		(6)	Nuvectis shall ensure that there are included
                                            in any sub-licence terms which shall enable Nuvectis to comply with its obligations under
                                            this Agreement;

 

		(7)	subject to the provisions of clause 12.6,
                                            each sub-licence shall, and shall be expressed in each sub-licence agreement to, terminate
                                            automatically upon termination of the license under clause 2.1 and/or any commercial licence
                                            to the Collaboration Option IP;

 

		(8)	[***];

 

		(9)	it shall diligently collect all amounts
                                            due under each sub-licence;

 

		(10)	Nuvectis shall ensure that each Sub-Licence
                                            does not prohibit Nuvectis’s grant and the implementation of any [***] hereunder;

 

		(11)	it shall be responsible for any breach
                                            of the sub-licence by the Sub-Licensee of Licensed Products and/or Additional Licensed Products,
                                            as if the breach had been that of Nuvectis under this Agreement;

 

		(12)	the grant of any sub-licence shall be
                                            without prejudice to Nuvectis’s obligations under this Agreement. Any act or omission
                                            of any Sub-Licensee which, if it were the act or omission of Nuvectis would be a breach of
                                            any of the provisions of this Agreement, will be deemed to be a breach of this Agreement
                                            by Nuvectis who will be liable to the University accordingly;

 

		(13)	the obligations in Clause 2.4 (3), (4),
                                            (5), (6) (excluding the development and commercialisation obligations set out in Clause 5.1),
                                            (8) and (9) shall not apply in relation to agreements that Nuvectis and/or a Sub-Licensee
                                            enters into with Third Party Service Providers, provided that: (a) such agreements relate
                                            to the provision of research, development and/or manufacturing services to Nuvectis and/or
                                            a Sub-Licensee in connection with Licensed Products and/or Additional Licensed Products;
                                            and (b) no rights are granted to such Third Party Service Providers to: (i) research, develop
                                            or manufacture its own products; and/or (ii) sell the Licensed Products and/or Additional
                                            Licensed Products;

 

		(14)	each subclause of this Clause 2.4 shall
                                            apply to each tier of sub-licence unless expressly stated otherwise.

 

		2.5	Special case of sub-licensing.
                                            Nuvectis shall be entitled to grant a sub-licence of its rights under this Agreement
                                            to any Affiliate of Nuvectis, provided that (i) all the requirements of Clause 2.4 shall
                                            apply to any further sub-licence granted by such Affiliate; and (ii) for the avoidance of
                                            doubt, Nuvectis shall share all Net Sales and Sub-Licensee Revenues obtained by such Affiliate
                                            with University in accordance with the provisions of Clauses 3.4 to 3.6 inclusive.

 

    29 

     

    

 

		2.6	[***]

 

		2.7	Reservation of rights.

 

		(1)	University (and the inventors of the Licensed
                                            Technology) reserve the perpetual, irrevocable, non-exclusive, fully paid-up, worldwide right
                                            to:

 

(i)       use
the Licensed Technology to carry out educational and research activities whether alone or in collaboration with others (including accepting
external charitable, government or other sponsorship for such purposes and granting sub-licences to other academic or not-for-profit
third party institutions for the same purposes) with the right to sub-license for such purposes as aforesaid;

 

(ii)       make
publications in relation to the Licensed Technology and any Results of research using the same in accordance with generally accepted
academic practice, subject to the provisions of Clause 8;

 

(iii)       transfer
the Licensed Compounds and samples of Licensed Materials which are the subject of Compound IP (and/or transfer elements or constituent
parts of such materials) to academic or other not-for-profit third party institutions solely for the purpose of non-commercial research
and academic purposes (including publication of the results of the research), provided that, in the event that (i) the main focus of
any such research is clinical or to satisfy any toxicological regulatory requirement, or (ii) any such Licensed Compounds or Licensed
Materials have been provided by Nuvectis, Nuvectis’s prior written consent has been obtained for such transfer.

 

		(2)	If any collaborators or funders of the
                                            research which led to the creation of the Licensed Technology, retain any rights to continue
                                            to use the Licensed Technology, then the licences granted under this Agreement to Nuvectis
                                            referred to above shall be subject to such rights as are set out in Schedule 9 and paragraph
                                            3 below.

 

		(3)	Nuvectis acknowledges that certain collaborators
                                            have retained rights to publish in relation to [***] pursuant to material transfer agreements
                                            entered into prior to the Effective Date as set out in Schedule 9. University will use reasonable
                                            endeavours to ensure that Nuvectis is given the opportunity to review publications and request
                                            delays for patenting purposes (through the University) in respect of material transfer agreements
                                            entered into on or after the Effective Date in respect of [***] for the Term.

 

		2.8	Provision of Licensed Know-How, Licensed
                                            Compound Know-How, Licensed Compounds and Licensed Materials. University shall, within
                                            30 days of Nuvectis’s written request, provide Nuvectis with: (a) copies of the Licensed
                                            Know-How and the Licensed Compound Know-How to the extent that the Licensed Know-How and
                                            the Licensed Compound Know-How have not already been provided to Nuvectis, and; (b) the Licensed
                                            Materials and Licensed Compounds. The University shall transfer the Licensed Materials to
                                            Nuvectis or a location specified by Nuvectis in writing within thirty days of Nuvectis’s
                                            request, and at Nuvectis’s cost. Nuvectis shall, and shall procure that its Affiliates
                                            and Sub-Licensees shall, use the Licensed Materials and Licensed Compounds solely for the
                                            purposes of exercising the licenses set out in this Agreement.

 

		2.9	Academic Research Licence to Nuvectis
                                            Results and Nuvectis IP. Subject to the provisions of Clause 8, Nuvectis hereby grants
                                            to the University a perpetual, irrevocable, non-exclusive, fully paid-up, worldwide right
                                            to use Nuvectis Results and Nuvectis IP to carry out academic research, teaching and development
                                            (including accepting external charitable, government or other sponsorship for such purposes)
                                            with the right to sub-license for such purposes as aforesaid.

 

    30 

     

    

 

		3.	PAYMENTS

 

		3.1	Signature Fee

 

A signature fee
for the execution of this Agreement is payable in two installments as follows:

 

3.1.1       three
million and five hundred thousand US dollars ($3,500,000) within thirty (30) days after the Effective Date, subject to Nuvectis’s
receipt of an invoice therefor; and

 

3.1.2       [***]
($[***]) on the [***] of the Effective Date, subject to Nuvectis’s receipt of an invoice therefor.

 

Payment is due
within thirty (30) days of the date of the University’s invoice.

 

		3.2	[***]

 

[***].

 

		3.3	Milestone Payments.

 

		3.3.1	Financing milestones. Nuvectis shall pay to the University, upon the occurrence of each
                                                                     Financing Event, 2.5% of the total gross amount of each Financing Event, (except for the initial funding round of ten million US
                                                                     dollars ($10,000,000) for which no payment will be made); provided that, such obligation shall be satisfied once Nuvectis has paid
                                                                     University a cumulative total of three million US dollars ($3,000,000) under this Section 3.3.1.

 

		3.3.2	Licensed Product.

 

		(a)	Nuvectis shall pay to University the
                                            non-refundable Milestone Payments on each Milestone Event.

 

		(b)	The Milestone Payment shall be due
                                            regardless of whether such Milestone Event is achieved as a result of the actions of Nuvectis,
                                            its Affiliates and/or its Sub-Licensees.

 

		(c)	[***].

 

		(d)	[***].

 

		(e)	The Milestone Payments may be triggered
                                            by a second or further Licensed Product in respect of an Indication, unless such Milestone
                                            Event has already been triggered by a preceding Licensed Product in that Indication.

 

		(f)	[***].

 

		(g)	Each Milestone Payment is distinct,
                                            and each is payable in addition to, and not instead of, any of other applicable Milestone
                                            Payment.

 

		(h)	An NDA may be submitted in respect
                                            of the entire European Union (through a Regulatory Authority such as the European Medicines
                                            Agency) or in respect of one or more individual countries within the European Union (through
                                            the Regulatory Authority of each such country).

 

    31 

     

    

 

		3.3.3	Nuvectis will notify the University
                                            within thirty (30) days after Nuvectis and/or its Affiliates becomes aware of the achievement
                                            of the Milestone Event and/or Financing Event for which a payment to the University is required
                                            and University shall send Nuvectis an invoice for same. Each Milestone Payment and/or payment
                                            for a Financing Event shall be due with thirty (30) days of the date of the respective invoice.

 

		3.4	Royalties on Net Sales of Licensed
                                            Products. Commencing upon the First Commercial Sale of a Licensed Product and
                                            continuing for the remainder of the Royalty Term and in accordance with Clause 4.1, Nuvectis
                                            shall pay to the University royalties on Net Sales of Licensed Products sold by Nuvectis,
                                            its Affiliates or Sub-licensees at the rates set out below. The following rates shall apply
                                            on a Licensed Product-by-Licensed Product and country-by-country basis to the respective
                                            tiers of aggregate Net Sales of all Licensed Products achieved in a given Year during the
                                            Royalty Term:

 

3.4.1       [***]
percent ([***]%) on that portion of Net Sales in such Year that is less than [***] US dollars ($[***] million); and

 

3.4.2       [***]percent
([***]%) on that portion of Net Sales in such Year that is equal to or greater than [***] US dollars ($[***]),                     but less than [***]US
dollars ($[***]); and

 

3.4.3     [***]percent
([***]%) on that portion of Net Sales in such Year that is equal to or greater than [***] US dollars ($[***]) but less                     than [***] US
dollars ($[***]); and

 

3.4.4       eight
percent (8%) on that portion of Net Sales in such Year that is equal to or greater than [***] US dollars ($[***]).

 

		3.5	Royalties on
                                            Net Sales of Additional Licensed Products.       Commencing
                                            upon the First Commercial Sale of any Additional Licensed Products and continuing for
                                            the remainder of the Royalty Term and in accordance with Clause 4.1, Nuvectis shall pay
                                            to the University royalties on Net Sales of each Additional Licensed Product sold by
                                            Nuvectis, its Affiliates and/or Sub-licensees during the Royalty Term at the rate of
                                            [***]percent [***]%) of Net Sales sold during that Year.

 

		3.6	Sub-Licensee
                                            Revenues.

 

		3.6.1	Licensed Product

 

		[***]:

 

		3.6.1.1	[***];

 

		3.6.1.2	[***]; and

 

		3.6.1.3	[***].

 

    32 

     

    

 

To the extent that Patents, other
Intellectual Property Rights or other rights or obligations other than the Licensed Technology are sublicensed or granted by Nuvectis,
the [***] shall be equitably apportioned between the Licensed Patents and those other rights and obligations, and such apportionment
shall be reasonable and in accordance with customary standards in the industry, as determined by good faith negotiations between the
Parties prior to Nuvectis providing the [***] Revenues to the University. [***].

 

		3.6.2	Additional Licensed
                                            Product

 

Nuvectis shall within thirty (30)
days of the end of each Quarter pay to, or make over to, the University on each Additional Licensed Product (on an Additional Licensed
Product by Additional Licensed Product basis) [***] per cent ([***]%) of the [***]                generated in that Quarter.

 

		3.7	Minimum Annual Royalty.
                                            If the aggregate sum paid by Nuvectis to the University under Clauses 3.4 to 3.5 (inclusive)
                                            in any full Year, is less than the Minimum Annual Royalty for that full Year, then Nuvectis
                                            shall pay to the University, within thirty (30) days of the end of the relevant full Year,
                                            such further sums as shall be necessary to bring the total payment by Nuvectis to the University
                                            for the relevant full Year up to the Minimum Annual Royalty.

 

		3.8	Non-monetary consideration.
                                            Nuvectis shall neither enter into any agreement, nor permit any agreement to be made,
                                            under which any non-monetary Net Sales and/or Sub-Licensee Revenues are obtained or due to
                                            be obtained by Nuvectis and/or its Affiliates and/or its Sub-Licensees, except with prior
                                            written notification to the University. Where Nuvectis and/or its Affiliates accepts Sub-Licensee
                                            Revenues in the form of shares, Nuvectis shall, if so requested by the University, pay the
                                            royalty due under this Agreement on such Sub-Licensee Revenues by causing the appropriate
                                            percentage number of such shares to be transferred to, and registered in the name of the
                                            University’s nominee (Edinburgh Technology Fund Limited or such other notified entity).
                                            If the Parties disagree as to the cash value of any non-monetary receipt, such disagreement
                                            shall be referred to the Expert.

 

		3.9	Combination products.
                                            In the event that any Licensed Product is sold as part of a Combination Product in a particular
                                            country, the Net Sales of such Licensed Product shall be determined by [***], where:

 

A is the average sales price generally
achieved during the relevant Quarter for the Licensed Product in the country in which such sale occurred, when the Licensed Product (as
applicable): (a) incorporates the relevant Licensed Technology and/or Nuvectis Improvements but no other therapeutically effective active
ingredient; or (b) is sold separately without Other Products;

 

B is the sum of the average sales price
generally achieved during the relevant Quarter in that country (as applicable): (a) of each therapeutically effective active ingredient
incorporated in the Combination Product when such compound is sold as an Other Product and not as part of a Combination Product; or (b)
of each Other Product included in the Combination Product when such Other Product is sold separately.

 

In the event that
the Net Sales of a Licensed Product when included in a Combination Product cannot be determined using the methods above for any Quarter,
then the Net Sales attributed to the Licensed Product shall be determined by mutual agreement reached in good faith by the Parties as
soon as reasonably practicable following the end of the Quarter in question based on an equitable method of determining the same that
takes into account, in the relevant country in the Territory, the latest sales price (if any) that applied in any previous Quarter and
the respective fair market values of the Licensed Product and Other Product(s) included in such Combination Product. Failing such agreement
the matter shall be determined by the Expert.

 

    33 

     

    

 

		3.10	Royalty stacking.
                                            If Nuvectis (or any Affiliate or Sub-Licencee) obtains (following prior consultation with
                                            the University as regards the necessity of any licence) a licence from any Third Party (excluding
                                            any Sub-Licensee) (a “Third Party Licence”) in order to avoid infringing
                                            a Valid Claim in such Third Party’s Patents or other Intellectual Property Rights in
                                            the course of Nuvectis’s (or any Affiliate’s and/or Sub-Licencee’s) development,
                                            manufacture or sale of a Licensed Product, and the Third Party Licence provides that Nuvectis
                                            (or any Affiliate and/or Sub-Licencee) shall pay such Third Party a royalty (a “Third
                                            Party Royalty”), then Nuvectis (or any Affiliate or Sub-Licensee) may deduct from
                                            any royalty due to the University hereunder [***] percent ([***]%) of the Third Party Royalty
                                            payable to such Third Party Licence, provided that the amount of royalties payable by Nuvectis
                                            to University under Clause 3.4 shall not be reduced by more than [***] percent ([***]%) by
                                            virtue of this Clause 3.10. The deductions referred to in this Clause shall only be made
                                            where (and to the extent that) the technology that is the subject of the Licensed Technology
                                            cannot be used without infringing a Valid Claim of the Third Party Patents or other Intellectual
                                            Property Rights that are the subject of the Third Party Licence (and shall not be made in
                                            respect of any other Third Party (excluding any Sub-Licensee) technology or Intellectual
                                            Property that Nuvectis (or any Affiliate and/or Sub-Licensee) chooses to use in the manufacture
                                            or sale of any Licensed Product). For the avoidance of doubt, this Clause 3.10 shall not
                                            apply to Combination Products.

 

		3.11	Generic
                                            Reduction. If a Generic Product for a Licensed
                                            Product is being sold in a country, the royalties payable by Nuvectis in respect of such
                                            country and such Licensed Product shall, subject to Clause 3.12, be reduced by (a) [***]
                                            percent ([***]%) from the first full Quarter after the date on which Level 1 Generic Competition
                                            first exists in such country, or (b) [***] percent ([***]%) from the first full Quarter after
                                            the date on which Level 2 Generic Competition first exists in such country, but only for
                                            so long as the applicable (Level 1 or Level 2) Generic Product is being sold in such country.

 

		3.12	Absolute
                                            floor to reductions. Notwithstanding any other provision of this Agreement,
                                            in the event that either or both of the reduction mechanisms set out in Clause 3.10 or
                                            3.11 are applicable to any Net Sales generated in any Year, in no circumstances shall Nuvectis
                                            be entitled to reduce the aggregate amount of the Net Sales royalties payable to the University
                                            in such Year, by more than [***] per cent ([***]%) of the amount which would have been payable
                                            to the University in the absence of the reduction mechanisms provided by Clause 3.10 and/or
                                            Clause 3.11 as applicable. 

 

		3.13	Historical Patent Costs. Nuvectis
                                            shall pay to the University within thirty (30) days of the Effective Date the following Patent
                                            Costs incurred up to and including the Effective Date: [***] ([***]).

 

    34 

     

    

 

		4.	PAYMENT TERMS AND
                                            AUDIT RIGHTS

 

		4.1	Payment frequency. Nuvectis
                                            shall pay to the University:

 

		(a)	the Signature Fee on
                                            the dates specified in Clause 3.1;

 

		(b)	[***];

 

		(c)	the Milestone Payments
                                            on the dates specified in Clause 3.3;

 

		(d)	the percentage of [***]
                                            on the dates and as specified in Clause 3.6;

 

		(e)	the royalties due pursuant
                                            to Clauses 3.4 and 3.5 shall be paid Quarterly within thirty (30) days of the end
                                            of each Quarter in respect of Net Sales generated;

 

		(f)	the Patent Costs in
                                            accordance with Clause 3.13 and Clause 6.

 

		(g)	the Minimum Annual Royalty
                                            on the dates specified in Clause 3.7.

 

		4.2	Payment mechanism.
                                            All sums due under this Agreement:

 

		4.2.1	are exclusive of Value Added Tax, or
                                            similar sales tax, which where applicable will be paid by Nuvectis to University in addition;

 

		4.2.2	shall be paid in US DOLLARS (unless
                                            stated otherwise) in cash (cleared funds) by transferring an amount to the bank account as
                                            specified by the University in Schedule 11, and in the case of Net Sales generated and Sub-Licensee
                                            Revenues received by Nuvectis in a currency other than US DOLLARS, the rate of exchange to
                                            be used for converting such other currency into US DOLLARS shall be the average of the exchange
                                            rate published in the Wall Street Journal, Western Edition, under the heading “Currency
                                            Trading” on the first Business Day of each month in the Quarter. All costs of transmission
                                            and currency conversion shall be borne by Nuvectis;

 

		4.2.3	shall be made without deduction of income
                                            tax or other taxes charges or duties that may be imposed, except insofar as Nuvectis is required
                                            to deduct the same to comply with applicable laws. The Parties shall cooperate and take all
                                            steps reasonably and lawfully available to them to avoid deducting such taxes and to obtain
                                            double taxation relief. If Nuvectis is required to make any such deduction it shall provide
                                            University with such certificates or other documents as it can reasonably obtain to enable
                                            University to obtain appropriate relief from double taxation of the payment in question;
                                            and

 

		4.2.4	shall be made by the due date, failing
                                            which University may charge interest on any outstanding amount from the due date onwards
                                            on a daily basis at a rate equivalent to [***] per cent ([***]%) per annum above the Royal
                                            Bank of Scotland plc base lending rate then in force in Edinburgh, provided in each case
                                            that University has notified Nuvectis in writing of such non-payment.

 

		4.3	Exchange controls. If, at
                                            any time during the Term, Nuvectis is prohibited from making any of the payments required
                                            hereunder by a governmental authority in any country then Nuvectis shall within the prescribed
                                            period for making the said payments in the appropriate manner use its best endeavours to
                                            secure from the proper authority in the relevant country permission to make the said payments
                                            and shall make them within seven (7) days of receiving such permission. If such permission
                                            is not received within thirty (30) days of Nuvectis making a request for such permission
                                            then, at the option of the University, either Nuvectis shall deposit the royalty payments
                                            due in the currency of the relevant country in a bank account designated by University within
                                            such country or such royalty payments shall be made to an associated company of University
                                            designated by University and having offices in the relevant country designated by the University.

 

    35 

     

    

 

		4.4	Royalty statements. At the
                                            same time as each royalty payment is due under Clauses 3.4 to 3.6 (inclusive), Nuvectis shall
                                            send to University a statement (the template for which will be provided by the University
                                            in due course) setting out, in respect of the Quarter to which the royalty payment relates
                                            and in respect of each country in the Territory in which Licensed Products and/or Additional
                                            Licensed Products are sold, disposed of and/or supplied:

 

		(a)	the amount of each type
                                            of Licensed Product and/or Additional Licensed Products sold, disposed of and/or supplied
                                            by Nuvectis, its Affiliates and/or Sub-Licensees in each country in the Territory during
                                            that Quarter and, if none, a statement to that effect;

 

		(b)	the amount of Licensed
                                            Products and/or Additional Licensed Products produced during the previous Quarter
                                            but not yet supplied, and, if none, a statement to that effect;

 

		(c)	the Net Sales in respect
                                            of each such type of Licensed Product and/or Additional Licensed Products sold, disposed
                                            of and/or supplied in each country in the Territory during that Quarter;

 

		(d)	the aggregate Net Sales
                                            in respect of that Quarter for Licensed Product and/or Additional Licensed Product;

 

		(e)	list of any sub-licences
                                            granted and, if none, a statement to that effect;

 

		(f)	details of all Sub-Licensee
                                            Revenues both due to, and received by, Nuvectis and/or its Affiliates during the
                                            previous Quarter and, if none, statement to that effect;

 

		(g)	the sums due and payable
                                            under Clause 3 and, if none, a statement to that effect;

 

		(h)	subject to Clause 4.2.2,
                                            any currency conversions, showing the rates used;

 

		(i)	the amount of royalties
                                            due to University in respect of that Quarter;

 

		(j)	the type and amount
                                            of any permitted deductions made by the Company from the sums referred to in Clause
                                            3 (by type of Licensed Product and/or Additional Licensed Product and country); and

 

		(k)	together with sufficient
                                            information to enable University to ascertain whether any Milestone Payments have become
                                            due or if any specific diligence conditions have occurred pursuant to Clause 5.2, expressed
                                            both in local currency and US Dollars and showing the conversion rates used, during the
                                            Quarter to which the royalty payment relates.

 

    36 

     

    

 

		4.5	Records. Nuvectis shall and
                                            shall procure that each Sub-Licensee and its Affiliate shall:

 

		4.5.1	keep at its normal place of business
                                            detailed and up-to-date records and accounts (including any underlying documents supporting
                                            such accounts and records) showing the quantity, description and value of Licensed Products
                                            and/or Additional Licensed Products sold, disposed of and/or supplied by it, its Sub-Licensees
                                            and/or its Affiliates and the amount and basis of Sub-Licensee Revenues received by it on
                                            a country-by-country basis, and being sufficient to ascertain the payments due under this
                                            Agreement for the Royalty Term and for a period of six (6) years after the expiry or termination
                                            of this Agreement; and

 

		4.5.2	make such records and accounts reasonably
                                            available, on not less than thirty (30) days’ written notice, for inspection during
                                            business hours by an independent chartered accountant nominated by University for the purpose
                                            of verifying the accuracy of any statement or report given by Nuvectis to University under
                                            this Clause 4. The accountant shall be required to keep confidential all information learnt
                                            during any such inspection, and to disclose to University only such details as may be necessary
                                            to report on the accuracy of Nuvectis’s statement or report. University shall be responsible
                                            for the accountant’s charges unless the accountant certifies that there is an inaccuracy
                                            of more than [***] percent ([***]%) in any royalty statement, in which case Nuvectis shall
                                            pay the charges in respect of that inspection within thirty (30) days of the University’s
                                            invoice for same. Such right of inspection may only be exercised once in any Year subject
                                            to Clause 4.6.

 

		4.6	Audit rights.
                                            University (and/or its nominee) shall not be entitled to carry out more than one inspection
                                            pursuant to this Clause 4.6 in any one Year except where an inspection confirms a shortfall
                                            exceeding [***] per cent ([***]%) of the sum properly payable. In such event, University
                                            (and/or its nominee) will then be entitled to carry out a second inspection each year for
                                            a further period of [***] following the date on which such a shortfall was confirmed.

 

If, following any inspection pursuant
to this Clause 4.6, University’s nominated accountant confirms to Nuvectis that the payments in respect of any Quarter or Year
fall short of the sums which were properly payable in respect of that Quarter or Year under this Agreement, University shall send a copy
of the certificate to Nuvectis and Nuvectis shall within thirty (30) days of the date of receipt of the certificate pay the shortfall
to University including the accountant’s charges if the shortfall exceeds [***] per cent ([***]%) in that Quarter or Year.

 

If, within thirty (30) days of the
date of receipt by Nuvectis any certificate produced pursuant to this Clause 4.6, Nuvectis notifies University in writing that it disputes
the certificate, the dispute shall be referred for resolution by the Expert.

 

For the purpose of verifying the
calculation of the sums payable under this Agreement, at any time during normal business hours upon providing seven (7) days’ written
notice, University (and/or its nominee) may:

 

		(a)	inspect all records,
                                            information and books of account of Nuvectis and any Affiliates and Sub-Licensees;

 

		(b)	subject to Clause 4.10, make and remove
                                            copies of, or extracts of, all relevant records, information and books of account of
                                            Nuvectis, its Affiliates and/or Sub-Licensees; and

 

		(c)	interview any of Nuvectis’s and/or
                                            its Affiliate’sand/or Sub-Licensees’ employees and directors who may reasonably
                                            be considered to have information relevant to the University’s enquiries that is not
                                            available to it under one of the preceding sub-Clauses.

 

    37 

     

    

 

		4.7	Nuvectis shall use reasonable commercial endeavours
                                            to ensure that, for the purpose of verifying the sums payable under this Agreement to the
                                            University (and/or its nominee), Nuvectis and the University (and/or its nominee) are granted
                                            the following rights (or substantially similar rights) in respect of each sub-licence granted
                                            pursuant to this Agreement:

 

		(a)	the right to inspect
                                            all records, information and books of account of the Sub-Licensee that are applicable
                                            to the sub-licence; and

 

		(b)	subject to appropriate
                                            obligations of confidentiality, the right to make and remove copies of, or extracts
                                            of, all relevant records, information and books of account of the Sub-Licensee that are
                                            applicable to the sub-licence (the “Audit Rights”). And upon the reasonable
                                            request of the University, Nuvectisshall exercise those Audit Rights and thereafter disclose
                                            all information received by Nuvectis as a result of the exercise of the Audit Rights,
                                            to the University (and/or its nominee).

 

		4.8	Nuvectis shall reasonably co-operate and shall
                                            require its agents and other professional advisers to reasonably co-operate, and shall use
                                            reasonable commercial endeavours to procure that its subcontractors, Sub-Licensees, Affiliates
                                            and its agents and other professional advisers reasonably co-operate, with the University
                                            or its duly authorised agent or representative whilst they are exercising the rights set
                                            out above.

 

		4.9	As provided in Clause 4.6, if the verification
                                            carried out above should reveal a discrepancy between the sums actually paid to the University
                                            as against the sums which were due to be paid under this Agreement, Nuvectis shall within
                                            thirty (30) days make up any shortfall to the University. If an inspection reveals an overpayment
                                            by Nuvectis, University will deduct such overpayment from any other amounts payable hereunder
                                            by Nuvectis to University.

 

		4.10	The University shall maintain, or shall require
                                            its duly authorised agent or representative to maintain, as confidential all financial information
                                            or information of a confidential or proprietary nature received from Nuvectis and/or its
                                            Affiliates and/or Sub-Licensee under this Clause 4.

 

		5	DILIGENCE, COMMERCIALISATION AND ADDITIONAL
                                            OBLIGATIONS

 

		5.1	Development and Commercialisation.
                                            During the Term, Nuvectis shall use Diligent and Reasonable Endeavours to:

 

		5.1.1	carry out the Development
                                            Plan;

 

		5.1.2	develop, promote,
                                            distribute, supply and sell one or more Licensed Products within the Field in each Major
                                            Market in the Territory and provide such marketing resources as may reasonably be expected
                                            to bring the Licensed Products to the attention of as many buyers and potential buyers as
                                            possible to maximise Net Sales and Sub-Licensee Revenue;

 

		5.1.3	pursue Regulatory
                                            Approval in each Major Market in the Territory for those Licensed Products in the Field in
                                            clinical development;

 

		5.1.4	pursue market penetration
                                            in each Major Market in the Territory for Licensed Products in the Field to maximise availability
                                            to patients;

 

    38 

     

    

 

		5.1.5	without prejudice
                                            to the generality of the foregoing, develop and commercialise in each Major Market at least
                                            one Licensed Product with an application in an Oncology Indication;

 

		5.1.6	provide such production
                                            facilities as may be reasonably necessary in Nuvectis’s discretion to meet all reasonable
                                            demands for the development, manufacture and commercialisation of Licensed Products in the
                                            Field in the Territory;

 

		5.1.7	produce the Licensed
                                            Products in accordance with good industry standards;

 

		5.1.8	subject to obtaining
                                            required Regulatory Approval in the United Kingdom with respect to a Licensed Product:

 

(i) make such Licensed Product available
in commercial markets in the United Kingdom within [***] of that Licensed Product being made available anywhere else in the Territory
provided that such period shall be extended to the extent of any delays caused by any Regulatory Authority;

 

(ii) [***]; and

 

		5.1.9	[***]

 

		5.2	[***].

 

		5.3	Development Plan. Nuvectis
                                            shall provide University with an updated, written Development Plan at least once every six
                                            (6) months and within fourteen (14) days before each regularly scheduled JAC meeting scheduled
                                            pursuant to Clause 7. The format of such Development Plan shall be no less detailed than
                                            the version annexed at Schedule 6 at the Effective Date, unless agreed otherwise by University
                                            and Nuvectis.

 

		5.4	Progress Report. Nuvectis
                                            shall:

 

		5.4.1	provide University with a Progress Report
                                            at least once every six (6) months and within fourteen (14) days before each regularly scheduled
                                            JAC meeting scheduled pursuant to Clause 7 (except that, where applicable, Nuvectis will
                                            provide Progress Reports at least once every Quarter during the eighteen (18) month period
                                            immediately following a change of Control of Nuvectis). University’s receipt or approval
                                            of any such Progress Report shall not be taken to waive or qualify Nuvectis’s obligations
                                            under Clause 5.1.

 

		5.4.2	promptly respond to any queries that
                                            University may have following receipt of a Progress Report;

 

		5.4.3	at University’s request, meet
                                            with University (either in person or by telephone, or videoconference) at least once every
                                            six (6) months to discuss the subject matter of the Development Plan or Progress Report as
                                            set out above (with at least one representative of Edinburgh Innovations), unless the matter
                                            has been discussed at the JAC. In addition, the Development Plan and Progress Report will
                                            be discussed by the Scientific Advisory Board in the Development Collaboration Agreement,
                                            at such frequencies as are set out therein.

 

		5.5	[***], then:

 

		5.5.1	[***];

 

		5.5.2	[***];

 

		5.5.3	[***].

 

    39 

     

    

 

		5.6	[***]:

 

		5.6.1	[***]

 

[***].

 

		5.7	Applicable Laws.

 

		(a)	Nuvectis shall, in exercising its rights
                                            and performing its obligations under this Agreement, comply with all applicable laws, regulations,
                                            codes of practice and Good Industry Practice.

 

		5.8	Marketing Authorisation.

 

		(a)	Nuvectis shall give University thirty
                                            (30) days’ written notice before submission of any Marketing Authorisation Application.

 

		(b)	If the Licensed Product and/or Additional
                                            Licensed Product fails on efficacy, safety or toxicological grounds or if Nuvectis fails
                                            to obtain Regulatory Approval for the Licensed Product and/or Additional Licensed Product
                                            in a country in the Territory, Nuvectis shall promptly give to University written notice
                                            and a summary of relevant information. Nuvectis shall, if requested, give further evidence
                                            reasonably required by University, at University’s cost.

 

		5.9	Insurance.

 

		(a)	Nuvectis shall, at its expense, carry
                                            product liability and comprehensive general liability insurance of an amount adequate to
                                            support its liabilities under this Agreement. Nuvectis shall ensure that such insurance policy
                                            remains in effect throughout the Term and for a period of [***] after termination or expiry
                                            of this Agreement, and shall supply University with a copy of such policy on request.

 

		(b)	Nuvectis shall obtain at its own expense
                                            all licences, permits and consents (including Marketing Authorisations) necessary for the
                                            development, manufacture and commercialization of the Licensed Products and/or Additional
                                            Licensed Products in the Field in the Territory.

 

		(c)	Nuvectis shall use Diligent and Reasonable
                                            Endeavours to perform its obligations in connection with the development, manufacture and
                                            commercialization of the Licensed Products and/or Additional Licensed Products in the Field
                                            in the Territory with all due skill, care and diligence, including Good Industry Practice.

 

		(d)	Nuvectis shall to the extent that it is
                                            required by applicable law, use pseudonymised or anonymised data in any Product Safety Information.

 

		(e)	Nuvectis shall use Diligent and Reasonable
                                            Endeavours to, and to the extent that it is practicable to do so, obtain explicit consent
                                            from clinical trial participants and others referred to in the Product Safety Information
                                            for Marketing Authorisation holders from time to time to process the participants’
                                            and other’s personal data for the purpose of development, manufacture, use, supply
                                            and marketing of Licensed Products and/or Additional Licensed Products and for the transfer
                                            of their personal data (including their sensitive personal data) between countries or regions
                                            within the Territory, including countries or regions whose data protection laws neither match
                                            nor exceed those applicable within Europe.

 

		(f)	Nuvectis shall ensure that its data protection
                                            officer co-operates fully with that of University in relation to any of the purposes in Clause
                                            5.9(e) and in connection with any security breach relating to any such personal data, reasonably
                                            determined by University to be sufficiently serious or substantial to justify the notification
                                            to the Information Commissioner or other relevant data protection supervisory authority.

 

		(g)	Nuvectis shall, if requested, execute
                                            any further documents reasonably required by University for any of the purposes in Clause
                                            5.9(f) or in connection with any such security breach.

 

    40 

     

    

 

		5.10	Additional Obligations.
                                            Nuvectis shall, and shall procure that its Affiliates and Sub-Licensees shall:

 

		(a)	use due skill, care
                                            and diligence including Good Industry Practice to ensure that the Licensed Products
                                            and/or Additional Licensed Products are safe for the use for which they were
                                            intended;

 

		(b)	obtain at its own expense
                                            all licences, permits and consents necessary for the provision of the Licensed Products
                                            and/or Additional Licensed Products in the Territory;

 

		(c)	perform its obligations
                                            in connection with the provision of the Licensed Products and/or Additional Licensed
                                            Products with all due skill, care and diligence including good industry practice;

 

		(d)	only make use of the
                                            Licensed Technology for the purposes authorised in this Agreement;

 

		(e)	without limitation,
                                            exploit the Licensed Technology solely in the Field;

 

		(f)	comply with all regulations
                                            and practices in force or use in the Territory required to safeguard the University’s
                                            rights in the Licensed Technology;

 

		(g)	obtain any Government
                                            approval required for this Agreement in any country in the Territory or the country
                                            of Nuvectis; and

 

		(h)	not use any child labour
                                            in the manufacture or distribution of the Licensed Products and/or Additional Licensed
                                            Products, and where third parties are to manufacture or distribute those Licensed
                                            Products and/or Additional Licensed Products, Nuvectis shall procure from those
                                            third parties written confirmation that they shall not use any child labour in the manufacture
                                            or distribution of the Licensed Products and/or Additional Licensed Products.

 

For clarity,
the Parties agree that the undertakings under this clause 5.10 shall (insofar as it relates to the Licensed Know-How, Licensed Compound
Know-How and Know-How in the Collaboration IP) survive expiry or earlier termination of this Agreement, except to the extent that they
enter the public domain after that date other than by breach of this Agreement by Nuvectis, its Affiliates and/or Sub-Licensees.

 

    41 

     

    

 

		5.11	EAMS and PIP. Nuvectis acknowledges
                                            that the inventors of the Licensed Technology have a particular interest in paediatric clinical
                                            pathways and care. Accordingly, Nuvectis will, if reasonably practicable, and in good faith,
                                            in respect of Licensed Products:

 

		5.11.1	make an application
                                            for a PIM designation and if awarded, continue with an application for approval under
                                            EAMS. If a positive scientific opinion (or equivalent) is given, continue with a
                                            Marketing Authorisation Application and following any Marketing Approval, make Licensed
                                            Products available for the approved Indication; and

 

		5.11.2	create a PIP and
                                            include paediatric investigations in clinical trials of the Licensed Products, seek
                                            Marketing Approval and following any Marketing Approval, make Licensed Products available
                                            for the approved Indication.

 

Nuvectis will provide regular written
updates on the matters, and its reasonable efforts to expedite access to Licensed Products, as set out in this Clause 5.11.

 

		6.	INTELLECTUAL PROPERTY

 

		6.1	Filing, Prosecution and Maintenance
                                            of Licensed Patents and Additional Licensed Patents. From the Effective Date
                                            Nuvectis shall, at Nuvectis’s expense:

 

		6.1.1	be responsible for the filing, prosecution
                                            and maintenance of the Licensed Patents and/or Additional Licensed Patents (in the name of
                                            University where they are owned solely by or jointly with the University) and will use its
                                            Diligent and Reasonable Endeavours to maximise the duration and scope thereof. With respect
                                            to each Licensed Product and/or Additional Licensed Product, Nuvectis shall, at the time
                                            of receipt of the relevant Regulatory Approval (or such other time as appropriate) and where
                                            it is commercially reasonable to do so, apply for a Supplementary Protection Certificate,
                                            patent term extension and/or any other available exclusivity in respect of such Licensed
                                            Product and/or Additional Licensed Products in each of the Major Markets;

 

		6.1.2	consult with University and agree a
                                            patent filing and prosecution strategy in respect of the Licensed Patents and/or Additional
                                            Licensed Patents and shall take into consideration all comments received from University
                                            in respect thereof, all in accordance with the provisions of the JAC;

 

		6.1.3	consult with University in relation
                                            to all material changes to the patent claims or specifications that would have the effect
                                            of reducing or limiting the scope of the Licensed Patents and/or Additional Licensed Patents,
                                            and not make any such changes without the prior written consent of the University. Such consent
                                            shall not be unreasonably withheld or delayed, provided that University has been given as
                                            much notice as is practicable, and in any event no less than [***] notice of such proposed
                                            changes, and has been given an opportunity to file divisionals, continuations and/or such
                                            other types of protection to cover any claims or subject matter that Nuvectis intends to
                                            remove from the scope of the Licensed Patents and/or Additional Licensed Patents;

 

    42 

     

    

 

		6.1.4	ensure that University promptly receives
                                            copies of all official correspondence in respect of the Licensed Patents and/or Additional
                                            Licensed Patents, including copies of all documents enclosed with such correspondence
                                            and is copied in all correspondence with patent agents; and

 

		6.1.5	subject to Clause 6.2, pay all fees
                                            in respect of all Licensed Patents and/or Additional Licensed Patents by their due date.

 

		6.2	Step-In. If Nuvectis
                                            elects not to prosecute or maintain any part of the Licensed Patents and/or Additional Licensed
                                            Patents or not to file a Patent application, in any Target Patent Country, it shall give
                                            University no less than [***] written notice of its intention together with all information
                                            necessary to enable University to determine whether to maintain or file such Patent or Patent
                                            application. During that [***] notice period, Nuvectis shall retain the responsibility for
                                            the prosecution and maintenance of the Licensed Patents and/or Additional Licensed Patents
                                            identified in such notice (each, an “Abandoned Patent”). From the date
                                            of expiry of such notice:

 

		6.2.1	Nuvectis shall cease to be licensed
                                            under the Patents identified in the notice and such Patents shall be deemed to be removed
                                            from the definition of Licensed Patents and/or Additional Licensed Patents;

 

		6.2.2	Nuvectis shall, at University’s
                                            request, promptly transfer a copy to University of any and all documents and information
                                            in Nuvectis’s control and possession relating to the Abandoned Patents (subject to
                                            any redactions relating to Patents other than the Abandoned Patents); and

 

		6.2.3	University may prosecute or abandon
                                            the Abandoned Patents at University’s sole discretion, cost and expense and grant rights
                                            under the Abandoned Patents to any person without further reference to Nuvectis.

 

		6.3	Infringement by Third Parties.
                                            Each Party shall notify the other Party promptly if it becomes aware of any infringement
                                            or potential infringement of the Licensed Patents and/or Additional Licensed Patents or misappropriation
                                            or potential misappropriation of any of the Licensed Know-How, Know-How in the Collaboration
                                            IP and/or Licensed Compound Know-How and the Parties shall consult with each other to agree
                                            how to respond. If the Parties fail to agree on a joint programme of action, including how
                                            the costs of any such action are to be borne and how any damages or other sums received from
                                            such action are to be distributed, then:

 

		6.3.1	Nuvectis shall be entitled to take action
                                            against the third party at its sole expense and in its sole discretion, subject to Clauses
                                            6.1 to 6.5 inclusive and shall report to University on the steps taken; and

 

		6.3.2	all damages or other sums received from
                                            such action including any settlements, after deduction of the out-of-pocket costs incurred
                                            by Nuvectis directly in connection with taking the action, will be considered Net Sales in
                                            respect of Licensed Products and/or Additional Licensed Products and Nuvectis shall pay royalties
                                            on such Net Sales in accordance with this Agreement.

 

In any such proceedings, University shall,
at Nuvectis’s cost, promptly provide Nuvectis with all documents and assistance as Nuvectis may reasonably require. Nuvectis shall
promptly provide University with notice of such proceedings and keep University regularly informed of progress and promptly provide University
with such information as it may require including copies of all documents filed at court in the proceedings.

 

    43 

     

    

 

		6.3.3	If Nuvectis does not take action against
                                            the third party within [***] of Nuvectis first giving or receiving notice of the infringement
                                            or potential infringement of the Licensed Patents and/or Additional Licensed Patents or the
                                            misappropriation or potential misappropriation of the Licensed Know-How, Licensed Compound
                                            Know-How, and/or any Know-How in the Collaboration IP and/or Improvement Compound Know-How
                                            (as the case may be), University shall be entitled to take action against the third party
                                            at its sole expense and in its sole discretion, and shall have the right to retain any damages
                                            or other sums received from such action. In any such proceedings Nuvectis shall promptly
                                            provide University (at University’s cost) with all documents and assistance as University
                                            may reasonably require and the University shall promptly provide Nuvectis with notice of
                                            such proceedings.

 

		6.4	Challenge to the Licensed Technology.
                                            Each of the Parties shall notify the other promptly if it becomes aware of:

 

		6.4.1	any opposition, re-examination, interference,
                                            or action for revocation or declaration of non-infringement, or other similar action alleging
                                            the invalidity, unenforceability or non-infringement of any Licensed Patents and/or Additional
                                            Licensed Patents; or

 

		6.4.2	any action or proceedings relating to
                                            the Licensed Know-How, Licensed Compound Know-How, Know-How in the Collaboration IP and/or
                                            Improvement Compound Know-How; and

 

the Parties shall consult with each
other to determine the best way to respond to such action. If University notifies Nuvectis that it does not wish to defend such action
then Nuvectis shall be entitled to defend such action at its sole expense and in its sole discretion subject to Clause 6.9, and in such
circumstances Nuvectis shall have the right to retain any costs awarded in relation to such action.

 

		6.5	Response to infringement of or challenge
                                            to Licensed Patents and/or Additional Licensed Patents. In respect of any
                                            action taken by Nuvectis under Clause 6.3, 6.4 or 6.6, Nuvectis shall:

 

		6.5.1	before starting any such action, consult
                                            with University as to the advisability of the action or settlement, its effect on the good
                                            name of the University, the public interest, and how the action should be conducted; and

 

		6.5.2	reimburse University for any reasonable
                                            expenses incurred in assisting Nuvectis in such action unless otherwise agreed in writing.

 

[***] University may, at its
discretion, at any time, take an active part in any proceedings which have been brought or defended by Nuvectis, and shall have the
right to be separately represented by its own counsel. University shall bear the costs of its own counsel and involvement in any
proceedings solely brought or defended by Nuvectis.

 

    44 

     

    

 

		6.6	Infringement of third party rights.
                                            If any warning letter or other notice of infringement is received by a Party, or legal
                                            suit or other action is brought against a Party, alleging (i) infringement of third party
                                            rights through the manufacture, use, sale or supply of any Licensed Product and/or Additional
                                            Licensed Products; or (ii) misappropriation or misuse of third party Know-How in the course
                                            of manufacture, use, sale or supply of any Licensed Product and/or Additional Licensed Products,
                                            that Party shall promptly provide full details to the other Party, and the Parties shall
                                            discuss the best way to respond. Nuvectis shall have the right but not the obligation to
                                            defend such suit and shall have the right to settle with such third party, provided that
                                            if any action or proposed settlement involves the making of any statement concerning the
                                            validity of any Licensed Patent and/or Additional Licensed Patents or any statement which
                                            may have an effect on the good name of the University, the consent of University must be
                                            obtained before taking such action or making such settlement and University shall not unreasonably
                                            withhold or delay such consent.

 

		6.7	[***].

 

		6.8	Non delegation. Without prejudice
                                            to the generality of, and except as expressly set forth in, Clause 13.5, Nuvectis may not
                                            assign, sub-license or delegate its rights or obligations in Clause 6.1 to 6.9 inclusive
                                            without the prior written consent of the University.

 

		6.9	Restriction on enforcement.
                                            Nuvectis shall not (and shall ensure that its Sub-Licensees and Affiliates shall not) enforce
                                            the Licensed Technology against any charity or other not-for-profit organisation undertaking
                                            non-commercial research. Nuvectis shall consult with the University prior to enforcing the
                                            Licensed Technology against any charity or other not-for-profit organisation undertaking
                                            commercial research.

 

		6.10	Ownership of Licensed Patents and Additional
                                            Licensed Patents. Subject to the terms and conditions of this Agreement, (i) the
                                            Licensed Patents, (ii) any Additional Licensed Patents licensed as part of the Licensed Technology,
                                            and (iii) any Patents claiming priority from (i) and (ii), whether or not in existence at
                                            the Effective Date shall at all times remain vested solely in the University.

 

		6.11	Ownership of Collaboration IP.
                                            Ownership of Collaboration IP arising from work carried out under the Development Collaboration
                                            Agreement shall be determined in accordance with the terms of the Development Collaboration
                                            Agreement.

 

		6.12	Nuvectis Improvements and Nuvectis
                                            Improvement IP. If Nuvectis at any time devises, discovers or acquires rights
                                            in any Improvements (generated solely by Nuvectis, its Affiliates and/or Sub-Licensees during
                                            the Term) (“Nuvectis Improvements”), Nuvectis shall, to the extent that
                                            it is not prohibited by law promptly notify University in writing giving details of it and
                                            provide to the University such information or [***]. [***].

 

All rights, title and interest in and
to Nuvectis Improvements and all Intellectual Property Rights therein (“Nuvectis Improvement IP”), are and shall remain
solely with Nuvectis. Nuvectis acknowledges that all such products embodying [***].

 

		6.13	[***].

 

		7.	JOINT ADVISORY COMMITTEE.

 

		7.1	Composition. The JAC
                                            shall be comprised of [***] representatives from [***] and in the case of Edinburgh this
                                            shall include [***], each with the requisite experience and seniority to enable such person
                                            to have discussions with respect to the issues falling within the jurisdiction of the JAC.
                                            Nuvectis shall select from its representatives the chairperson for the JAC. From time to
                                            time, Nuvectis may change the representative who will serve as chairperson on written notice
                                            to University. Each Party may allow up to three (3) observers
                                            to attend the JAC subject to ensuring that the observers are under obligations of confidentiality
                                            no less onerous than those set out in this Agreement but for the avoidance of doubt such
                                            observers will have no voting rights.

 

    45 

     

    

 

 

		7.2	Replacements. Each Party may remove any representative
nominated by it to the JAC and appoint any person (with the necessary expertise) to fill a vacancy arising from such removal or arising
from the retirement from the JAC of any representative nominated by it. Each Party shall give the other prior written notice of any proposed
changes in the identity of their representatives on the JAC.

 

		7.3	Purpose. The JAC shall:

 

(a) discuss and make recommendations for
the Intellectual Property strategy in relation to (i) Licensed Technology and (ii) Improvement Patents (iii) Nuvectis Improvements in
respect of which a University and/or Nuvectis employee is named as an inventor, (iv) Additional Licensed Patents in each case, including
Patent filing and prosecution strategy; provided that these activities shall be conducted through a patent sub-committee to be established
by the JAC and such patent sub-committee shall operate under the same rules as the JAC;

 

(b) operate as a forum for Nuvectis to
update University on its exploitation activities (including activities under the Development Plan) with respect to Licensed Products and/or
Additional Licensed Products;

 

(c) categorise Collaboration IP in conjunction
with the SAB (as defined under the Development Collaboration Agreement).

 

Nuvectis shall have the right, but not
the obligation to consult the JAC on matters relating to the exploitation of the Licensed Products and/or Additional Licensed Products.
At each meeting of the JAC:

 

(a) Nuvectis shall provide University
with an update on progress achieved in the exploitation of Licensed Products and/or Additional Licensed Products since the previous meeting
of the JAC. Each update shall contain such information as University may reasonably require to assess Nuvectis’s performance of
its obligations under Clause 5 in the period since the previous meeting of the JAC; and

 

(b) Nuvectis’s representatives shall
respond to any reasonable questions raised by University arising from such updates or the most recent Development Plan.

 

		7.4	Decisions. The JAC shall serve as a forum for discussion, updates and recommendations. Nuvectis
shall consider in good faith any guidance or recommendations given by University’s representatives on the JAC, but shall have no
obligation to follow any such guidance or recommendations and, without prejudice to its obligations under this Agreement, shall have the
sole right to make final decisions with respect to the development and commercialisation of [***] and Licensed Products
and/or Additional Licensed Products and the exploitation thereof.

 

		7.5	Frequency. The JAC shall meet by videoconference or in person:

                                                                                at least once every six (6) months until Nuvectis has completed the first Phase I Trial; and at least once every twelve (12) months for the rest of the Term.

 

    46 

     

    

 

		7.6	Quorum. The quorum for meetings of the
JAC shall be at least one (1) member of the JAC nominated by each Party.

 

		7.7	Location. All JAC meetings shall take place at mutually agreed locations or by video conference.
Neither Party will unreasonably withhold its consent to a request by the other Party to conduct a JAC meeting by video conference.

 

		7.8	Minutes. Minutes of each JAC meeting shall
be taken, and shall, at a minimum, record: amendments proposed or made to the Development Plan by Nuvectis; and material issues raised
by University, and responses provided by Nuvectis, in respect of Nuvectis’s diligence obligations under Clause 5.

 

The draft minutes of each meeting of the JAC shall be prepared by a member of the JAC nominated at the meeting (but excluding the chairperson)
for each such meeting. Drafts of the minutes shall be delivered by the JAC chairperson to the JAC Managers within fourteen (14) days
after the relevant JAC meeting. Minutes shall require the approval of both JAC Managers, and the chairperson shall send a copy of the
final minutes of each meeting as approved by the JAC Managers to each JAC representative. Either Party may escalate any dispute in respect
of issues raised with respect to the minutes, or the approval of any minutes of a JAC meeting pursuant to Clause 13.2. The meeting minutes
shall be Confidential Information of Nuvectis.

 

		7.9	Expenses. Each Party shall be responsible for all travel and related costs and expenses
for its members and other representatives to attend meetings of, and otherwise participate on, the JAC.

 

		7.10	JAC Manager. Each Party shall appoint a person(s)
who shall oversee contact between the Parties for all matters between meetings of each JAC and shall have such other responsibilities
as the Parties may agree in writing after the Effective Date (each, a “JAC Manager”). Each Party may replace its JAC
Manager at any time by notice in writing to the other Party.

 

		8	CONFIDENTIAL INFORMATION AND PUBLICATION

 

8.1 Confidentiality obligations.
Each Receiving Party undertakes:

 

		8.1.1	to maintain as secret and confidential all Confidential Information
of the Disclosing Party and take all reasonable precautions (but in no event less than such precautions consistent with reasonable
care) to prevent the unauthorised disclosure of it;

 

		8.1.2	not to disclose or permit the disclosure of any Confidential
Information of the Disclosing Party, in whole or in part, to any person, except in accordance with the provisions of this Agreement;

 

		8.1.3	not to use the Confidential Information of the Disclosing Party
for any purpose except the purposes of performing its obligations and exercising its rights under this Agreement and/or the Development
Collaboration Agreement (together the “Purpose”); and

 

		8.1.4	to inform the Disclosing Party immediately if it becomes aware
of the possession or use of any of the Confidential Information of the Disclosing Party by any unauthorised person, and to provide
all reasonable assistance to the other Party in relation to such unauthorised possession or use.

 

    47 

     

    

 

8.2 Additional confidentiality
obligations. Subject to this Clause 8.2, University agrees to maintain as secret and confidential all Licensed Compound Know-How
and not to use such information for any purpose except the Purpose after the Effective Date. University may disclose such information
under conditions of confidentiality to its patent agents and other appropriate advisors and to any other licensees under the Licensed
Technology (to the extent that University is permitted to grant such licences under the terms of this Agreement).

 

8.3 Exceptions to confidentiality
obligations. The obligations set out in Clauses 8.1 and 8.2 shall not apply to that part of the Confidential Information of the
Disclosing Party which the Receiving Party can demonstrate by reasonable, written evidence:

 

		8.3.1	was, prior to its receipt by the Receiving
Party from the Disclosing Party, in the possession of the Receiving Party without any obligations of confidence; or

 

		8.3.2	is subsequently disclosed to the Receiving Party, without any
obligations of confidence, by a third party who is entitled to disclose it without breaching any confidentiality obligations
to the Disclosing Party; or

 

		8.3.3	is or becomes generally available to the public through no fault
of the Receiving Party, its Affiliates and/or Sub-Licensees or its or their Representatives; or

 

		8.3.4	is permitted pursuant to the provisions of Clause 8.10; or

 

		8.3.5	is independently developed by or on behalf of the Receiving
Party, as evidenced by written records, without reference to, reliance upon, or use of the Confidential Information of the Disclosing
Party.

 

Specific aspects or details of Confidential
Information shall not be deemed to be generally available to the public or in the possession of the Receiving Party merely because the
Confidential Information is covered or embraced by a more general class of information generally available to the public or in the possession
of the Receiving Party. Any combination of information shall not be considered to be generally available to the public or in the possession
of the Receiving Party merely because individual elements of such information are generally available to the public or in the possession
of the Receiving Party.

 

		8.4	Required disclosure. The Receiving Party will not be in breach of its obligations
under Clauses 8.1 or 8.2 to the extent that it is required to disclose any Confidential Information of the Disclosing Party by or to a
court or other public body that has jurisdiction over it, or otherwise in accordance with applicable law, including any required disclosure
to any Regulatory Authority for the purpose of obtaining Marketing Approval, provided that the Receiving Party has given the Disclosing
Party written notice of the requirement as soon as possible prior to disclosing the Confidential Information and discloses only the minimum
amount necessary to comply with the requirement and, at the Disclosing Party’s request, seeks to petition the court or public body
to have the information treated in a confidential manner, where this is possible under the court or public body’s procedures.

 

    48 

     

    

 

		8.5	Permitted disclosure. The Receiving Party may:

 

		8.5.1	disclose the Confidential Information of the Disclosing Party to those of its Affiliates and Sub-Licensees
and its and their Representatives who reasonably need to access such Confidential Information for the Purpose; and

 

		8.5.2	disclose the Confidential Information of the Disclosing Party and details of its prosecution to potential
collaborators, royalty purchasers, potential investors, and actual investors who reasonably need to access such Confidential Information
for the purpose of the relevant collaboration or investment;

 

in each case, provided that before they
are given access to such Confidential Information they are made aware of its confidential nature, and are under a legally binding written
obligation to treat such Confidential Information in accordance with the terms of this Agreement. The Receiving Party shall procure that
all those to whom access to such Confidential Information has been given comply with the provisions of this Agreement. The Receiving Party
shall be liable to the Disclosing Party for any disclosure or misuse of such Confidential Information by those to whom access to such
Confidential Information has been given, whether directly or indirectly, by the Receiving Party.

 

		8.6	Additional University permitted disclosure. University may disclose Confidential Information
of Nuvectis to: (i) any University Group Member and its advisers; and/or (ii) any third party to whom the University is, at the Effective
Date, under a legal or contractual obligation to disclose such information and/or who was involved in the development of the Licensed
Technology, including without limitation the creation, invention or funding of the Licensed Technology. University shall, ensure that
such Confidential Information is treated in accordance with this Agreement.

 

		8.7	Term of confidentiality obligations. The Receiving Party’s obligations of confidence
and non-use in this Clause 8 shall, with respect to any Confidential Information, remain in full force until [***] after the expiration
or termination of this Agreement. The Parties acknowledge that either or both Parties may be obligated to file under applicable
law a copy of this Agreement with the SEC or other governmental authorities. Each Party shall be entitled to make such a required filing,
provided that it requests confidential treatment of at least the financial terms and sensitive technical terms hereof and thereof to the
extent such confidential treatment is reasonably available to such Party. In the event of any such filing, each Party will provide the
other Party with a copy of this Agreement marked to show provisions for which such Party intends to seek confidential treatment not less
than ten (10) Business Days (or a shorter period of time if required by applicable law) prior to such filing (and any revisions to such
portions of the proposed filing a reasonable time prior to the filing thereof), and shall reasonably consider the other Party’s
comments thereon to the extent consistent with the legal requirements, with respect to the filing Party, governing disclosure of material
agreements and material information that must be publicly filed, and shall only disclose Confidential Information which it is advised
by counsel or the applicable governmental authority is legally required to be disclosed. No such notice shall be required under this Clause
8.7 if the substance of the description of or reference to this Agreement contained in the proposed filing has been included in any previous
filing made by either Party hereunder or otherwise approved by the other Party and such information remains accurate as of such time.

 

		8.8	Confidentiality of this Agreement. The Parties shall use reasonable endeavours to
ensure that, to the extent permitted by relevant authorities, this Agreement shall not form part of any public record but may disclose
the terms of this Agreement to the funders of the Licensed Technology, if required.

 

    49 

     

    

 

		8.9	Permitted Reporting. Notwithstanding any other provision of this Agreement, the University
may identify the sums received from Nuvectis in the University’s Annual Report and similar publications, and Nuvectis may, in order
to comply with any transparency reporting obligations to which it is subject, publish details of any transfers of value, subject to Clause
13.2.

 

		8.10 	Publication.

 

		8.10.1	Process. Publications by the University of scientific
papers and/or proposed presentations at any conference, seminar or other public forum which in either case contain details of any
work that relates to the Licensed Technologyshall be sent to Nuvectis and Edinburgh Innovations (the “Reviewers”)
for review prior to submission for publication or prior to making the presentation (as applicable). The Reviewers shall review and make
any comments on the same within thirty (30) days of their receipt. A Reviewer may request that:

 

		(i)	Confidential Information of a Party be removed from the proposed
 publication or presentation excluding Results; and/or

 

		(ii)	any such publication or presentation be delayed if in the Reviewer’s reasonable opinion it is
necessary to delay publication or presentation in order to file a patent application or application for other proprietary protection in
respect of any invention made in the course of work relating to the Licensed Compound IP and/or Licensed Products and or Additional Licensed
Products. Any such delay will in no event extend beyond sixty (60) days from the date the proposed publication or presentation was provided
to the Reviewers.

 

		8.10.2	Acknowledgement. From the Effective Date, Nuvectis shall (and shall procure that each Sub-Licensee
shall) ensure that the University’s researchers shall be named as authors on the first publication of any Licensed Technology if
required by, and in accordance with, customary standards of scientific attribution; and acknowledge the University’s contribution
or involvement in the research and development of any Licensed Product and/or Additional Licensed Product (which, in the case of a Sub-Licensee
is the subject of the sub-licence) and the support of the Wellcome Trust in any academic publication, other trade publication or press
release relating to that Licensed Product and/or Additional Licensed Product, provided that Nuvectis obtains the University’s prior
written consent if it wishes to use the name or logo of the University or the Wellcome Trust in such publication.

 

		8.10.3	Nuvectis and DCA Publications. Publications related to work conducted under the DCA by Nuvectis
and/or University will be managed in accordance with the provisions of the DCA.

 

		8.10.4	Nuvectis acknowledges that the University has informed Nuvectis on the [***] of [***] of the submission
of [***] which will not be subject to the publications provisions in this Clause 8.10.

 

		9	WARRANTIES

 

		9.1	Mutual warranties. Each Party warrants to the other Party that:

 

		9.1.1	it is duly incorporated and validly existing under the laws of the jurisdiction in which it is incorporated;

 

    50 

     

    

 

		9.1.2	it has full power and authority to enter into, and to exercise its rights and perform its obligations
under, this Agreement; and

 

this Agreement, when executed, will constitute
valid, lawful and binding obligations on it, in accordance with its terms.

 

		9.2	University warranty. University warrants that:

 

		(a)	[***];

 

		(b)	[***]; and 

 

		(c)	[***].

 

		9.3	Acknowledgements. Nuvectis acknowledges that:

 

		9.3.1	the inventions claimed in ANY LICENSED technology are at an early
stage of development. Accordingly, specific results cannot be guaranteed and any results, licensed materials, licensed compounds information,
or other items provided under this Agreement are provided ‘as is’ and without any express or implied warranties, representations,
or undertakings. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, As examples, but without limiting the foregoing, University doES not
give any warranty that any such results, licensed materials, licensed compounds, information, or other items are of merchantable or satisfactory
quality, are fit for any particular purpose, comply with any sample or description, or are viable, uncontaminated, safe, or non-toxic;

 

		9.3.2	University haS not performed any searches or investigations into
the existence of any third party rights that may affect any of the Licensed Technology or its exploitation; and

 

		9.3.3	UNIVERSITY including ITS REPRESENTATIVES make no representations,
extend no warranties of any kind, either express or implied, including but not limited to the implied warranties of merchantability or
fitness for a particular purpose, and assume no responsibilities whatever with respect to DESIGN, development, manufacture, use or other
disposition of licensed products and/or additional licensed products.

 

		9.4	No other warranties

 

		9.4.1	Each of Nuvectis and University acknowledges that it does not
enter into this Agreement in reliance on any representation, warranty or other provision except as expressly provided in this Agreement,
and any conditions, warranties or other terms implied by statute or common law are excluded from this Agreement to the fullest extent
permitted by law.

 

    51 

     

    

 

		9.4.2	Without limiting the scope of CLAUSE 9.4.1 above, and subject
to clauses 9.1 and 9.2 above, UNIVERSITY doES not make any representation or give any warranty or undertaking:

 

		9.4.2.1	as to the efficacy or usefulness of the Licensed Technology; or

 

		9.4.2.2	that the use of any of the Licensed Technology, the manufacture,
sale, supply or use of Licensed Products and/or the additional licensed products or the exercise of any of the rights granted under this
Agreement will not infringe any other intellectual property or other rights of any other person; or

 

		9.4.2.3	that any information communicated by University to Nuvectis and/or
its affiliates under or in connection with this Agreement will produce Licensed Products and/or additional licensed products of satisfactory
quality or fit for the purpose for which Nuvectis intended; or

 

		9.4.2.4	imposing any obligation on University to bring or prosecute actions
or proceedings against third parties for infringement or to defend any action or proceedings for revocation of any of the Licensed Technology.

 

		10	INDEMNITY AND LIMITATION OF LIABILITY

 

		10.1	Indemnity. Nuvectis shall defend and indemnify, the University and each of its respective
Affiliates and the Representatives (together the “Indemnified Parties”) for any Loss. “Loss” shall
(i) mean any loss, demand, liability, judgment, fine, penalty, charge or other cost or expense of any nature or kind whatsoever including
legal costs and costs of recovery, resulting from, but not limited to, death, personal injury, illness, property damage, economic loss
or products liability, including errors and omissions, arising from or in connection with any third party claim relating to: (a) any use,
manufacture, or disposition of a Licensed Product and/or Additional Licensed Products or use of a method upon or utilising the Licensed
Technology and/or Additional Licensed Patents and/or Improvement Compound IP by Nuvectis (its Sub-Licencees and/or Affiliates) or any
other use of the Licensed Technology and/or Additional Licensed Patents and/or Improvement Compound IP by Nuvectis (its Sub-Licensees
and/or Affiliates); (b) any breach of the provisions of this Agreement by Nuvectis and/or its Affiliates; and (c) the negligence or fraud
of Nuvectis, its Affiliates and/or its Sub-Licensees, its servants or agents or others for whom Nuvectis is responsible including without
limitation any sub-contractors, Third Party Service Providers and Representatives; (d) Nuvectis’s exercise of the rights granted
to it under this Agreement; and (ii) all claims, demands, losses, causes of action, damages and expenses which are paid or payable by
a University Indemnitee arising from or in connection with such proceedings detailed in Clause 6.5.2, except that Nuvectis’s liability
for Losses under its indemnity (including as described in the foregoing clauses (i) and (ii)) shall be reduced or apportioned to the extent
any claim is caused by the University’s negligence or wilful misconduct. University shall notify Nuvectis upon becoming aware of
any Loss. Nuvectis shall have the right to control the defense of any claim for which it is providing indemnification hereunder and shall
have the right to settle any such claim provided that such settlement imposes no liability on an Indemnified Party and includes no admission
of wrongdoing by any Indemnified Party.

 

    52 

     

    

 

		10.2	Limitation of liability. Subject to clause
10.3, neither Party shall have any liability to the other under or in connection with this Agreement for any:

 

		(a)	wasted management or other staff time;

 

		(b)	losses or liabilities under or in relation to any other contract.

 

IN NO EVENT SHALL EITHER PARTY OR ITS
AFFILIATES (INCLUDING ITS REPRESENTATIVES) BE RESPONSIBLE OR LIABLE FOR ANY DIRECT, INDIRECT, SPECIAL, INCIDENTAL, OR CONSEQUENTIAL DAMAGES,
LOST PROFITS, OR OTHER ECONOMIC LOSS OR DAMAGE TO THE OTHER PARTY, ITS AFFILIATES AND/OR ITS SUB-LICENSEES REGARDLESS OF WHETHER SUCH
LOSS OR DAMAGE ARISES UNDER CONTRACT, TORT OR BASED UPON STRICT LIABILITY OR OTHER THEORY OF LAW OR EQUITY. THE ABOVE LIMITATIONS ON LIABILITY
APPLY EVEN THOUGH THE PARTIES HAVE BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGE.

 

		10.3	Exceptions to limitation of liability. Notwithstanding any other provision of this
Agreement, neither Party’s liability under or in connection with this Agreement shall be excluded or reduced for death or personal
injury arising from its negligence or breach of duty or any other liability that cannot be excluded at law.

 

		10.4	University liability cap. Subject to Clauses 10.2 and 10.3, the total aggregate liability
of the University for all and any breaches of this Agreement, any negligence or arising in any other way out of the subject matter of
this Agreement, will not exceed [***].

 

		11	TERM AND TERMINATION

 

		11.1	Commencement and expiry. This Agreement will commence on the Effective Date and unless
terminated earlier in accordance with this Clause 11 shall continue in force on a country-by-country and Licensed Product-by-Licensed
Product (and/or Additional Licensed Product-by-Additional Licensed Product) basis until the expiration of the last to expire Royalty Term
for such Licensed Product and/or Additional Licensed Product in such country pursuant to this Agreement (“Date”) and
on such Date, this Agreement shall expire in the relevant country and Nuvectis shall benefit from a non-exclusive, perpetual, irrevocable,
fully-paid up, sub-licensable licence under the Licensed Know-How, Licensed Compound Know-How and any Improvement Compound Know-How in
the Field in the relevant country. For the avoidance of doubt, the non-exclusive licence shall not apply if this Agreement is terminated
by breach under Clause 11.2 or terminated pursuant to Clause 11.3, or by Nuvectis under Clause 11.4.

 

		11.2	Termination for breach.
                                            Either Party may terminate this Agreement immediately by written notice to the other
                                            Party on or at any time after becoming aware of any failure by the other Party in any material
                                            respect to perform or comply with any of the other Party’s obligations under this Agreement,
                                            which (if capable of remedy) is not remedied to the reasonable satisfaction of the terminating
                                            Party within thirty (30) Business Days after the service on the other Party of a notice specifying
                                            the breach and requiring it to be remedied.

 

		11.3	Termination by the University. University may terminate this Agreement by giving at
least [***] prior written notice to Nuvectis:

 

		11.3.1	if Nuvectis ceases or threatens to cease to carry on its business in relation to the treatment, prevention
and/or diagnosis of human diseases or disposes of the whole or a material part of its business or assets;

 

    53 

     

    

 

		11.3.2	pursuant to Clause 5.5 ([***]);

 

		11.3.3	if Nuvectis or any of its Affiliates and/or Sub-Licensees commences legal proceedings, or assists any
third party to commence legal proceedings, to challenge the validity, ownership or enforceability of any of the exclusively licensed Licensed
Technology;

 

		11.3.4	if Nuvectis discontinues the development (including prosecuting application for Regulatory Approval) of
Licensed Products and/or Additional Licensed Products in the Field in the Territory for a consecutive period of [***];

 

		11.3.5	if Nuvectis is subject to an Insolvency Event during the Term (but the Agreement will terminate immediately
in that event and not on [***] notice as aforesaid);

 

		11.3.6	if Nuvectis, its Affiliates and/or Sub-Licensees contests the secret or substantial nature of the Licensed
Compound Know-How and/or Improvement Compound Know-How and/or other Know-How licensed as part of the Collaboration IP, provided that,
with respect to any contestation made by a Sub-Licensee, University shall not have any right to terminate this Agreement pursuant to this
Clause 11.3.6 if Nuvectis terminates the applicable sublicense with such Sub-Licensee within [***] after such contestation; or

 

		11.3.7	if Nuvectis fails to pay any sum due under this Agreement within [***] of the due date.

 

		11.4	Termination by Nuvectis.
                                            Nuvectis may terminate this Agreement at any time by giving at least ninety (90) days’ notice
                                            in writing to the University (if in Nuvectis’s reasonable opinion it is not scientifically
                                            or commercially viable to research, develop or commercialise the Licensed Products taking
                                            into account any reasonably relevant circumstances including any one or more of the following
                                            factors: safety, efficacy, product profile, the likelihood of obtaining regulatory approvals,
                                            the proprietary position of the compound or product and/or the cost of development or commercialisation).

 

		12	CONSEQUENCES OF TERMINATION

 

		12.1	Termination without prejudice to accrued rights. The termination or expiry of this
Agreement shall be without prejudice to any obligations, rights (including right to payment of amounts earned but not paid) or liabilities
of any of the Parties which have accrued before such termination or expiry. If a Party exercises a right to terminate under Clause 11,
such termination shall be without prejudice to any rights which the Party exercising such right may have in respect of such breach, and
such Party shall be entitled to recover from the other Party any Loss suffered as a result of the early termination of the Agreement.

 

		12.2	Surviving provisions. The provisions of Clauses 1, 2.6, 2.7, 2.9, 3 (solely with
respect to amounts that are due and payable as of the effective date of termination and in accordance with Clause 12.4), 4, 5.9(a), 6.10,
6.11, 6.12, 6.13, 8 (excluding Clause 8.10.1), 9, 10, 12, 13.1, 13.2, 13.4, 13.5, 13.6, 13.7, 13.8, 13.9, 13.10 and 13.12 shall remain
in effect notwithstanding termination or expiry of this Agreement.

 

    54 

     

    

 

		12.3	Return of Confidential Information. Upon termination of this Agreement, the Receiving
Party shall immediately return to the Disclosing Party (or destroy at the request of the
Disclosing Party) all Confidential Information of the Disclosing Party, make no further use of any of the Confidential Information of
the Disclosing Party save as is permitted by the terms of this Agreement, and permanently delete all electronic copies of any Confidential
Information of the Disclosing Party from the computer systems of the Receiving Party, its Affiliates and/or Sub-Licensees. The Receiving
Party shall procure that all those to whom access to such Confidential Information has been given comply with the provisions of this Clause.
With respect to Nuvectis, this Clause shall apply to the Licensed Know-How, Licensed Compound Know-How, Improvement Compound Know-How
and any Know-How in the Collaboration IP which are the Confidential Information of University.

 

		12.4	Termination of licences. Upon termination of this Agreement under Clause 11.2, 11.4
or 11.3 by the University:

 

		12.4.1	Nuvectis and its Sub-Licensees shall be entitled to sell and supply (subject to payment of royalties and
financial reporting in accordance with this Agreement and compliance with the other applicable terms of the Agreement) any unsold or unused
stocks of the Licensed Products and/or Additional Licensed Products for a period of [***] following the date of termination in accordance
with the terms of this Agreement;

 

		12.4.2	subject to Clause 12.4.1 above, Nuvectis, its Affiliates and/or its Sub-Licensees shall no longer be licensed
to use, sub-license or otherwise exploit in any way, either directly or indirectly, the Licensed Technology;

 

		12.4.3	subject to Clause 12.4.1 above, Nuvectis shall consent to the cancellation of any formal licence granted
to it, or of any registration of it in any register, in relation to any of the Licensed Patents and/or Additional Licensed Patents licensed
as part of the Collaboration IP;

 

		12.4.4	subject to Clause 12.4.1 above, all rights and licences granted to Nuvectis, its Affiliates and/or to
any Sub-Licensees hereunder shall cease;

 

		12.4.5	Nuvectis shall, at the request and option of University, return or destroy the Licensed Materials
and/or Licensed Compounds in its possession or control;

 

		12.4.6	Nuvectis shall promptly transfer a copy to University of any and all documents and information in Nuvectis’s
possession and Control that relate to the Licensed Patents, Improvement Compound Patents and/or Additional Licensed Patents, as applicable,
and University may assume responsibility for the prosecution and maintenance of the same;

 

		12.4.7	Nuvectis will return or destroy (as directed by the University) to the University all of the University’s
Confidential Information disclosed to it pursuant to this Agreement; and

 

		12.4.8	the University will return to Nuvectis or destroy (as directed by Nuvectis) all of Nuvectis’s Confidential
Information disclosed to it pursuant to this Agreement.

 

    55 

     

    

 

		12.5	Transfer of Licensed Products, Additional Licensed Products, Nuvectis IP and Nuvectis Results.
Upon termination of this Agreement under Clause 11.2 or 11.3 by the University, or under Clause 11.4 by Nuvectis:

 

[***][***]

 

		12.6	Third Party Rights. Within [***] of the applicable termination, Nuvectis shall notify University
and provide details of the extent to which any Nuvectis IP and/or Nuvectis Results to be licensed under the [***] would include
a sub-licence of rights granted to Nuvectis (or Affiliates) by a third party and provide such information and assistance as University
may reasonably request to assess the relevance of such third party Intellectual Property and, subject to applicable confidentiality restrictions,
the terms associated with the licence granted to Nuvectis under it.

 

		12.7	Sub-licensees. Upon early termination of this Agreement by University for any reason, where
such termination has been caused through no fault of a Sub-Licensee, University may, if requested by a Sub-Licensee within [***] after
the effective date of termination, grant to the Sub-Licensee a direct licence under the Licensed Technology of the scope of the original
sub-licence, but otherwise on the terms of this Agreement or such other terms as deemed appropriate by the University and such Sub-Licensee.

 

		12.8	Certain Provisions. Upon the expiry or termination of this Agreement solely in respect of
a particular Licensed Product and/or Additional Licensed Product, the provisions of Clauses 12.1 to 12.7 inclusive (as applicable) shall
apply, but only in respect of the relevant Licensed Product and/or Additional Licensed Product.

 

		12.9	Payments. Subject to Clause 12.4.1, upon termination of this Agreement: payment of royalties
and all other sums due to University prior to termination shall be payable to University in accordance with the terms of this Agreement
and Nuvectis shall, within [***] of notice of termination or expiry of this Agreement, provide University with a final written statement
detailing, in respect of the time elapsed since the last report under Clause 4.4, the matters set forth in Clause 4.4. In respect of the
matters detailed in Clause 12.4.1, Nuvectis shall provide the final written statement within [***] of the end of the [***] period stated
therein.

 

		13	GENERAL

 

		13.1	Entire agreement. This Agreement and all documents referred to in it (including the
Development Collaboration Agreement) constitute the entire agreement between the Parties about the subject matter of this Agreement
and, in relation to such subject matter, supersede and extinguish all earlier understandings and agreements between the Parties
and all earlier representations by any Party or its Affiliates. The Parties have not enteredinto this Agreement in reliance upon any
representation, warranty or promise. No representation or warranty or condition or any other term is to be implied in this Agreement whether
by virtue of any usage or course of dealing or otherwise except as expressly set out in it. For clarity, this Agreement supersedes that certain Confidentiality
Agreement by and between the University and Nuvectis, dated [***].

 

    56 

     

    

 

		13.2	Announcements and use of names. Neither Party shall make, or procure or permit the
making of, any announcement which relates to this Agreement or the matters contained in it, or make use of the name of the other Party,
without the written approval of the other Party (such approval not to be unreasonably withheld or delayed), except to the extent required
by law or any public body with appropriate jurisdiction. The Parties will issue a joint press release to announce the execution of this
Agreement and will mutually agree on the content of such press release in advance of disclosure.

 

		13.3	Force majeure.  If Nuvectis is prevented from or delayed in performing any of its
obligations under this Agreement (the “Affected Obligations”) due to a Force Majeure Event it shall give written notice
to University within three (3) Business Days of the first occurrence of the Force Majeure Event specifying the circumstances giving rise
to the Force Majeure Event and the period by or during which it estimates performance of the Affected Obligations may be delayed or prevented.
If such notice is given within such period, the time for performing the Affected Obligations shall be suspended for the duration for which
Nuvectis is unable to perform or delayed in performing the Affected Obligations by reason of the Force Majeure Event. If the period of
suspension or delay extends for a continuous period of [***] or an aggregate period of [***], University may terminate this Agreement
immediately by written notice to Nuvectis. Nuvectis shall use its reasonable endeavours to mitigate the effects of the Force Majeure Event
on the performance of its obligations under this Agreement.

 

		13.4	Amendment. This Agreement may only be amended in writing signed by duly authorised
representatives of the University and Nuvectis.

 

		13.5	Assignment. Except as set out in this Clause, a Party may not, without the written
consent of the other Party, assign or delegate of any of its rights or obligations under or in connection with this Agreement, nor sub-contract
any of its obligations under this Agreement. Notwithstanding the foregoing, Nuvectis may assign this Agreement without such consent to
its Affiliates or to any third party in connection with the sale of all or substantially all of the assets of Nuvectis to which this Agreement
relates, and University may legally or equitably dispose of any of its rights or obligations under or in connection with this Agreement
to any University Group Member or to any third party. No assignment shall be valid and effective unless and until the assignee shall agree
in writing to be bound by the provisions of this Agreement.

 

		13.6	Third party rights. Except as provided in this Clause, a person who is not a Party
has no right to enforce any term of this Agreement. Notwithstanding the foregoing, the Indemnified Parties may enforce the terms of Clause
10.1 to the extent consistent with applicable law.

 

		13.7	Waiver. A waiver of any term, provision or condition of, and any consent granted
under, this Agreement will be valid only if it is in writing, signed by the Party giving it. Any such waiver, consent or approval will
be valid only in the particular instance and for the particular purpose for which it is given and will not constitute a waiver of any
other right or remedy. Any failure (in whole or in part) to exercise or delay in exercising any right, power or remedy (“Right”)
available under this Agreement or in law will not constitute a waiver of that or any other Right, nor will any single or partial exercise
of any Right preclude any other or further exercise of that or any other Right. The rights and remedies provided by this Agreement are
cumulative and (unless otherwise expressly stated in this Agreement) may be exercised without excluding any other rights or remedies available in law.

 

    57 

     

    

 

		13.8	Relationship of the Parties. This Agreement is not intended and does not operate
to create a partnership between the Parties, or to authorise any Party to act as agent for the other, and neither Party shall have authority
to act in the name or on behalf of or otherwise to bind the other Party.

 

		13.9	Notices. Where this Agreement provides for the giving of notice or the making of
any other communication, such notice or communication shall not (unless otherwise expressly provided) be effective unless given or made
in writing in accordance with this Clause. Any notice or communication may be delivered or sent by the methods set out below, to the address
for notices detailed below and will be deemed to have been received at the corresponding time set out below:

 

	Method of Delivery	Deemed time of receipt
	By hand or courier	At the time actually received
	By recorded delivery post	The next Business Day after sending
	By electronic mail	At the time of sending except that if an automatic electronic notification is received by the sender within 24 hours after sending the electronic mail that the electronic mail has not been delivered to the recipient or that the recipient is out of office, that electronic mail will be deemed not to have been served

 

In the case of notices to the University
to: 

 

[***]

 

and marked for the attention of the
CEO, with a copy to the Director of Legal Services (reference [***]) or such other address as may be intimated from time to time in writing
by the University to Nuvectis.

 

In the case of notices to Nuvectis
at its registered office 

 

1 Bridge Plaza N., Suite 275, Fort
Lee, NJ 07024

 

marked for the attention of [***]

with a copy by email to [***] or such
other address as may be intimated from time to time in writing by Nuvectis to the University.

 

		13.10	Law and jurisdiction. Any dispute arising out of or in connection with this Agreement,
including any question regarding its existence, validity or termination shall, except as expressly provided in this Agreement, be referred
to and finally resolved by arbitration under the International Centre for Dispute Resolution in accordance with its International Arbitration
Rules. The number of arbitrators shall be three. The seat, or legal place, of arbitration shall be London. The language to be used in
the arbitral proceedings shall be English. The governing law of this Agreement shall be English law.

 

    58 

     

    

 

		13.11	Further action. At any time after the date of this Agreement each Party shall, and
shall use all reasonable endeavours to procure that any necessary third party shall, at the sole cost and expense of that Party, execute
and deliver all such deeds and documents in a form reasonably satisfactory to the other Party and do such matters, acts and things as
may reasonably be required for the purpose of giving the other Party the full benefit of all the terms, conditions and provisions of this
Agreement.

 

		13.12	Escalation. If there is a dispute, controversy
or claim arising out of or relating to this Agreement, the breach, termination or invalidity hereof or any non-contractual obligations
arising out of or in connection with this Agreement (each, a “Dispute”), either Party shall refer such Dispute to
the respective Executive Officers, and the Executive Officers shall attempt in good faith to resolve the Dispute. If the Parties are
unable to resolve a given Dispute pursuant to this Clause 13.12 within fifteen (15) Business Days after delivery of a written notice
referring the Dispute to the Executive Officers, either Party may:

 

have the given Dispute settled by
an Expert and where the Dispute relates to the scope, validity, enforceability or infringement of any Patents Covering a Licensed Product
and/or Additional Licensed Product, submit the dispute to a court of competent jurisdiction in the country in which such Patent rights
were granted or arose; or where the Dispute does not relate to any matter described above, have the given Dispute settled by binding arbitration
pursuant to Clause 13.10.

 

It shall be a condition precedent
to the reference of any Dispute to an Expert, to arbitration or to any action in court or other tribunal (other than an action for an
interim injunction or relief) that the Parties have sought to resolve the Dispute through their respective Executive Officers under this
Clause 13.12.

 

	Signed for and on behalf of THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH	 	Signed for and on behalf of NUVECTIS PHARMA, INC.
	 	 	 	 	 
	Signed:	 	 	Signed:	      
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

SCHEDULE 1

 

LICENSED PATENTS

 

 

[***]

 

    59 

     

    

 

SCHEDULE 2

 

LICENSED COMPOUND KNOW-HOW

 

 

This section includes all Know-How directly
related to Licensed Compounds, including chemical structures and physicochemical profile, methods of synthesis and biological properties.

 

[***]

  

    60 

     

    

 

SCHEDULE 3

 

LICENSED KNOW-HOW

 

PART
A: [***]

 

PART
B: [***]

  

    61 

     

    

 

SCHEDULE 4

 

PART A: LICENSED MATERIALS

 

		·	[***]

 

PART B: LICENSED COMPOUNDS 

 

Licensed Compounds in existence at the Effective
Date are listed in the Data Room, folder 1, file “Structures of all compounds synthesised (University of Edinburgh).

 

    62 

     

    

 

SCHEDULE 5

 

COLLABORATION IP

 

		I.	Collaboration Compound
                                            IP

 

		II.	Collaboration Non-Compound
                                            IP

 

		III.	Collaboration
                                            Option IP

 

		IV.	Additional Licensed
                                            Patents

 

		V.	Improvement Compound
                                            Know-How

 

		VI.	Improvement Compound
                                            Patent

 

    63 

     

    

 

SCHEDULE 6

 

DEVELOPMENT PLAN

NXP900Nuvectis
Pharma Development Plan

 

 [***]

 

[***]

 

[***]

 

		a.	[***]

 

		b.	[***]

 

		c.	[***]

 

		d.	[***]

 

[***]

 

[***]

 

		a.	 

 

[***]

 

	Total	[***]	[***]

Notes to Table 1

 

    64 

     

    

 

SCHEDULE 7

 

MILESTONE PAYMENTS

 

    65 

     

    

 

SCHEDULE 8

 

DEVELOPMENT MILESTONES

 

	
    Development Milestone
	Development Milestone Date
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
	[***]	[***]
		[***]

 

    66 

     

    

 

Commercial Milestones

 

	[***]	[***]
	[***]	[***]

 

    67 

     

    

 

SCHEDULE 9

 

THIRD PARTY RIGHTS AND OBLIGATIONS 

 

[***]

 

    68 

     

    

  

SCHEDULE 10

 

EXPERT DETERMINATION PROCEDURE

 

		1.	The Party wishing to refer a matter to an independent expert
pursuant to a provision of this Agreement shall give written notice to that effect to the other Party giving details of the matters
it wishes to refer to the expert (“Referral Notice”).

 

		2.	The Parties shall agree the identity of a single independent,
impartial expert to determine such terms. In the absence of such agreement within 14 days after receipt of the Referral Notice,
either Party may apply to the Expert Appointment Body to appoint, as an independent expert, a person qualified by education, experience
and training to determine the matter in dispute (the “Expert”).

 

		3.	Within 14 days after the appointment of the Expert the Parties shall exchange, as appropriate their statements
of case, or proposed terms together with any relevant explanation of the basis of those terms, (the “Submission”) and
shall simultaneously send a copy of its Submission to the Expert.

 

		4.	Each of the Parties may, within 30 days of the date of exchange of their Submissions, serve a reply to
the other Party’s Submissions. A copy of any such reply shall be simultaneously sent to the Expert.

 

		5.	The Expert shall make his decision on the matter in dispute on the basis of the Submissions and replies
and supporting documentation only and there shall be no oral hearing. The Expert shall, to the extent reasonably possible issue his decision
in writing with reasons within 30 days of the date of the last reply pursuant to paragraph 4 above or, in the absence of receipt of any
replies, within 60 days of the date of exchange pursuant to paragraph 3 above.

 

		6.	The determination of the Expert shall be final and binding upon the Parties. Both Parties agree to be
bound by and, subject to any relevant provision in this Agreement, to implement the written decision of the Expert with no right of appeal.

 

		7.	Any person appointed to determine a dispute in accordance with this procedure shall act as an Expert and
not as an arbitrator and the provisions of the Arbitration Act 1996 (as amended from time to time) and the law relating to arbitrations
shall not apply to such Expert or his determination or the procedure by which he reaches his determination.

 

    69 

     

    

 

		8.	Each Party shall bear their own costs in connection with the reference of a dispute to an Expert and the
costs of the Expert (including the costs of any advisers engaged by him) will be paid by the parties to the dispute in equal proportions
unless otherwise determined by the Expert.

 

SCHEDULE 11

 

UNIVERSITY BANK DETAILS

 

Payment to be made
by direct bank credit (or BACS) to the following bank account:

 

[***]

 

Account Name: [***]

Sort Code: [***]Account number: [***]

 

IBAN :   [***]

IBAN BIC :   [***]

 

Quoting references: [***]

 

    70 

     

    

 

SCHEDULE 12

 

CONFIRMATORY FORMAL LICENCES

 

THIS AGREEMENT is made the day of [202[ ]]

 

1) THE UNIVERSITY COURT OF THE UNIVERSITY OF
EDINBURGH, a charitable body registered in Scotland under registration number SC005336, incorporated under the Universities (Scotland)
Acts and having its main administrative offices at Old College, South Bridge Edinburgh, EH8 9YL (the “University”);

 

and

 

2) NUVECTIS PHARMA, INC (File Number 3319093),
a corporation organised and existing under and by virtue of the Delaware General Corporation Law (“Nuvectis”).

RECITALS:

 

By an agreement (the “Main Agreement”)
dated [        ] and made between University and Nuvectis, University agreed for the consideration therein contained, among other things, to
grant to Nuvectis a licence under the Licensed Patents and/or Additional Licensed Patents detailed in ANNEX 1 (the “Licensed
Patents” and/or “Additional Licensed Patents” as applicable), of which this Agreement is a confirmatory licence.

 

OPERATIVE PROVISIONS:

 

		1.	Capitalised terms as are defined in the Main Agreement unless
stated otherwise.

 

		2.	In pursuance of, and subject to the terms of the Main Agreement,
and for the consideration referred to in the Main Agreement, University hereby grants to Nuvectis:

 

		2.1.1	an exclusive licence, with the right to sublicense (in accordance
with Clause 2.4 and 2.5), under Licensed Patents in the Field and in the Territory for the Term to develop, manufacture,
have manufactured, use, have used, market, sell, have sold, offer to sell, have offered for sale, supply, dispose of and import,
have imported, export, have exported and otherwise exploit Licensed Products, including the right to apply for Marketing Authorisations
or carry out clinical trials for the purpose of obtaining a Marketing Authorisation; and

 

		2.1.2	a non-exclusive licence, with the right to sublicense (in accordance
with Clause 2.4 and 2.5) under Additional Licensed Patents in the Field and in the Territory for the Term to develop, manufacture, have manufactured, use, have used, market, sell, have sold, offer to sell, have offered for sale,
supply, dispose of and import, have imported, export, have exported and otherwise exploit Licensed Products and/or Additional Licensed
Products, including the right to apply for Marketing Authorisations or carry out clinical trials for the purpose of obtaining a Marketing
Authorisation.

 

    71 

     

    

 

		3.	Subject to the provisions of the Main Agreement, this Agreement shall terminate without notice in the
event of the expiry or termination for any reason of the Main Agreement.

 

		4.	In the event of any conflict between the terms of the Main Agreement
and this Agreement, the terms of the Main Agreement shall prevail. 5.

 

		5.	This Agreement shall be governed by and construed in accordance
with English Law. Any dispute arising out of or in connection with this Agreement, including any question regarding its existence,
validity or termination shall be resolved in accordance with the provisions of the Main Agreement.

 

In witness whereof
this Agreement is executed as follows:

 

	Signed for and on behalf of THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH	 	Signed for and on behalf of NUVECTIS PHARMA, INC.
	 	 	 	 	 
	Signed:	 	 	Signed:	      
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

ANNEX 1

[Licensed Patents and/or Additional Licensed Patents
to be added]

 

AGREED BY THE PARTIES BY THEIR DULY AUTHORISED
REPRESENTATIVES.

 

    72 

     

    

 

	Signed for and on behalf of THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH	 	Signed for and on behalf of NUVECTIS PHARMA, INC.
	 	 	 	 	 
	Signed:	 	 	Signed:	      
	 	 	 	 	 
	Name:	 	 	Name:	 
	 	 	 	 	 
	Title:	 	 	Title:	 
	 	 	 	 	 
	Date:	 	 	Date:	 

 

    73

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00334-of-00352.parquet"}]]